Terrylikabos personal page - To The Moon

Terrylikabos

Terrylikabos

No personal profile

48Follow

7Followers

0Topic

0Badge

2021-02-23

Hvgvg

2021-02-23

H

Bitcoin slips sharply from record highs

2021-02-22

$Vaxart, Inc(VXRT)$J

2021-02-22

K

Pfizer-BioNTech Shot Stops Covid Spread, Israeli Study Shows

2021-02-22

B

Pfizer-BioNTech Shot Stops Covid Spread, Israeli Study Shows

2021-02-21

$Vaxart, Inc(VXRT)$Hi

2021-02-21

B

2 Top Tech Stocks to Buy Now for Big Growth

2021-02-20

$Vaxart, Inc(VXRT)$Hi

2021-02-20

??comon

2021-02-20

H

2 Top Tech Stocks to Buy Now for Big Growth

2021-02-20

S

2 Top Tech Stocks to Buy Now for Big Growth

2021-02-19

$Vaxart, Inc(VXRT)$Pluto

2021-02-19

J

Dollar slips further after disappointing jobs data, sterling shines

2021-02-18

H//@Legostonks:Comment pls

Singapore Exchange hopes to list SPACs as early as this year

2021-02-18

Reply to my reply

@Equinoxcry:$Bitcoin Investment Trust(GBTC)$see yall at mars

2021-02-18

$Vaxart, Inc(VXRT)$Pluto

2021-02-18

H

Sorry, the original content has been removed

2021-02-18

G

Barclays reports 38% slide in net profit for 2020, resumes dividend payouts

2021-02-17

H

Sorry, the original content has been removed

2021-02-17

G//@Equinoxcry:to ur madder

@Terrylikabos:To the moon

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":3565272871212062,"uuid":"3565272871212062","gmtCreate":1602179911405,"gmtModify":1612105149418,"name":"Terrylikabos","pinyin":"terrylikabos","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/abbe3eacbb08c5542185b511b376fdd1","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":7,"headSize":48,"tweetSize":76,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"44212b71d0be4ec88898348dbe882e03-2","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Executive Tiger","description":"The transaction amount of the securities account reaches $300,000","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"80.35%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.10","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"60.87%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":4,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":369665901,"gmtCreate":1614040639003,"gmtModify":1704887190605,"author":{"id":"3565272871212062","authorId":"3565272871212062","name":"Terrylikabos","avatar":"https://static.tigerbbs.com/abbe3eacbb08c5542185b511b376fdd1","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Hvgvg","listText":"Hvgvg","text":"Hvgvg","images":[{"img":"https://static.tigerbbs.com/c18ece95df0f3f0f3c4b0de43c73711c","width":"750","height":"1762"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":4,"repostSize":0,"link":"https://ttm.financial/post/369665901","isVote":1,"tweetType":1,"viewCount":123,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":369662049,"gmtCreate":1614040549681,"gmtModify":1704887189143,"author":{"id":"3565272871212062","authorId":"3565272871212062","name":"Terrylikabos","avatar":"https://static.tigerbbs.com/abbe3eacbb08c5542185b511b376fdd1","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"H","listText":"H","text":"H","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/369662049","repostId":"1100241886","repostType":4,"repost":{"id":"1100241886","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1613990937,"share":"https://www.laohu8.com/m/news/1100241886?lang=&edition=full","pubTime":"2021-02-22 18:48","market":"fut","language":"en","title":"Bitcoin slips sharply from record highs","url":"https://stock-news.laohu8.com/highlight/detail?id=1100241886","media":"Reuters","summary":"Bitcoin fell sharply on Monday after surging to a record $58,354 a day earlier, as a selloff in glob","content":"<p>Bitcoin fell sharply on Monday after surging to a record $58,354 a day earlier, as a selloff in global equities curbed risk appetite.</p>\n<p>The most popular cryptocurrency rallied over the weekend to record levels, almost doubling year-to-date. It hit a market capitalisation of $1 trillion on Friday.</p>\n<p>Bitcoin’s gains have been fueled by signs it is gaining acceptance among mainstream investors and companies, from Tesla Inc and Mastercard Inc to BNY Mellon.</p>\n<p>It fell as much as 6% on Monday, and was last trading down 4.4% at $54,941. Rival cryptocurrency ether fell 7% to $1,798 after also hitting a record high on Saturday.</p>\n<p>Traders said the move was largely technical, and not tied to any particular news catalyst.</p>\n<p>“We did finally see some momentum gathering over the weekend, but weekend rallies haven’t been sustainable lately,” said Joseph Edwards of Enigma Securities, a cryptocurrency broker in London.</p>\n<p>“We do tend to think that there’s a good chance of a down week and small correction coming in off of this, although it does little to dull medium-term prospects.”</p>\n<p>Tesla boss Elon Musk, whose tweets on bitcoin have added fuel to the cryptocurrency’s rally, said on Saturday the price of bitcoin and ethereum seemed high.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bitcoin slips sharply from record highs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBitcoin slips sharply from record highs\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-02-22 18:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Bitcoin fell sharply on Monday after surging to a record $58,354 a day earlier, as a selloff in global equities curbed risk appetite.</p>\n<p>The most popular cryptocurrency rallied over the weekend to record levels, almost doubling year-to-date. It hit a market capitalisation of $1 trillion on Friday.</p>\n<p>Bitcoin’s gains have been fueled by signs it is gaining acceptance among mainstream investors and companies, from Tesla Inc and Mastercard Inc to BNY Mellon.</p>\n<p>It fell as much as 6% on Monday, and was last trading down 4.4% at $54,941. Rival cryptocurrency ether fell 7% to $1,798 after also hitting a record high on Saturday.</p>\n<p>Traders said the move was largely technical, and not tied to any particular news catalyst.</p>\n<p>“We did finally see some momentum gathering over the weekend, but weekend rallies haven’t been sustainable lately,” said Joseph Edwards of Enigma Securities, a cryptocurrency broker in London.</p>\n<p>“We do tend to think that there’s a good chance of a down week and small correction coming in off of this, although it does little to dull medium-term prospects.”</p>\n<p>Tesla boss Elon Musk, whose tweets on bitcoin have added fuel to the cryptocurrency’s rally, said on Saturday the price of bitcoin and ethereum seemed high.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GBTC":"Grayscale Bitcoin Trust"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1100241886","content_text":"Bitcoin fell sharply on Monday after surging to a record $58,354 a day earlier, as a selloff in global equities curbed risk appetite.\nThe most popular cryptocurrency rallied over the weekend to record levels, almost doubling year-to-date. It hit a market capitalisation of $1 trillion on Friday.\nBitcoin’s gains have been fueled by signs it is gaining acceptance among mainstream investors and companies, from Tesla Inc and Mastercard Inc to BNY Mellon.\nIt fell as much as 6% on Monday, and was last trading down 4.4% at $54,941. Rival cryptocurrency ether fell 7% to $1,798 after also hitting a record high on Saturday.\nTraders said the move was largely technical, and not tied to any particular news catalyst.\n“We did finally see some momentum gathering over the weekend, but weekend rallies haven’t been sustainable lately,” said Joseph Edwards of Enigma Securities, a cryptocurrency broker in London.\n“We do tend to think that there’s a good chance of a down week and small correction coming in off of this, although it does little to dull medium-term prospects.”\nTesla boss Elon Musk, whose tweets on bitcoin have added fuel to the cryptocurrency’s rally, said on Saturday the price of bitcoin and ethereum seemed high.","news_type":1},"isVote":1,"tweetType":1,"viewCount":407,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":360542135,"gmtCreate":1613959860527,"gmtModify":1704886156247,"author":{"id":"3565272871212062","authorId":"3565272871212062","name":"Terrylikabos","avatar":"https://static.tigerbbs.com/abbe3eacbb08c5542185b511b376fdd1","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/VXRT\">$Vaxart, Inc(VXRT)$</a>J","listText":"<a href=\"https://laohu8.com/S/VXRT\">$Vaxart, Inc(VXRT)$</a>J","text":"$Vaxart, Inc(VXRT)$J","images":[{"img":"https://static.tigerbbs.com/1ead8d1f455ca58ad2f5dbf61e64f261","width":"828","height":"1434"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":5,"repostSize":0,"link":"https://ttm.financial/post/360542135","isVote":1,"tweetType":1,"viewCount":142,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":360548674,"gmtCreate":1613959796298,"gmtModify":1704886153471,"author":{"id":"3565272871212062","authorId":"3565272871212062","name":"Terrylikabos","avatar":"https://static.tigerbbs.com/abbe3eacbb08c5542185b511b376fdd1","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"K","listText":"K","text":"K","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/360548674","repostId":"1145886989","repostType":4,"repost":{"id":"1145886989","pubTimestamp":1613957711,"share":"https://www.laohu8.com/m/news/1145886989?lang=&edition=full","pubTime":"2021-02-22 09:35","market":"us","language":"en","title":"Pfizer-BioNTech Shot Stops Covid Spread, Israeli Study Shows","url":"https://stock-news.laohu8.com/highlight/detail?id=1145886989","media":"Bloomberg","summary":"Vaccine reported to be 89% effective at preventing infections\nStopping virus transmission is key to ","content":"<ul>\n <li>Vaccine reported to be 89% effective at preventing infections</li>\n <li>Stopping virus transmission is key to ending Covid-19 pandemic</li>\n</ul>\n<p>The&nbsp;Pfizer Inc.&nbsp;and&nbsp;BioNTech SE&nbsp;Covid-19 vaccine appeared to stop the vast majority of recipients in Israel becoming infected, providing the first real-world indication that the immunization will curb transmission of the coronavirus.</p>\n<p>The vaccine, which is being rolled out in a national immunization program that began Dec. 20, was 89.4% effective at preventing laboratory-confirmed infections, according to a copy of a draft publication that was posted on Twitter and confirmed by a person familiar with the work. The companies worked with Israel’s Health Ministry on the preliminary observational analysis, which wasn’t peer-reviewed. Some scientists disputed its accuracy.</p>\n<p>The results, also reported in&nbsp;Der Spiegel, are the latest in aseries&nbsp;of&nbsp;positive&nbsp;data to emerge out of Israel, which has given more Covid vaccines per capita than anywhere else in the world. Almost half of the population has had at least one dose of vaccine. Separately, Israeli authorities on Saturday said the Pfizer-BioNTech shot was 99% effective at&nbsp;preventing deaths&nbsp;from the virus.</p>\n<p>If confirmed, the early results on lab-tested infections are encouraging because they indicate the vaccine may also prevent asymptomatic carriers from spreading the virus that causes Covid-19. That’s not been clear because the clinical trials that tested the safety and efficacy of vaccines focused on the ability to stop symptomatic infections.</p>\n<p><b>Herd Immunity</b></p>\n<p>“These are the data we need to see to estimate the potential for achieving herd immunity with vaccines,” said Raina MacIntyre, professor of biosecurity at the University of New South Wales in Sydney, in an email Monday. “However, we do need to be able to see the data published in a peer-reviewed journal and to be able to scrutinize the data in detail.”</p>\n<p>Pfizer and BioNTech said they are working on a real-world analysis of data from Israel, which will be shared as soon as it’s complete. Spokespeople declined to comment on unpublished data.</p>\n<p>The study wasn’t designed to accurately measure a reduction in transmission of SARS-CoV-2 because it used national testing data without accounting for differences in testing rates between vaccinated and unvaccinated people, said&nbsp;Zoe McLaren, an associate professor in the school of public policy at the University of Maryland Baltimore County.</p>\n<p>“The main result overstates the reduction in transmission from the Pfizer vaccine,” McLaren said in an email.</p>\n<p>The study compares the number of reported cases between those who had been fully vaccinated and those who hadn’t been vaccinated, but vaccinated people are less likely to get tested so the data will undercount cases, especially asymptomatic cases, in this group, she said.</p>\n<p><b>‘Need More Evidence’</b></p>\n<p>“That means that the true reduction in transmission is lower than the estimate of 89.4%,” McLaren said. “How much lower? We need more evidence to know for sure. But I expect that, once we account for the bias, we’ll still find that this vaccine does reduce transmission. And that would be very good news.”</p>\n<p>About 80% of SARS-CoV-2 cases in Israel during the time period of the study, from Jan. 17 to Feb. 6, were caused by the more transmissible strain first identified in the U.K. Israel’s vaccination drive began just before the so-called B.1.1.7 variant emerged, fueling infections and leading to a third lockdown on Jan. 8.</p>\n<p>Through Feb. 6, about 27% of peopleaged15 and older in Israel were fully vaccinated, with the Pfizer-BioNTech shot the only vaccine available in the country at the time. People were considered fully vaccinated and included in the analysis if the data collected were more than seven days after they received their second dose.</p>\n<p>Based on SARS-CoV-2’s infectiousness, a vaccine that is 89% effective at preventing infection is likely to be effective at eliminating Covid-19 in a population in which high vaccination coverage is achieved, said Helen Petousis-Harris, a vaccinologist at the University of Auckland.</p>\n<p>Elimination of Covid-19 will depend on potential “reservoirs” of SARS-CoV-2 in animals, genetic changes in the virus that might enable it to escape vaccine-induced immunity, and the ability to stop transmission across the world, said Petousis-Harris, who is co-leader of the Global Vaccine Data Network, a multinational group that collaborates on vaccine safety studies.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer-BioNTech Shot Stops Covid Spread, Israeli Study Shows</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer-BioNTech Shot Stops Covid Spread, Israeli Study Shows\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-02-22 09:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-02-21/pfizer-biontech-shot-stops-covid-s-spread-israeli-study-shows><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Vaccine reported to be 89% effective at preventing infections\nStopping virus transmission is key to ending Covid-19 pandemic\n\nThe Pfizer Inc. and BioNTech SE Covid-19 vaccine appeared to stop the vast...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-02-21/pfizer-biontech-shot-stops-covid-s-spread-israeli-study-shows\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","BNTX":"BioNTech SE"},"source_url":"https://www.bloomberg.com/news/articles/2021-02-21/pfizer-biontech-shot-stops-covid-s-spread-israeli-study-shows","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1145886989","content_text":"Vaccine reported to be 89% effective at preventing infections\nStopping virus transmission is key to ending Covid-19 pandemic\n\nThe Pfizer Inc. and BioNTech SE Covid-19 vaccine appeared to stop the vast majority of recipients in Israel becoming infected, providing the first real-world indication that the immunization will curb transmission of the coronavirus.\nThe vaccine, which is being rolled out in a national immunization program that began Dec. 20, was 89.4% effective at preventing laboratory-confirmed infections, according to a copy of a draft publication that was posted on Twitter and confirmed by a person familiar with the work. The companies worked with Israel’s Health Ministry on the preliminary observational analysis, which wasn’t peer-reviewed. Some scientists disputed its accuracy.\nThe results, also reported in Der Spiegel, are the latest in aseries of positive data to emerge out of Israel, which has given more Covid vaccines per capita than anywhere else in the world. Almost half of the population has had at least one dose of vaccine. Separately, Israeli authorities on Saturday said the Pfizer-BioNTech shot was 99% effective at preventing deaths from the virus.\nIf confirmed, the early results on lab-tested infections are encouraging because they indicate the vaccine may also prevent asymptomatic carriers from spreading the virus that causes Covid-19. That’s not been clear because the clinical trials that tested the safety and efficacy of vaccines focused on the ability to stop symptomatic infections.\nHerd Immunity\n“These are the data we need to see to estimate the potential for achieving herd immunity with vaccines,” said Raina MacIntyre, professor of biosecurity at the University of New South Wales in Sydney, in an email Monday. “However, we do need to be able to see the data published in a peer-reviewed journal and to be able to scrutinize the data in detail.”\nPfizer and BioNTech said they are working on a real-world analysis of data from Israel, which will be shared as soon as it’s complete. Spokespeople declined to comment on unpublished data.\nThe study wasn’t designed to accurately measure a reduction in transmission of SARS-CoV-2 because it used national testing data without accounting for differences in testing rates between vaccinated and unvaccinated people, said Zoe McLaren, an associate professor in the school of public policy at the University of Maryland Baltimore County.\n“The main result overstates the reduction in transmission from the Pfizer vaccine,” McLaren said in an email.\nThe study compares the number of reported cases between those who had been fully vaccinated and those who hadn’t been vaccinated, but vaccinated people are less likely to get tested so the data will undercount cases, especially asymptomatic cases, in this group, she said.\n‘Need More Evidence’\n“That means that the true reduction in transmission is lower than the estimate of 89.4%,” McLaren said. “How much lower? We need more evidence to know for sure. But I expect that, once we account for the bias, we’ll still find that this vaccine does reduce transmission. And that would be very good news.”\nAbout 80% of SARS-CoV-2 cases in Israel during the time period of the study, from Jan. 17 to Feb. 6, were caused by the more transmissible strain first identified in the U.K. Israel’s vaccination drive began just before the so-called B.1.1.7 variant emerged, fueling infections and leading to a third lockdown on Jan. 8.\nThrough Feb. 6, about 27% of peopleaged15 and older in Israel were fully vaccinated, with the Pfizer-BioNTech shot the only vaccine available in the country at the time. People were considered fully vaccinated and included in the analysis if the data collected were more than seven days after they received their second dose.\nBased on SARS-CoV-2’s infectiousness, a vaccine that is 89% effective at preventing infection is likely to be effective at eliminating Covid-19 in a population in which high vaccination coverage is achieved, said Helen Petousis-Harris, a vaccinologist at the University of Auckland.\nElimination of Covid-19 will depend on potential “reservoirs” of SARS-CoV-2 in animals, genetic changes in the virus that might enable it to escape vaccine-induced immunity, and the ability to stop transmission across the world, said Petousis-Harris, who is co-leader of the Global Vaccine Data Network, a multinational group that collaborates on vaccine safety studies.","news_type":1},"isVote":1,"tweetType":1,"viewCount":283,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":360541238,"gmtCreate":1613959770424,"gmtModify":1704886152328,"author":{"id":"3565272871212062","authorId":"3565272871212062","name":"Terrylikabos","avatar":"https://static.tigerbbs.com/abbe3eacbb08c5542185b511b376fdd1","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"B","listText":"B","text":"B","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/360541238","repostId":"1145886989","repostType":4,"repost":{"id":"1145886989","pubTimestamp":1613957711,"share":"https://www.laohu8.com/m/news/1145886989?lang=&edition=full","pubTime":"2021-02-22 09:35","market":"us","language":"en","title":"Pfizer-BioNTech Shot Stops Covid Spread, Israeli Study Shows","url":"https://stock-news.laohu8.com/highlight/detail?id=1145886989","media":"Bloomberg","summary":"Vaccine reported to be 89% effective at preventing infections\nStopping virus transmission is key to ","content":"<ul>\n <li>Vaccine reported to be 89% effective at preventing infections</li>\n <li>Stopping virus transmission is key to ending Covid-19 pandemic</li>\n</ul>\n<p>The&nbsp;Pfizer Inc.&nbsp;and&nbsp;BioNTech SE&nbsp;Covid-19 vaccine appeared to stop the vast majority of recipients in Israel becoming infected, providing the first real-world indication that the immunization will curb transmission of the coronavirus.</p>\n<p>The vaccine, which is being rolled out in a national immunization program that began Dec. 20, was 89.4% effective at preventing laboratory-confirmed infections, according to a copy of a draft publication that was posted on Twitter and confirmed by a person familiar with the work. The companies worked with Israel’s Health Ministry on the preliminary observational analysis, which wasn’t peer-reviewed. Some scientists disputed its accuracy.</p>\n<p>The results, also reported in&nbsp;Der Spiegel, are the latest in aseries&nbsp;of&nbsp;positive&nbsp;data to emerge out of Israel, which has given more Covid vaccines per capita than anywhere else in the world. Almost half of the population has had at least one dose of vaccine. Separately, Israeli authorities on Saturday said the Pfizer-BioNTech shot was 99% effective at&nbsp;preventing deaths&nbsp;from the virus.</p>\n<p>If confirmed, the early results on lab-tested infections are encouraging because they indicate the vaccine may also prevent asymptomatic carriers from spreading the virus that causes Covid-19. That’s not been clear because the clinical trials that tested the safety and efficacy of vaccines focused on the ability to stop symptomatic infections.</p>\n<p><b>Herd Immunity</b></p>\n<p>“These are the data we need to see to estimate the potential for achieving herd immunity with vaccines,” said Raina MacIntyre, professor of biosecurity at the University of New South Wales in Sydney, in an email Monday. “However, we do need to be able to see the data published in a peer-reviewed journal and to be able to scrutinize the data in detail.”</p>\n<p>Pfizer and BioNTech said they are working on a real-world analysis of data from Israel, which will be shared as soon as it’s complete. Spokespeople declined to comment on unpublished data.</p>\n<p>The study wasn’t designed to accurately measure a reduction in transmission of SARS-CoV-2 because it used national testing data without accounting for differences in testing rates between vaccinated and unvaccinated people, said&nbsp;Zoe McLaren, an associate professor in the school of public policy at the University of Maryland Baltimore County.</p>\n<p>“The main result overstates the reduction in transmission from the Pfizer vaccine,” McLaren said in an email.</p>\n<p>The study compares the number of reported cases between those who had been fully vaccinated and those who hadn’t been vaccinated, but vaccinated people are less likely to get tested so the data will undercount cases, especially asymptomatic cases, in this group, she said.</p>\n<p><b>‘Need More Evidence’</b></p>\n<p>“That means that the true reduction in transmission is lower than the estimate of 89.4%,” McLaren said. “How much lower? We need more evidence to know for sure. But I expect that, once we account for the bias, we’ll still find that this vaccine does reduce transmission. And that would be very good news.”</p>\n<p>About 80% of SARS-CoV-2 cases in Israel during the time period of the study, from Jan. 17 to Feb. 6, were caused by the more transmissible strain first identified in the U.K. Israel’s vaccination drive began just before the so-called B.1.1.7 variant emerged, fueling infections and leading to a third lockdown on Jan. 8.</p>\n<p>Through Feb. 6, about 27% of peopleaged15 and older in Israel were fully vaccinated, with the Pfizer-BioNTech shot the only vaccine available in the country at the time. People were considered fully vaccinated and included in the analysis if the data collected were more than seven days after they received their second dose.</p>\n<p>Based on SARS-CoV-2’s infectiousness, a vaccine that is 89% effective at preventing infection is likely to be effective at eliminating Covid-19 in a population in which high vaccination coverage is achieved, said Helen Petousis-Harris, a vaccinologist at the University of Auckland.</p>\n<p>Elimination of Covid-19 will depend on potential “reservoirs” of SARS-CoV-2 in animals, genetic changes in the virus that might enable it to escape vaccine-induced immunity, and the ability to stop transmission across the world, said Petousis-Harris, who is co-leader of the Global Vaccine Data Network, a multinational group that collaborates on vaccine safety studies.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer-BioNTech Shot Stops Covid Spread, Israeli Study Shows</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer-BioNTech Shot Stops Covid Spread, Israeli Study Shows\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-02-22 09:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-02-21/pfizer-biontech-shot-stops-covid-s-spread-israeli-study-shows><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Vaccine reported to be 89% effective at preventing infections\nStopping virus transmission is key to ending Covid-19 pandemic\n\nThe Pfizer Inc. and BioNTech SE Covid-19 vaccine appeared to stop the vast...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-02-21/pfizer-biontech-shot-stops-covid-s-spread-israeli-study-shows\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","BNTX":"BioNTech SE"},"source_url":"https://www.bloomberg.com/news/articles/2021-02-21/pfizer-biontech-shot-stops-covid-s-spread-israeli-study-shows","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1145886989","content_text":"Vaccine reported to be 89% effective at preventing infections\nStopping virus transmission is key to ending Covid-19 pandemic\n\nThe Pfizer Inc. and BioNTech SE Covid-19 vaccine appeared to stop the vast majority of recipients in Israel becoming infected, providing the first real-world indication that the immunization will curb transmission of the coronavirus.\nThe vaccine, which is being rolled out in a national immunization program that began Dec. 20, was 89.4% effective at preventing laboratory-confirmed infections, according to a copy of a draft publication that was posted on Twitter and confirmed by a person familiar with the work. The companies worked with Israel’s Health Ministry on the preliminary observational analysis, which wasn’t peer-reviewed. Some scientists disputed its accuracy.\nThe results, also reported in Der Spiegel, are the latest in aseries of positive data to emerge out of Israel, which has given more Covid vaccines per capita than anywhere else in the world. Almost half of the population has had at least one dose of vaccine. Separately, Israeli authorities on Saturday said the Pfizer-BioNTech shot was 99% effective at preventing deaths from the virus.\nIf confirmed, the early results on lab-tested infections are encouraging because they indicate the vaccine may also prevent asymptomatic carriers from spreading the virus that causes Covid-19. That’s not been clear because the clinical trials that tested the safety and efficacy of vaccines focused on the ability to stop symptomatic infections.\nHerd Immunity\n“These are the data we need to see to estimate the potential for achieving herd immunity with vaccines,” said Raina MacIntyre, professor of biosecurity at the University of New South Wales in Sydney, in an email Monday. “However, we do need to be able to see the data published in a peer-reviewed journal and to be able to scrutinize the data in detail.”\nPfizer and BioNTech said they are working on a real-world analysis of data from Israel, which will be shared as soon as it’s complete. Spokespeople declined to comment on unpublished data.\nThe study wasn’t designed to accurately measure a reduction in transmission of SARS-CoV-2 because it used national testing data without accounting for differences in testing rates between vaccinated and unvaccinated people, said Zoe McLaren, an associate professor in the school of public policy at the University of Maryland Baltimore County.\n“The main result overstates the reduction in transmission from the Pfizer vaccine,” McLaren said in an email.\nThe study compares the number of reported cases between those who had been fully vaccinated and those who hadn’t been vaccinated, but vaccinated people are less likely to get tested so the data will undercount cases, especially asymptomatic cases, in this group, she said.\n‘Need More Evidence’\n“That means that the true reduction in transmission is lower than the estimate of 89.4%,” McLaren said. “How much lower? We need more evidence to know for sure. But I expect that, once we account for the bias, we’ll still find that this vaccine does reduce transmission. And that would be very good news.”\nAbout 80% of SARS-CoV-2 cases in Israel during the time period of the study, from Jan. 17 to Feb. 6, were caused by the more transmissible strain first identified in the U.K. Israel’s vaccination drive began just before the so-called B.1.1.7 variant emerged, fueling infections and leading to a third lockdown on Jan. 8.\nThrough Feb. 6, about 27% of peopleaged15 and older in Israel were fully vaccinated, with the Pfizer-BioNTech shot the only vaccine available in the country at the time. People were considered fully vaccinated and included in the analysis if the data collected were more than seven days after they received their second dose.\nBased on SARS-CoV-2’s infectiousness, a vaccine that is 89% effective at preventing infection is likely to be effective at eliminating Covid-19 in a population in which high vaccination coverage is achieved, said Helen Petousis-Harris, a vaccinologist at the University of Auckland.\nElimination of Covid-19 will depend on potential “reservoirs” of SARS-CoV-2 in animals, genetic changes in the virus that might enable it to escape vaccine-induced immunity, and the ability to stop transmission across the world, said Petousis-Harris, who is co-leader of the Global Vaccine Data Network, a multinational group that collaborates on vaccine safety studies.","news_type":1},"isVote":1,"tweetType":1,"viewCount":163,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":360183301,"gmtCreate":1613870592603,"gmtModify":1704885544024,"author":{"id":"3565272871212062","authorId":"3565272871212062","name":"Terrylikabos","avatar":"https://static.tigerbbs.com/abbe3eacbb08c5542185b511b376fdd1","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/VXRT\">$Vaxart, Inc(VXRT)$</a>Hi","listText":"<a href=\"https://laohu8.com/S/VXRT\">$Vaxart, Inc(VXRT)$</a>Hi","text":"$Vaxart, Inc(VXRT)$Hi","images":[{"img":"https://static.tigerbbs.com/1ead8d1f455ca58ad2f5dbf61e64f261","width":"828","height":"1434"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/360183301","isVote":1,"tweetType":1,"viewCount":211,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":360189871,"gmtCreate":1613870494293,"gmtModify":1704885543053,"author":{"id":"3565272871212062","authorId":"3565272871212062","name":"Terrylikabos","avatar":"https://static.tigerbbs.com/abbe3eacbb08c5542185b511b376fdd1","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"B","listText":"B","text":"B","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/360189871","repostId":"1143100356","repostType":4,"repost":{"id":"1143100356","pubTimestamp":1613792715,"share":"https://www.laohu8.com/m/news/1143100356?lang=&edition=full","pubTime":"2021-02-20 11:45","market":"us","language":"en","title":"2 Top Tech Stocks to Buy Now for Big Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=1143100356","media":"Nasdaq","summary":"The S&P 500 and the tech-heavy Nasdaq slipped during the week of February 15, after they closed at new records last week. Despite the drop in some of the big tech names such as AppleAAPL, FacebookFB, MicrosoftMSFT, Zoom VideoZM, and countless others this week, the market fundamentals remain relatively strong.Ebbs and flows, as well as pullbacks and corrections are healthy aspects of the market. And they need not be viewed as anything but normal occurrences, especially as strong earnings results ","content":"<p>The S&amp;P 500 and the tech-heavy Nasdaq slipped during the week of February 15, after they closed at new records last week. Despite the drop in some of the big tech names such as AppleAAPL, FacebookFB, MicrosoftMSFT, Zoom VideoZM, and countless others this week, the market fundamentals remain relatively strong.</p><p>Ebbs and flows, as well as pullbacks and corrections are healthy aspects of the market. And they need not be viewed as anything but normal occurrences, especially as strong earnings results continue to pour in. Better yet, the outlook for the first quarter and the rest of 2021 has improved significantly.</p><p>Vaccine distribution will hopefully help the economy roar back by the summer and lift some of the hardest-hit areas of the economy. Meanwhile, Wall Street is banking on more spending under the Biden administration and the Fed remains firmly committed to keeping interest rates low.</p><p>All of these factors set up a bullish outlook for 2021. But instead of focusing on companies that need a vaccine to really grow, let’s look at two tech stocks that have posted big sales growth during the pandemic and are ready to expand for years within futuristic industries…</p><p><b>NIO Inc.NIO</b></p><p>Every major automaker, from FordFto Volvo, is racing to roll out more electric vehicles as they try to catch TeslaTSLA. Luckily for investors, the EV market is far from a zero-sum game and newcomers continue to enter the space. Chinese EV maker NIO is a rising star in the booming market, as its sales continue to grow. The company is also focused on autonomous driving tech, as well as batteries, which are the lifeblood of the industry.</p><p>NIO sells multiple models that are somewhat in-line with Tesla, from smaller SUVs to sedans. The company said in early January that it delivered 17,353 vehicles in the fourth quarter, which marked a 110% jump.</p><p>Overall, NIO’s full-year deliveries surged 113% to nearly 44,000 vehicles in 2020. And its January 2021 figures were even more impressive, with deliveries up 350% from the year-ago period to push its overall cumulative deliveries to 83K.</p><p>With this in mind, Zacks estimates call for NIO’s FY20 revenue to jump 120% to $2.49 billion, with FY21 projected to come in another 97% higher to reach $4.89 billion. The Chinese EV company is also expected to significantly shrink its adjusted losses during this stretch.</p><p>NIO has topped our EPS estimates in the trailing two periods and its positive earnings revisions help it land a Zacks Rank #2 (Buy) heading into the release of its Q4 results on March 1.</p><p><img src=\"https://static.tigerbbs.com/5b6233d1784a5cb7db62b437f7632a3f\" tg-width=\"620\" tg-height=\"314\" referrerpolicy=\"no-referrer\"></p><p>NIO, which rocks an “A” grade for Growth in our Style Scores system, has seen its stock skyrocket over 1,000% in the last year and 300% in the past six months. Luckily for investors who missed the ride, NIO has cooled down, up only 12% in the last three months.</p><p>At roughly $55 per share, it’s down about 13% from its late January records. The recent downturn has seen it fall from overbought in terms of the Relative Strength Index to around 45—an RSI above 70 is often regarded as overbought, with any number below 30 considered oversold.</p><p>NIO’s recent price performance could give it room to run if it’s able to impress Wall Street. And the stock jumped over 1% through morning trading Friday, as it bounces off its 50-day moving average. NIO shares also trade at a discount compared to other high-flyers at 12.7X forward sales, which marks a discount against Tesla’s 15.5X and comes in 25% below its own six-months highs.</p><p>Three out of the nine brokerage recommendations that Zacks has for NIO come in at a “Strong Buy,” with none below a “Hold.” NIO might be worth buying as a long-term play that’s far less expensive than Tesla ($784 a share), in a world where EVs already accounted for over 30% of Volvo’s new car sales in Europe in 2020. And let’s remember that China is one of the world’s largest EV markets.</p><p><b>CrowdStrikeCRWD</b></p><p>CrowdStrike is a cloud-focused cybersecurity firm that utilizes machine learning and AI to protect endpoints and cloud workloads. This is crucial in the cloud age that’s full of rapidly expanding endpoints, which include laptops, desktops, smartphones, IoT devices, and more.</p><p>Remote work and schooling pushed this area of the ever-growing cybersecurity space to the forefront, but it was already booming. More importantly, as devices proliferate and our digitally-connected world grows more complex, it becomes more vulnerable.</p><p>CrowdStrike on February announced plans to bolster its offerings through the acquisition of Humio for $400 million—expected to close in the first quarter. Humio provides high-performance cloud log management and observability technology. The deal is set to “further expand its eXtended Detection and Response (XDR) capabilities by ingesting and correlating data from any log, application or feed to deliver actionable insights and real-time protection.”</p><p><img src=\"https://static.tigerbbs.com/9f684cfbac7ba46e2cf8ab6e063461a2\" tg-width=\"620\" tg-height=\"280\" referrerpolicy=\"no-referrer\"></p><p>CrowdStrike, which went public in the summer of 2019, has soared nearly 280% in the past 12 months. More recently, the stock is up 65% in the last six months, and it already bounced back to new records—which it hit earlier in the week—after it slipped in mid-January.</p><p>The stock is firmly a growth play at the moment, trading at 42.7X forward sales, which puts it right in line with e-commerce giant ShopifySHOP. Despite its run, the stock is not currently considered overbought, with an RSI of 64.</p><p>CRWD’s positive earnings revisions help it grab a Zacks Rank #2 (Buy) at the moment, with it set to release its fourth quarter fiscal 2021 results on March 16. Meanwhile, 14 of the 19 brokerage ratings Zacks has for CRWD come in at a “Strong Buy,” with none lower than a “Hold.”</p><p>Looking back, the company crushed our Q3 estimates in December, with sales up 86%. CrowdStrike also lifted its guidance at the time. Zacks estimates currently call for it to swing from an adjusted loss of -$0.02 a share in the year-ago period to +$0.09 in the fourth quarter on 65% stronger sales.</p><p>In total, the cybersecurity firm is projected to soar from a loss of -$0.42 a share to +$0.23 in fiscal 2021. Plus, CRWD’s FY22 EPS figure is projected to climb another 70% higher, all the way to $0.39 a share. Meanwhile, its revenue is projected to jump 79% to hit $861 million in FY21 and then climb another 42% to $1.22 billion in FY22.</p><p>CrowdStrike’s expected growth would come on top of FY20’s 93% sales expansion. The stock has clearly already gone on an impressive run. But it is poised to continue to grow in a world where everything is connected and data is endless. Therefore, cybersecurity firms such as CrowdStrike might make for strong long-term growth plays.</p><p><b>These Stocks Are Poised to Soar Past the Pandemic</b>The COVID-19 outbreak has shifted consumer behavior dramatically, and a handful of high-tech companies have stepped up to keep America running. Right now, investors in these companies have a shot at serious profits. For example, Zoom jumped 108.5% in less than 4 months while most other stocks were sinking.</p><p>Our research shows that 5 cutting-edge stocks could skyrocket from the exponential increase in demand for “stay at home” technologies. This could be one of the biggest buying opportunities of this decade, especially for those who get in early.</p>","source":"lsy1604288433698","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Top Tech Stocks to Buy Now for Big Growth</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Top Tech Stocks to Buy Now for Big Growth\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-02-20 11:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.nasdaq.com/articles/2-top-tech-stocks-to-buy-now-for-big-growth-2021-02-19><strong>Nasdaq</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The S&P 500 and the tech-heavy Nasdaq slipped during the week of February 15, after they closed at new records last week. Despite the drop in some of the big tech names such as AppleAAPL, FacebookFB, ...</p>\n\n<a href=\"https://www.nasdaq.com/articles/2-top-tech-stocks-to-buy-now-for-big-growth-2021-02-19\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.nasdaq.com/articles/2-top-tech-stocks-to-buy-now-for-big-growth-2021-02-19","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1143100356","content_text":"The S&P 500 and the tech-heavy Nasdaq slipped during the week of February 15, after they closed at new records last week. Despite the drop in some of the big tech names such as AppleAAPL, FacebookFB, MicrosoftMSFT, Zoom VideoZM, and countless others this week, the market fundamentals remain relatively strong.Ebbs and flows, as well as pullbacks and corrections are healthy aspects of the market. And they need not be viewed as anything but normal occurrences, especially as strong earnings results continue to pour in. Better yet, the outlook for the first quarter and the rest of 2021 has improved significantly.Vaccine distribution will hopefully help the economy roar back by the summer and lift some of the hardest-hit areas of the economy. Meanwhile, Wall Street is banking on more spending under the Biden administration and the Fed remains firmly committed to keeping interest rates low.All of these factors set up a bullish outlook for 2021. But instead of focusing on companies that need a vaccine to really grow, let’s look at two tech stocks that have posted big sales growth during the pandemic and are ready to expand for years within futuristic industries…NIO Inc.NIOEvery major automaker, from FordFto Volvo, is racing to roll out more electric vehicles as they try to catch TeslaTSLA. Luckily for investors, the EV market is far from a zero-sum game and newcomers continue to enter the space. Chinese EV maker NIO is a rising star in the booming market, as its sales continue to grow. The company is also focused on autonomous driving tech, as well as batteries, which are the lifeblood of the industry.NIO sells multiple models that are somewhat in-line with Tesla, from smaller SUVs to sedans. The company said in early January that it delivered 17,353 vehicles in the fourth quarter, which marked a 110% jump.Overall, NIO’s full-year deliveries surged 113% to nearly 44,000 vehicles in 2020. And its January 2021 figures were even more impressive, with deliveries up 350% from the year-ago period to push its overall cumulative deliveries to 83K.With this in mind, Zacks estimates call for NIO’s FY20 revenue to jump 120% to $2.49 billion, with FY21 projected to come in another 97% higher to reach $4.89 billion. The Chinese EV company is also expected to significantly shrink its adjusted losses during this stretch.NIO has topped our EPS estimates in the trailing two periods and its positive earnings revisions help it land a Zacks Rank #2 (Buy) heading into the release of its Q4 results on March 1.NIO, which rocks an “A” grade for Growth in our Style Scores system, has seen its stock skyrocket over 1,000% in the last year and 300% in the past six months. Luckily for investors who missed the ride, NIO has cooled down, up only 12% in the last three months.At roughly $55 per share, it’s down about 13% from its late January records. The recent downturn has seen it fall from overbought in terms of the Relative Strength Index to around 45—an RSI above 70 is often regarded as overbought, with any number below 30 considered oversold.NIO’s recent price performance could give it room to run if it’s able to impress Wall Street. And the stock jumped over 1% through morning trading Friday, as it bounces off its 50-day moving average. NIO shares also trade at a discount compared to other high-flyers at 12.7X forward sales, which marks a discount against Tesla’s 15.5X and comes in 25% below its own six-months highs.Three out of the nine brokerage recommendations that Zacks has for NIO come in at a “Strong Buy,” with none below a “Hold.” NIO might be worth buying as a long-term play that’s far less expensive than Tesla ($784 a share), in a world where EVs already accounted for over 30% of Volvo’s new car sales in Europe in 2020. And let’s remember that China is one of the world’s largest EV markets.CrowdStrikeCRWDCrowdStrike is a cloud-focused cybersecurity firm that utilizes machine learning and AI to protect endpoints and cloud workloads. This is crucial in the cloud age that’s full of rapidly expanding endpoints, which include laptops, desktops, smartphones, IoT devices, and more.Remote work and schooling pushed this area of the ever-growing cybersecurity space to the forefront, but it was already booming. More importantly, as devices proliferate and our digitally-connected world grows more complex, it becomes more vulnerable.CrowdStrike on February announced plans to bolster its offerings through the acquisition of Humio for $400 million—expected to close in the first quarter. Humio provides high-performance cloud log management and observability technology. The deal is set to “further expand its eXtended Detection and Response (XDR) capabilities by ingesting and correlating data from any log, application or feed to deliver actionable insights and real-time protection.”CrowdStrike, which went public in the summer of 2019, has soared nearly 280% in the past 12 months. More recently, the stock is up 65% in the last six months, and it already bounced back to new records—which it hit earlier in the week—after it slipped in mid-January.The stock is firmly a growth play at the moment, trading at 42.7X forward sales, which puts it right in line with e-commerce giant ShopifySHOP. Despite its run, the stock is not currently considered overbought, with an RSI of 64.CRWD’s positive earnings revisions help it grab a Zacks Rank #2 (Buy) at the moment, with it set to release its fourth quarter fiscal 2021 results on March 16. Meanwhile, 14 of the 19 brokerage ratings Zacks has for CRWD come in at a “Strong Buy,” with none lower than a “Hold.”Looking back, the company crushed our Q3 estimates in December, with sales up 86%. CrowdStrike also lifted its guidance at the time. Zacks estimates currently call for it to swing from an adjusted loss of -$0.02 a share in the year-ago period to +$0.09 in the fourth quarter on 65% stronger sales.In total, the cybersecurity firm is projected to soar from a loss of -$0.42 a share to +$0.23 in fiscal 2021. Plus, CRWD’s FY22 EPS figure is projected to climb another 70% higher, all the way to $0.39 a share. Meanwhile, its revenue is projected to jump 79% to hit $861 million in FY21 and then climb another 42% to $1.22 billion in FY22.CrowdStrike’s expected growth would come on top of FY20’s 93% sales expansion. The stock has clearly already gone on an impressive run. But it is poised to continue to grow in a world where everything is connected and data is endless. Therefore, cybersecurity firms such as CrowdStrike might make for strong long-term growth plays.These Stocks Are Poised to Soar Past the PandemicThe COVID-19 outbreak has shifted consumer behavior dramatically, and a handful of high-tech companies have stepped up to keep America running. Right now, investors in these companies have a shot at serious profits. For example, Zoom jumped 108.5% in less than 4 months while most other stocks were sinking.Our research shows that 5 cutting-edge stocks could skyrocket from the exponential increase in demand for “stay at home” technologies. This could be one of the biggest buying opportunities of this decade, especially for those who get in early.","news_type":1},"isVote":1,"tweetType":1,"viewCount":231,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":360024678,"gmtCreate":1613798682094,"gmtModify":1704885175357,"author":{"id":"3565272871212062","authorId":"3565272871212062","name":"Terrylikabos","avatar":"https://static.tigerbbs.com/abbe3eacbb08c5542185b511b376fdd1","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/VXRT\">$Vaxart, Inc(VXRT)$</a>Hi","listText":"<a href=\"https://laohu8.com/S/VXRT\">$Vaxart, Inc(VXRT)$</a>Hi","text":"$Vaxart, Inc(VXRT)$Hi","images":[{"img":"https://static.tigerbbs.com/1ead8d1f455ca58ad2f5dbf61e64f261","width":"828","height":"1434"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":1,"link":"https://ttm.financial/post/360024678","isVote":1,"tweetType":1,"viewCount":319,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":360025170,"gmtCreate":1613798567890,"gmtModify":1704885174060,"author":{"id":"3565272871212062","authorId":"3565272871212062","name":"Terrylikabos","avatar":"https://static.tigerbbs.com/abbe3eacbb08c5542185b511b376fdd1","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"??comon","listText":"??comon","text":"??comon","images":[{"img":"https://static.tigerbbs.com/5aa7092e8ee41875ab4047d6bc02515c","width":"750","height":"1817"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/360025170","isVote":1,"tweetType":1,"viewCount":121,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":360026705,"gmtCreate":1613798460707,"gmtModify":1704885172122,"author":{"id":"3565272871212062","authorId":"3565272871212062","name":"Terrylikabos","avatar":"https://static.tigerbbs.com/abbe3eacbb08c5542185b511b376fdd1","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"H","listText":"H","text":"H","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/360026705","repostId":"1143100356","repostType":4,"repost":{"id":"1143100356","pubTimestamp":1613792715,"share":"https://www.laohu8.com/m/news/1143100356?lang=&edition=full","pubTime":"2021-02-20 11:45","market":"us","language":"en","title":"2 Top Tech Stocks to Buy Now for Big Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=1143100356","media":"Nasdaq","summary":"The S&P 500 and the tech-heavy Nasdaq slipped during the week of February 15, after they closed at new records last week. Despite the drop in some of the big tech names such as AppleAAPL, FacebookFB, MicrosoftMSFT, Zoom VideoZM, and countless others this week, the market fundamentals remain relatively strong.Ebbs and flows, as well as pullbacks and corrections are healthy aspects of the market. And they need not be viewed as anything but normal occurrences, especially as strong earnings results ","content":"<p>The S&amp;P 500 and the tech-heavy Nasdaq slipped during the week of February 15, after they closed at new records last week. Despite the drop in some of the big tech names such as AppleAAPL, FacebookFB, MicrosoftMSFT, Zoom VideoZM, and countless others this week, the market fundamentals remain relatively strong.</p><p>Ebbs and flows, as well as pullbacks and corrections are healthy aspects of the market. And they need not be viewed as anything but normal occurrences, especially as strong earnings results continue to pour in. Better yet, the outlook for the first quarter and the rest of 2021 has improved significantly.</p><p>Vaccine distribution will hopefully help the economy roar back by the summer and lift some of the hardest-hit areas of the economy. Meanwhile, Wall Street is banking on more spending under the Biden administration and the Fed remains firmly committed to keeping interest rates low.</p><p>All of these factors set up a bullish outlook for 2021. But instead of focusing on companies that need a vaccine to really grow, let’s look at two tech stocks that have posted big sales growth during the pandemic and are ready to expand for years within futuristic industries…</p><p><b>NIO Inc.NIO</b></p><p>Every major automaker, from FordFto Volvo, is racing to roll out more electric vehicles as they try to catch TeslaTSLA. Luckily for investors, the EV market is far from a zero-sum game and newcomers continue to enter the space. Chinese EV maker NIO is a rising star in the booming market, as its sales continue to grow. The company is also focused on autonomous driving tech, as well as batteries, which are the lifeblood of the industry.</p><p>NIO sells multiple models that are somewhat in-line with Tesla, from smaller SUVs to sedans. The company said in early January that it delivered 17,353 vehicles in the fourth quarter, which marked a 110% jump.</p><p>Overall, NIO’s full-year deliveries surged 113% to nearly 44,000 vehicles in 2020. And its January 2021 figures were even more impressive, with deliveries up 350% from the year-ago period to push its overall cumulative deliveries to 83K.</p><p>With this in mind, Zacks estimates call for NIO’s FY20 revenue to jump 120% to $2.49 billion, with FY21 projected to come in another 97% higher to reach $4.89 billion. The Chinese EV company is also expected to significantly shrink its adjusted losses during this stretch.</p><p>NIO has topped our EPS estimates in the trailing two periods and its positive earnings revisions help it land a Zacks Rank #2 (Buy) heading into the release of its Q4 results on March 1.</p><p><img src=\"https://static.tigerbbs.com/5b6233d1784a5cb7db62b437f7632a3f\" tg-width=\"620\" tg-height=\"314\" referrerpolicy=\"no-referrer\"></p><p>NIO, which rocks an “A” grade for Growth in our Style Scores system, has seen its stock skyrocket over 1,000% in the last year and 300% in the past six months. Luckily for investors who missed the ride, NIO has cooled down, up only 12% in the last three months.</p><p>At roughly $55 per share, it’s down about 13% from its late January records. The recent downturn has seen it fall from overbought in terms of the Relative Strength Index to around 45—an RSI above 70 is often regarded as overbought, with any number below 30 considered oversold.</p><p>NIO’s recent price performance could give it room to run if it’s able to impress Wall Street. And the stock jumped over 1% through morning trading Friday, as it bounces off its 50-day moving average. NIO shares also trade at a discount compared to other high-flyers at 12.7X forward sales, which marks a discount against Tesla’s 15.5X and comes in 25% below its own six-months highs.</p><p>Three out of the nine brokerage recommendations that Zacks has for NIO come in at a “Strong Buy,” with none below a “Hold.” NIO might be worth buying as a long-term play that’s far less expensive than Tesla ($784 a share), in a world where EVs already accounted for over 30% of Volvo’s new car sales in Europe in 2020. And let’s remember that China is one of the world’s largest EV markets.</p><p><b>CrowdStrikeCRWD</b></p><p>CrowdStrike is a cloud-focused cybersecurity firm that utilizes machine learning and AI to protect endpoints and cloud workloads. This is crucial in the cloud age that’s full of rapidly expanding endpoints, which include laptops, desktops, smartphones, IoT devices, and more.</p><p>Remote work and schooling pushed this area of the ever-growing cybersecurity space to the forefront, but it was already booming. More importantly, as devices proliferate and our digitally-connected world grows more complex, it becomes more vulnerable.</p><p>CrowdStrike on February announced plans to bolster its offerings through the acquisition of Humio for $400 million—expected to close in the first quarter. Humio provides high-performance cloud log management and observability technology. The deal is set to “further expand its eXtended Detection and Response (XDR) capabilities by ingesting and correlating data from any log, application or feed to deliver actionable insights and real-time protection.”</p><p><img src=\"https://static.tigerbbs.com/9f684cfbac7ba46e2cf8ab6e063461a2\" tg-width=\"620\" tg-height=\"280\" referrerpolicy=\"no-referrer\"></p><p>CrowdStrike, which went public in the summer of 2019, has soared nearly 280% in the past 12 months. More recently, the stock is up 65% in the last six months, and it already bounced back to new records—which it hit earlier in the week—after it slipped in mid-January.</p><p>The stock is firmly a growth play at the moment, trading at 42.7X forward sales, which puts it right in line with e-commerce giant ShopifySHOP. Despite its run, the stock is not currently considered overbought, with an RSI of 64.</p><p>CRWD’s positive earnings revisions help it grab a Zacks Rank #2 (Buy) at the moment, with it set to release its fourth quarter fiscal 2021 results on March 16. Meanwhile, 14 of the 19 brokerage ratings Zacks has for CRWD come in at a “Strong Buy,” with none lower than a “Hold.”</p><p>Looking back, the company crushed our Q3 estimates in December, with sales up 86%. CrowdStrike also lifted its guidance at the time. Zacks estimates currently call for it to swing from an adjusted loss of -$0.02 a share in the year-ago period to +$0.09 in the fourth quarter on 65% stronger sales.</p><p>In total, the cybersecurity firm is projected to soar from a loss of -$0.42 a share to +$0.23 in fiscal 2021. Plus, CRWD’s FY22 EPS figure is projected to climb another 70% higher, all the way to $0.39 a share. Meanwhile, its revenue is projected to jump 79% to hit $861 million in FY21 and then climb another 42% to $1.22 billion in FY22.</p><p>CrowdStrike’s expected growth would come on top of FY20’s 93% sales expansion. The stock has clearly already gone on an impressive run. But it is poised to continue to grow in a world where everything is connected and data is endless. Therefore, cybersecurity firms such as CrowdStrike might make for strong long-term growth plays.</p><p><b>These Stocks Are Poised to Soar Past the Pandemic</b>The COVID-19 outbreak has shifted consumer behavior dramatically, and a handful of high-tech companies have stepped up to keep America running. Right now, investors in these companies have a shot at serious profits. For example, Zoom jumped 108.5% in less than 4 months while most other stocks were sinking.</p><p>Our research shows that 5 cutting-edge stocks could skyrocket from the exponential increase in demand for “stay at home” technologies. This could be one of the biggest buying opportunities of this decade, especially for those who get in early.</p>","source":"lsy1604288433698","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Top Tech Stocks to Buy Now for Big Growth</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Top Tech Stocks to Buy Now for Big Growth\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-02-20 11:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.nasdaq.com/articles/2-top-tech-stocks-to-buy-now-for-big-growth-2021-02-19><strong>Nasdaq</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The S&P 500 and the tech-heavy Nasdaq slipped during the week of February 15, after they closed at new records last week. Despite the drop in some of the big tech names such as AppleAAPL, FacebookFB, ...</p>\n\n<a href=\"https://www.nasdaq.com/articles/2-top-tech-stocks-to-buy-now-for-big-growth-2021-02-19\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.nasdaq.com/articles/2-top-tech-stocks-to-buy-now-for-big-growth-2021-02-19","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1143100356","content_text":"The S&P 500 and the tech-heavy Nasdaq slipped during the week of February 15, after they closed at new records last week. Despite the drop in some of the big tech names such as AppleAAPL, FacebookFB, MicrosoftMSFT, Zoom VideoZM, and countless others this week, the market fundamentals remain relatively strong.Ebbs and flows, as well as pullbacks and corrections are healthy aspects of the market. And they need not be viewed as anything but normal occurrences, especially as strong earnings results continue to pour in. Better yet, the outlook for the first quarter and the rest of 2021 has improved significantly.Vaccine distribution will hopefully help the economy roar back by the summer and lift some of the hardest-hit areas of the economy. Meanwhile, Wall Street is banking on more spending under the Biden administration and the Fed remains firmly committed to keeping interest rates low.All of these factors set up a bullish outlook for 2021. But instead of focusing on companies that need a vaccine to really grow, let’s look at two tech stocks that have posted big sales growth during the pandemic and are ready to expand for years within futuristic industries…NIO Inc.NIOEvery major automaker, from FordFto Volvo, is racing to roll out more electric vehicles as they try to catch TeslaTSLA. Luckily for investors, the EV market is far from a zero-sum game and newcomers continue to enter the space. Chinese EV maker NIO is a rising star in the booming market, as its sales continue to grow. The company is also focused on autonomous driving tech, as well as batteries, which are the lifeblood of the industry.NIO sells multiple models that are somewhat in-line with Tesla, from smaller SUVs to sedans. The company said in early January that it delivered 17,353 vehicles in the fourth quarter, which marked a 110% jump.Overall, NIO’s full-year deliveries surged 113% to nearly 44,000 vehicles in 2020. And its January 2021 figures were even more impressive, with deliveries up 350% from the year-ago period to push its overall cumulative deliveries to 83K.With this in mind, Zacks estimates call for NIO’s FY20 revenue to jump 120% to $2.49 billion, with FY21 projected to come in another 97% higher to reach $4.89 billion. The Chinese EV company is also expected to significantly shrink its adjusted losses during this stretch.NIO has topped our EPS estimates in the trailing two periods and its positive earnings revisions help it land a Zacks Rank #2 (Buy) heading into the release of its Q4 results on March 1.NIO, which rocks an “A” grade for Growth in our Style Scores system, has seen its stock skyrocket over 1,000% in the last year and 300% in the past six months. Luckily for investors who missed the ride, NIO has cooled down, up only 12% in the last three months.At roughly $55 per share, it’s down about 13% from its late January records. The recent downturn has seen it fall from overbought in terms of the Relative Strength Index to around 45—an RSI above 70 is often regarded as overbought, with any number below 30 considered oversold.NIO’s recent price performance could give it room to run if it’s able to impress Wall Street. And the stock jumped over 1% through morning trading Friday, as it bounces off its 50-day moving average. NIO shares also trade at a discount compared to other high-flyers at 12.7X forward sales, which marks a discount against Tesla’s 15.5X and comes in 25% below its own six-months highs.Three out of the nine brokerage recommendations that Zacks has for NIO come in at a “Strong Buy,” with none below a “Hold.” NIO might be worth buying as a long-term play that’s far less expensive than Tesla ($784 a share), in a world where EVs already accounted for over 30% of Volvo’s new car sales in Europe in 2020. And let’s remember that China is one of the world’s largest EV markets.CrowdStrikeCRWDCrowdStrike is a cloud-focused cybersecurity firm that utilizes machine learning and AI to protect endpoints and cloud workloads. This is crucial in the cloud age that’s full of rapidly expanding endpoints, which include laptops, desktops, smartphones, IoT devices, and more.Remote work and schooling pushed this area of the ever-growing cybersecurity space to the forefront, but it was already booming. More importantly, as devices proliferate and our digitally-connected world grows more complex, it becomes more vulnerable.CrowdStrike on February announced plans to bolster its offerings through the acquisition of Humio for $400 million—expected to close in the first quarter. Humio provides high-performance cloud log management and observability technology. The deal is set to “further expand its eXtended Detection and Response (XDR) capabilities by ingesting and correlating data from any log, application or feed to deliver actionable insights and real-time protection.”CrowdStrike, which went public in the summer of 2019, has soared nearly 280% in the past 12 months. More recently, the stock is up 65% in the last six months, and it already bounced back to new records—which it hit earlier in the week—after it slipped in mid-January.The stock is firmly a growth play at the moment, trading at 42.7X forward sales, which puts it right in line with e-commerce giant ShopifySHOP. Despite its run, the stock is not currently considered overbought, with an RSI of 64.CRWD’s positive earnings revisions help it grab a Zacks Rank #2 (Buy) at the moment, with it set to release its fourth quarter fiscal 2021 results on March 16. Meanwhile, 14 of the 19 brokerage ratings Zacks has for CRWD come in at a “Strong Buy,” with none lower than a “Hold.”Looking back, the company crushed our Q3 estimates in December, with sales up 86%. CrowdStrike also lifted its guidance at the time. Zacks estimates currently call for it to swing from an adjusted loss of -$0.02 a share in the year-ago period to +$0.09 in the fourth quarter on 65% stronger sales.In total, the cybersecurity firm is projected to soar from a loss of -$0.42 a share to +$0.23 in fiscal 2021. Plus, CRWD’s FY22 EPS figure is projected to climb another 70% higher, all the way to $0.39 a share. Meanwhile, its revenue is projected to jump 79% to hit $861 million in FY21 and then climb another 42% to $1.22 billion in FY22.CrowdStrike’s expected growth would come on top of FY20’s 93% sales expansion. The stock has clearly already gone on an impressive run. But it is poised to continue to grow in a world where everything is connected and data is endless. Therefore, cybersecurity firms such as CrowdStrike might make for strong long-term growth plays.These Stocks Are Poised to Soar Past the PandemicThe COVID-19 outbreak has shifted consumer behavior dramatically, and a handful of high-tech companies have stepped up to keep America running. Right now, investors in these companies have a shot at serious profits. For example, Zoom jumped 108.5% in less than 4 months while most other stocks were sinking.Our research shows that 5 cutting-edge stocks could skyrocket from the exponential increase in demand for “stay at home” technologies. This could be one of the biggest buying opportunities of this decade, especially for those who get in early.","news_type":1},"isVote":1,"tweetType":1,"viewCount":206,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":360026450,"gmtCreate":1613798451270,"gmtModify":1704885173091,"author":{"id":"3565272871212062","authorId":"3565272871212062","name":"Terrylikabos","avatar":"https://static.tigerbbs.com/abbe3eacbb08c5542185b511b376fdd1","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"S","listText":"S","text":"S","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/360026450","repostId":"1143100356","repostType":4,"repost":{"id":"1143100356","pubTimestamp":1613792715,"share":"https://www.laohu8.com/m/news/1143100356?lang=&edition=full","pubTime":"2021-02-20 11:45","market":"us","language":"en","title":"2 Top Tech Stocks to Buy Now for Big Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=1143100356","media":"Nasdaq","summary":"The S&P 500 and the tech-heavy Nasdaq slipped during the week of February 15, after they closed at new records last week. Despite the drop in some of the big tech names such as AppleAAPL, FacebookFB, MicrosoftMSFT, Zoom VideoZM, and countless others this week, the market fundamentals remain relatively strong.Ebbs and flows, as well as pullbacks and corrections are healthy aspects of the market. And they need not be viewed as anything but normal occurrences, especially as strong earnings results ","content":"<p>The S&amp;P 500 and the tech-heavy Nasdaq slipped during the week of February 15, after they closed at new records last week. Despite the drop in some of the big tech names such as AppleAAPL, FacebookFB, MicrosoftMSFT, Zoom VideoZM, and countless others this week, the market fundamentals remain relatively strong.</p><p>Ebbs and flows, as well as pullbacks and corrections are healthy aspects of the market. And they need not be viewed as anything but normal occurrences, especially as strong earnings results continue to pour in. Better yet, the outlook for the first quarter and the rest of 2021 has improved significantly.</p><p>Vaccine distribution will hopefully help the economy roar back by the summer and lift some of the hardest-hit areas of the economy. Meanwhile, Wall Street is banking on more spending under the Biden administration and the Fed remains firmly committed to keeping interest rates low.</p><p>All of these factors set up a bullish outlook for 2021. But instead of focusing on companies that need a vaccine to really grow, let’s look at two tech stocks that have posted big sales growth during the pandemic and are ready to expand for years within futuristic industries…</p><p><b>NIO Inc.NIO</b></p><p>Every major automaker, from FordFto Volvo, is racing to roll out more electric vehicles as they try to catch TeslaTSLA. Luckily for investors, the EV market is far from a zero-sum game and newcomers continue to enter the space. Chinese EV maker NIO is a rising star in the booming market, as its sales continue to grow. The company is also focused on autonomous driving tech, as well as batteries, which are the lifeblood of the industry.</p><p>NIO sells multiple models that are somewhat in-line with Tesla, from smaller SUVs to sedans. The company said in early January that it delivered 17,353 vehicles in the fourth quarter, which marked a 110% jump.</p><p>Overall, NIO’s full-year deliveries surged 113% to nearly 44,000 vehicles in 2020. And its January 2021 figures were even more impressive, with deliveries up 350% from the year-ago period to push its overall cumulative deliveries to 83K.</p><p>With this in mind, Zacks estimates call for NIO’s FY20 revenue to jump 120% to $2.49 billion, with FY21 projected to come in another 97% higher to reach $4.89 billion. The Chinese EV company is also expected to significantly shrink its adjusted losses during this stretch.</p><p>NIO has topped our EPS estimates in the trailing two periods and its positive earnings revisions help it land a Zacks Rank #2 (Buy) heading into the release of its Q4 results on March 1.</p><p><img src=\"https://static.tigerbbs.com/5b6233d1784a5cb7db62b437f7632a3f\" tg-width=\"620\" tg-height=\"314\" referrerpolicy=\"no-referrer\"></p><p>NIO, which rocks an “A” grade for Growth in our Style Scores system, has seen its stock skyrocket over 1,000% in the last year and 300% in the past six months. Luckily for investors who missed the ride, NIO has cooled down, up only 12% in the last three months.</p><p>At roughly $55 per share, it’s down about 13% from its late January records. The recent downturn has seen it fall from overbought in terms of the Relative Strength Index to around 45—an RSI above 70 is often regarded as overbought, with any number below 30 considered oversold.</p><p>NIO’s recent price performance could give it room to run if it’s able to impress Wall Street. And the stock jumped over 1% through morning trading Friday, as it bounces off its 50-day moving average. NIO shares also trade at a discount compared to other high-flyers at 12.7X forward sales, which marks a discount against Tesla’s 15.5X and comes in 25% below its own six-months highs.</p><p>Three out of the nine brokerage recommendations that Zacks has for NIO come in at a “Strong Buy,” with none below a “Hold.” NIO might be worth buying as a long-term play that’s far less expensive than Tesla ($784 a share), in a world where EVs already accounted for over 30% of Volvo’s new car sales in Europe in 2020. And let’s remember that China is one of the world’s largest EV markets.</p><p><b>CrowdStrikeCRWD</b></p><p>CrowdStrike is a cloud-focused cybersecurity firm that utilizes machine learning and AI to protect endpoints and cloud workloads. This is crucial in the cloud age that’s full of rapidly expanding endpoints, which include laptops, desktops, smartphones, IoT devices, and more.</p><p>Remote work and schooling pushed this area of the ever-growing cybersecurity space to the forefront, but it was already booming. More importantly, as devices proliferate and our digitally-connected world grows more complex, it becomes more vulnerable.</p><p>CrowdStrike on February announced plans to bolster its offerings through the acquisition of Humio for $400 million—expected to close in the first quarter. Humio provides high-performance cloud log management and observability technology. The deal is set to “further expand its eXtended Detection and Response (XDR) capabilities by ingesting and correlating data from any log, application or feed to deliver actionable insights and real-time protection.”</p><p><img src=\"https://static.tigerbbs.com/9f684cfbac7ba46e2cf8ab6e063461a2\" tg-width=\"620\" tg-height=\"280\" referrerpolicy=\"no-referrer\"></p><p>CrowdStrike, which went public in the summer of 2019, has soared nearly 280% in the past 12 months. More recently, the stock is up 65% in the last six months, and it already bounced back to new records—which it hit earlier in the week—after it slipped in mid-January.</p><p>The stock is firmly a growth play at the moment, trading at 42.7X forward sales, which puts it right in line with e-commerce giant ShopifySHOP. Despite its run, the stock is not currently considered overbought, with an RSI of 64.</p><p>CRWD’s positive earnings revisions help it grab a Zacks Rank #2 (Buy) at the moment, with it set to release its fourth quarter fiscal 2021 results on March 16. Meanwhile, 14 of the 19 brokerage ratings Zacks has for CRWD come in at a “Strong Buy,” with none lower than a “Hold.”</p><p>Looking back, the company crushed our Q3 estimates in December, with sales up 86%. CrowdStrike also lifted its guidance at the time. Zacks estimates currently call for it to swing from an adjusted loss of -$0.02 a share in the year-ago period to +$0.09 in the fourth quarter on 65% stronger sales.</p><p>In total, the cybersecurity firm is projected to soar from a loss of -$0.42 a share to +$0.23 in fiscal 2021. Plus, CRWD’s FY22 EPS figure is projected to climb another 70% higher, all the way to $0.39 a share. Meanwhile, its revenue is projected to jump 79% to hit $861 million in FY21 and then climb another 42% to $1.22 billion in FY22.</p><p>CrowdStrike’s expected growth would come on top of FY20’s 93% sales expansion. The stock has clearly already gone on an impressive run. But it is poised to continue to grow in a world where everything is connected and data is endless. Therefore, cybersecurity firms such as CrowdStrike might make for strong long-term growth plays.</p><p><b>These Stocks Are Poised to Soar Past the Pandemic</b>The COVID-19 outbreak has shifted consumer behavior dramatically, and a handful of high-tech companies have stepped up to keep America running. Right now, investors in these companies have a shot at serious profits. For example, Zoom jumped 108.5% in less than 4 months while most other stocks were sinking.</p><p>Our research shows that 5 cutting-edge stocks could skyrocket from the exponential increase in demand for “stay at home” technologies. This could be one of the biggest buying opportunities of this decade, especially for those who get in early.</p>","source":"lsy1604288433698","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Top Tech Stocks to Buy Now for Big Growth</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Top Tech Stocks to Buy Now for Big Growth\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-02-20 11:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.nasdaq.com/articles/2-top-tech-stocks-to-buy-now-for-big-growth-2021-02-19><strong>Nasdaq</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The S&P 500 and the tech-heavy Nasdaq slipped during the week of February 15, after they closed at new records last week. Despite the drop in some of the big tech names such as AppleAAPL, FacebookFB, ...</p>\n\n<a href=\"https://www.nasdaq.com/articles/2-top-tech-stocks-to-buy-now-for-big-growth-2021-02-19\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.nasdaq.com/articles/2-top-tech-stocks-to-buy-now-for-big-growth-2021-02-19","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1143100356","content_text":"The S&P 500 and the tech-heavy Nasdaq slipped during the week of February 15, after they closed at new records last week. Despite the drop in some of the big tech names such as AppleAAPL, FacebookFB, MicrosoftMSFT, Zoom VideoZM, and countless others this week, the market fundamentals remain relatively strong.Ebbs and flows, as well as pullbacks and corrections are healthy aspects of the market. And they need not be viewed as anything but normal occurrences, especially as strong earnings results continue to pour in. Better yet, the outlook for the first quarter and the rest of 2021 has improved significantly.Vaccine distribution will hopefully help the economy roar back by the summer and lift some of the hardest-hit areas of the economy. Meanwhile, Wall Street is banking on more spending under the Biden administration and the Fed remains firmly committed to keeping interest rates low.All of these factors set up a bullish outlook for 2021. But instead of focusing on companies that need a vaccine to really grow, let’s look at two tech stocks that have posted big sales growth during the pandemic and are ready to expand for years within futuristic industries…NIO Inc.NIOEvery major automaker, from FordFto Volvo, is racing to roll out more electric vehicles as they try to catch TeslaTSLA. Luckily for investors, the EV market is far from a zero-sum game and newcomers continue to enter the space. Chinese EV maker NIO is a rising star in the booming market, as its sales continue to grow. The company is also focused on autonomous driving tech, as well as batteries, which are the lifeblood of the industry.NIO sells multiple models that are somewhat in-line with Tesla, from smaller SUVs to sedans. The company said in early January that it delivered 17,353 vehicles in the fourth quarter, which marked a 110% jump.Overall, NIO’s full-year deliveries surged 113% to nearly 44,000 vehicles in 2020. And its January 2021 figures were even more impressive, with deliveries up 350% from the year-ago period to push its overall cumulative deliveries to 83K.With this in mind, Zacks estimates call for NIO’s FY20 revenue to jump 120% to $2.49 billion, with FY21 projected to come in another 97% higher to reach $4.89 billion. The Chinese EV company is also expected to significantly shrink its adjusted losses during this stretch.NIO has topped our EPS estimates in the trailing two periods and its positive earnings revisions help it land a Zacks Rank #2 (Buy) heading into the release of its Q4 results on March 1.NIO, which rocks an “A” grade for Growth in our Style Scores system, has seen its stock skyrocket over 1,000% in the last year and 300% in the past six months. Luckily for investors who missed the ride, NIO has cooled down, up only 12% in the last three months.At roughly $55 per share, it’s down about 13% from its late January records. The recent downturn has seen it fall from overbought in terms of the Relative Strength Index to around 45—an RSI above 70 is often regarded as overbought, with any number below 30 considered oversold.NIO’s recent price performance could give it room to run if it’s able to impress Wall Street. And the stock jumped over 1% through morning trading Friday, as it bounces off its 50-day moving average. NIO shares also trade at a discount compared to other high-flyers at 12.7X forward sales, which marks a discount against Tesla’s 15.5X and comes in 25% below its own six-months highs.Three out of the nine brokerage recommendations that Zacks has for NIO come in at a “Strong Buy,” with none below a “Hold.” NIO might be worth buying as a long-term play that’s far less expensive than Tesla ($784 a share), in a world where EVs already accounted for over 30% of Volvo’s new car sales in Europe in 2020. And let’s remember that China is one of the world’s largest EV markets.CrowdStrikeCRWDCrowdStrike is a cloud-focused cybersecurity firm that utilizes machine learning and AI to protect endpoints and cloud workloads. This is crucial in the cloud age that’s full of rapidly expanding endpoints, which include laptops, desktops, smartphones, IoT devices, and more.Remote work and schooling pushed this area of the ever-growing cybersecurity space to the forefront, but it was already booming. More importantly, as devices proliferate and our digitally-connected world grows more complex, it becomes more vulnerable.CrowdStrike on February announced plans to bolster its offerings through the acquisition of Humio for $400 million—expected to close in the first quarter. Humio provides high-performance cloud log management and observability technology. The deal is set to “further expand its eXtended Detection and Response (XDR) capabilities by ingesting and correlating data from any log, application or feed to deliver actionable insights and real-time protection.”CrowdStrike, which went public in the summer of 2019, has soared nearly 280% in the past 12 months. More recently, the stock is up 65% in the last six months, and it already bounced back to new records—which it hit earlier in the week—after it slipped in mid-January.The stock is firmly a growth play at the moment, trading at 42.7X forward sales, which puts it right in line with e-commerce giant ShopifySHOP. Despite its run, the stock is not currently considered overbought, with an RSI of 64.CRWD’s positive earnings revisions help it grab a Zacks Rank #2 (Buy) at the moment, with it set to release its fourth quarter fiscal 2021 results on March 16. Meanwhile, 14 of the 19 brokerage ratings Zacks has for CRWD come in at a “Strong Buy,” with none lower than a “Hold.”Looking back, the company crushed our Q3 estimates in December, with sales up 86%. CrowdStrike also lifted its guidance at the time. Zacks estimates currently call for it to swing from an adjusted loss of -$0.02 a share in the year-ago period to +$0.09 in the fourth quarter on 65% stronger sales.In total, the cybersecurity firm is projected to soar from a loss of -$0.42 a share to +$0.23 in fiscal 2021. Plus, CRWD’s FY22 EPS figure is projected to climb another 70% higher, all the way to $0.39 a share. Meanwhile, its revenue is projected to jump 79% to hit $861 million in FY21 and then climb another 42% to $1.22 billion in FY22.CrowdStrike’s expected growth would come on top of FY20’s 93% sales expansion. The stock has clearly already gone on an impressive run. But it is poised to continue to grow in a world where everything is connected and data is endless. Therefore, cybersecurity firms such as CrowdStrike might make for strong long-term growth plays.These Stocks Are Poised to Soar Past the PandemicThe COVID-19 outbreak has shifted consumer behavior dramatically, and a handful of high-tech companies have stepped up to keep America running. Right now, investors in these companies have a shot at serious profits. For example, Zoom jumped 108.5% in less than 4 months while most other stocks were sinking.Our research shows that 5 cutting-edge stocks could skyrocket from the exponential increase in demand for “stay at home” technologies. This could be one of the biggest buying opportunities of this decade, especially for those who get in early.","news_type":1},"isVote":1,"tweetType":1,"viewCount":87,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":387113175,"gmtCreate":1613726996397,"gmtModify":1704884192105,"author":{"id":"3565272871212062","authorId":"3565272871212062","name":"Terrylikabos","avatar":"https://static.tigerbbs.com/abbe3eacbb08c5542185b511b376fdd1","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/VXRT\">$Vaxart, Inc(VXRT)$</a>Pluto","listText":"<a href=\"https://laohu8.com/S/VXRT\">$Vaxart, Inc(VXRT)$</a>Pluto","text":"$Vaxart, Inc(VXRT)$Pluto","images":[{"img":"https://static.tigerbbs.com/09d4ccdf1c4f0643d053f42ecccad18c","width":"828","height":"1434"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/387113175","isVote":1,"tweetType":1,"viewCount":17,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":387110686,"gmtCreate":1613726885945,"gmtModify":1704884189687,"author":{"id":"3565272871212062","authorId":"3565272871212062","name":"Terrylikabos","avatar":"https://static.tigerbbs.com/abbe3eacbb08c5542185b511b376fdd1","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"J","listText":"J","text":"J","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/387110686","repostId":"2112149478","repostType":4,"repost":{"id":"2112149478","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1613724786,"share":"https://www.laohu8.com/m/news/2112149478?lang=&edition=full","pubTime":"2021-02-19 16:53","market":"other","language":"en","title":"Dollar slips further after disappointing jobs data, sterling shines","url":"https://stock-news.laohu8.com/highlight/detail?id=2112149478","media":"Reuters","summary":"LONDON, Feb 19 (Reuters) - The U.S. dollar slipped further on Friday and the euro rebounded after di","content":"<p>LONDON, Feb 19 (Reuters) - The U.S. dollar slipped further on Friday and the euro rebounded after disappointing U.S. data dented optimism for a speedy recovery from the COVID-19 pandemic, while sterling edged towards the $1.40 mark.</p>\n<p>The U.S. currency had been rising as a jump in Treasury yields on the back of the so-called reflation trade encouraged investors back into the greenback.</p>\n<p>But an unexpected increase in U.S. weekly jobless claims soured the economic outlook and sent the dollar lower overnight.</p>\n<p>On Friday it traded down 0.1% against a basket of currencies, the dollar index now at 90.474.</p>\n<p>The string of soft labour data is weighing on the dollar even as other indicators have shown resilience, and as President Joe Biden's pandemic relief efforts take shape, including a proposed $1.9 trillion spending package.</p>\n<p>The euro rose 0.2% to $1.2113 . The single currency showed little reaction to German and French flash purchasing manager index data, which unsurprisingly showed a slowdown in activity in January.</p>\n<p>Despite the recent rise in U.S. yields, many analysts think they won't climb too much higher, limiting the benefit for the dollar.</p>\n<p>ING analysts said that \"the rise in rates will be self-regulating, meaning the dollar need not correct too much higher.\"</p>\n<p>They see the greenback index trading down to the 90.10 to 91.05 range&nbsp;Sterling has been the standout performer in 2021 and on Friday rose to $1.3987, an almost three-year high amid Britain's aggressive vaccination programme.</p>\n<p>Given the size of Britain's vital services sector, analysts say the faster it can reopen the economy the better for the currency.</p>\n<p>The dollar bought 105.46 yen , down 0.2% and a continued retreat from the five-month high of 106.225 reached Wednesday.</p>\n<p>Many analysts expect the dollar to weaken over the course of the year as it has traditionally done during times of global economic recovery, though it might take some time to develop.</p>\n<p>\"It looks to me like there’s some exhaustion in that just-straight global reflation theme,\" leading the dollar to trend largely sideways for now, said Daniel Been, head of FX at ANZ in Sydney.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Dollar slips further after disappointing jobs data, sterling shines</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDollar slips further after disappointing jobs data, sterling shines\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-02-19 16:53</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>LONDON, Feb 19 (Reuters) - The U.S. dollar slipped further on Friday and the euro rebounded after disappointing U.S. data dented optimism for a speedy recovery from the COVID-19 pandemic, while sterling edged towards the $1.40 mark.</p>\n<p>The U.S. currency had been rising as a jump in Treasury yields on the back of the so-called reflation trade encouraged investors back into the greenback.</p>\n<p>But an unexpected increase in U.S. weekly jobless claims soured the economic outlook and sent the dollar lower overnight.</p>\n<p>On Friday it traded down 0.1% against a basket of currencies, the dollar index now at 90.474.</p>\n<p>The string of soft labour data is weighing on the dollar even as other indicators have shown resilience, and as President Joe Biden's pandemic relief efforts take shape, including a proposed $1.9 trillion spending package.</p>\n<p>The euro rose 0.2% to $1.2113 . The single currency showed little reaction to German and French flash purchasing manager index data, which unsurprisingly showed a slowdown in activity in January.</p>\n<p>Despite the recent rise in U.S. yields, many analysts think they won't climb too much higher, limiting the benefit for the dollar.</p>\n<p>ING analysts said that \"the rise in rates will be self-regulating, meaning the dollar need not correct too much higher.\"</p>\n<p>They see the greenback index trading down to the 90.10 to 91.05 range&nbsp;Sterling has been the standout performer in 2021 and on Friday rose to $1.3987, an almost three-year high amid Britain's aggressive vaccination programme.</p>\n<p>Given the size of Britain's vital services sector, analysts say the faster it can reopen the economy the better for the currency.</p>\n<p>The dollar bought 105.46 yen , down 0.2% and a continued retreat from the five-month high of 106.225 reached Wednesday.</p>\n<p>Many analysts expect the dollar to weaken over the course of the year as it has traditionally done during times of global economic recovery, though it might take some time to develop.</p>\n<p>\"It looks to me like there’s some exhaustion in that just-straight global reflation theme,\" leading the dollar to trend largely sideways for now, said Daniel Been, head of FX at ANZ in Sydney.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"EUO":"欧元ETF-ProShares两倍做空","FXC":"加元ETF-CurrencyShares","ANZ.AU":"ANZ GROUP HOLDINGS LTD","FXE":"欧元做多ETF-CurrencyShares","FXY":"日元ETF-CurrencyShares","FXA":"澳元ETF-CurrencyShares","YCS":"日元ETF-ProShares两倍做空"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2112149478","content_text":"LONDON, Feb 19 (Reuters) - The U.S. dollar slipped further on Friday and the euro rebounded after disappointing U.S. data dented optimism for a speedy recovery from the COVID-19 pandemic, while sterling edged towards the $1.40 mark.\nThe U.S. currency had been rising as a jump in Treasury yields on the back of the so-called reflation trade encouraged investors back into the greenback.\nBut an unexpected increase in U.S. weekly jobless claims soured the economic outlook and sent the dollar lower overnight.\nOn Friday it traded down 0.1% against a basket of currencies, the dollar index now at 90.474.\nThe string of soft labour data is weighing on the dollar even as other indicators have shown resilience, and as President Joe Biden's pandemic relief efforts take shape, including a proposed $1.9 trillion spending package.\nThe euro rose 0.2% to $1.2113 . The single currency showed little reaction to German and French flash purchasing manager index data, which unsurprisingly showed a slowdown in activity in January.\nDespite the recent rise in U.S. yields, many analysts think they won't climb too much higher, limiting the benefit for the dollar.\nING analysts said that \"the rise in rates will be self-regulating, meaning the dollar need not correct too much higher.\"\nThey see the greenback index trading down to the 90.10 to 91.05 range Sterling has been the standout performer in 2021 and on Friday rose to $1.3987, an almost three-year high amid Britain's aggressive vaccination programme.\nGiven the size of Britain's vital services sector, analysts say the faster it can reopen the economy the better for the currency.\nThe dollar bought 105.46 yen , down 0.2% and a continued retreat from the five-month high of 106.225 reached Wednesday.\nMany analysts expect the dollar to weaken over the course of the year as it has traditionally done during times of global economic recovery, though it might take some time to develop.\n\"It looks to me like there’s some exhaustion in that just-straight global reflation theme,\" leading the dollar to trend largely sideways for now, said Daniel Been, head of FX at ANZ in Sydney.","news_type":1},"isVote":1,"tweetType":1,"viewCount":213,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":384400134,"gmtCreate":1613663491528,"gmtModify":1704883482582,"author":{"id":"3565272871212062","authorId":"3565272871212062","name":"Terrylikabos","avatar":"https://static.tigerbbs.com/abbe3eacbb08c5542185b511b376fdd1","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"H//<a href=\"https://laohu8.com/U/3565701392504395\">@Legostonks</a>:Comment pls","listText":"H//<a href=\"https://laohu8.com/U/3565701392504395\">@Legostonks</a>:Comment pls","text":"H//@Legostonks:Comment pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/384400134","repostId":"1102078157","repostType":4,"repost":{"id":"1102078157","pubTimestamp":1613643052,"share":"https://www.laohu8.com/m/news/1102078157?lang=&edition=full","pubTime":"2021-02-18 18:10","market":"sg","language":"en","title":"Singapore Exchange hopes to list SPACs as early as this year","url":"https://stock-news.laohu8.com/highlight/detail?id=1102078157","media":"Bloomberg","summary":"[SINGAPORE] The Singapore Exchange (SGX)could list blank-cheque companies this year if it gets enoug","content":"<p>[SINGAPORE] The Singapore Exchange (SGX)could list blank-cheque companies&nbsp;this year if it gets enough support from the industry.</p><p>An impending marketconsultation on special purpose acquisition companies&nbsp;(SPAC)this quarter could take some time to get feedback, chief executive officer (CEO) Loh Boon Chye said in an interview Wednesday.</p><p>\"If the market is supportive, we hope to be able to do that sometime this year.\"</p><p>SPACs became a buzzword last year, sprouting by the dozen as the rich and famous - from hedge fund billionaire Bill Ackman to former US Speaker of the House Paul Ryan - and private equity firms rushed to set up new ones.</p><p>SPACs are increasingly seen as an appealing alternative route to public markets because the process avoids the risk and uncertainty of an initial public offering, though they've also been criticised for their structure, where managers - the founders - collect fees as an incentive to find a target and complete a deal. Many blank-cheque companies have turned to Asia to seek takeover targets.</p><p>The concept isn't new to the Singapore exchange. It had initiated a consultation on SPAC listings in 2010 - but there wasn't enough appetite among businesses and investors back then.</p><p>\"The world has changed, capital markets have evolved since then,\" said Mr Loh, who took over as CEO in 2015 after a long career in banking. He added that lower-for-longer interest rates, shorter business cycles, volatile markets and stimulus measures are heightening the need for and the ability to seek capital. SPACs could facilitate that while minimising market risk exposure by providing another avenue for investment, he said.</p><p>SPACs could be a way to revive investor interest in Singapore's stock market. The bourse has struggled to attract big-ticket IPOs over the past few years particularly in hot sectors such as technology. While the market volatility of 2020 was a boon, the value of shares traded remained below its five-year average.</p><p>SGX expects stock market listings this year in various sectors including technology, he said, as it awaits the mega IPO of Thai Beverage's brewery unit. The amount raised in first-time share sales in the city-state slumped to US$914 million last year from US$3.4 billion in 2017, according to data compiled by Bloomberg.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Singapore Exchange hopes to list SPACs as early as this year</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSingapore Exchange hopes to list SPACs as early as this year\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-02-18 18:10 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.businesstimes.com.sg/companies-markets/singapore-exchange-hopes-to-list-spacs-as-early-as-this-year><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>[SINGAPORE] The Singapore Exchange (SGX)could list blank-cheque companies this year if it gets enough support from the industry.An impending marketconsultation on special purpose acquisition companies...</p>\n\n<a href=\"https://www.businesstimes.com.sg/companies-markets/singapore-exchange-hopes-to-list-spacs-as-early-as-this-year\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"STI.SI":"富时新加坡海峡指数"},"source_url":"https://www.businesstimes.com.sg/companies-markets/singapore-exchange-hopes-to-list-spacs-as-early-as-this-year","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102078157","content_text":"[SINGAPORE] The Singapore Exchange (SGX)could list blank-cheque companies this year if it gets enough support from the industry.An impending marketconsultation on special purpose acquisition companies (SPAC)this quarter could take some time to get feedback, chief executive officer (CEO) Loh Boon Chye said in an interview Wednesday.\"If the market is supportive, we hope to be able to do that sometime this year.\"SPACs became a buzzword last year, sprouting by the dozen as the rich and famous - from hedge fund billionaire Bill Ackman to former US Speaker of the House Paul Ryan - and private equity firms rushed to set up new ones.SPACs are increasingly seen as an appealing alternative route to public markets because the process avoids the risk and uncertainty of an initial public offering, though they've also been criticised for their structure, where managers - the founders - collect fees as an incentive to find a target and complete a deal. Many blank-cheque companies have turned to Asia to seek takeover targets.The concept isn't new to the Singapore exchange. It had initiated a consultation on SPAC listings in 2010 - but there wasn't enough appetite among businesses and investors back then.\"The world has changed, capital markets have evolved since then,\" said Mr Loh, who took over as CEO in 2015 after a long career in banking. He added that lower-for-longer interest rates, shorter business cycles, volatile markets and stimulus measures are heightening the need for and the ability to seek capital. SPACs could facilitate that while minimising market risk exposure by providing another avenue for investment, he said.SPACs could be a way to revive investor interest in Singapore's stock market. The bourse has struggled to attract big-ticket IPOs over the past few years particularly in hot sectors such as technology. While the market volatility of 2020 was a boon, the value of shares traded remained below its five-year average.SGX expects stock market listings this year in various sectors including technology, he said, as it awaits the mega IPO of Thai Beverage's brewery unit. The amount raised in first-time share sales in the city-state slumped to US$914 million last year from US$3.4 billion in 2017, according to data compiled by Bloomberg.","news_type":1},"isVote":1,"tweetType":1,"viewCount":30,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":384800726,"gmtCreate":1613633879065,"gmtModify":1704882951266,"author":{"id":"3565272871212062","authorId":"3565272871212062","name":"Terrylikabos","avatar":"https://static.tigerbbs.com/abbe3eacbb08c5542185b511b376fdd1","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Reply to my reply","listText":"Reply to my reply","text":"Reply to my reply","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/384800726","repostId":"384976157","repostType":1,"repost":{"id":384976157,"gmtCreate":1613610777579,"gmtModify":1704882670326,"author":{"id":"3575436061349461","authorId":"3575436061349461","name":"Equinoxcry","avatar":"https://static.tigerbbs.com/1e5f0a63a5d584d30bb2bd55c093cb05","crmLevel":2,"crmLevelSwitch":1,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/GBTC\">$Bitcoin Investment Trust(GBTC)$</a>see yall at mars","listText":"<a href=\"https://laohu8.com/S/GBTC\">$Bitcoin Investment Trust(GBTC)$</a>see yall at mars","text":"$Bitcoin Investment Trust(GBTC)$see yall at mars","images":[{"img":"https://static.tigerbbs.com/92f220844197ee78a78b2f06d7d69acc","width":"1242","height":"2151"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/384976157","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":33,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":384177295,"gmtCreate":1613633768517,"gmtModify":1704882948799,"author":{"id":"3565272871212062","authorId":"3565272871212062","name":"Terrylikabos","avatar":"https://static.tigerbbs.com/abbe3eacbb08c5542185b511b376fdd1","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/VXRT\">$Vaxart, Inc(VXRT)$</a>Pluto","listText":"<a href=\"https://laohu8.com/S/VXRT\">$Vaxart, Inc(VXRT)$</a>Pluto","text":"$Vaxart, Inc(VXRT)$Pluto","images":[{"img":"https://static.tigerbbs.com/08397c707f5691685d0efee68056843b","width":"828","height":"1434"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/384177295","isVote":1,"tweetType":1,"viewCount":46,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":384174442,"gmtCreate":1613633699986,"gmtModify":1704882947646,"author":{"id":"3565272871212062","authorId":"3565272871212062","name":"Terrylikabos","avatar":"https://static.tigerbbs.com/abbe3eacbb08c5542185b511b376fdd1","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"H","listText":"H","text":"H","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/384174442","repostId":"1112683598","repostType":4,"isVote":1,"tweetType":1,"viewCount":19,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":384174591,"gmtCreate":1613633690913,"gmtModify":1704882947811,"author":{"id":"3565272871212062","authorId":"3565272871212062","name":"Terrylikabos","avatar":"https://static.tigerbbs.com/abbe3eacbb08c5542185b511b376fdd1","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"G","listText":"G","text":"G","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/384174591","repostId":"1112683598","repostType":4,"repost":{"id":"1112683598","pubTimestamp":1613632838,"share":"https://www.laohu8.com/m/news/1112683598?lang=&edition=full","pubTime":"2021-02-18 15:20","market":"us","language":"en","title":"Barclays reports 38% slide in net profit for 2020, resumes dividend payouts","url":"https://stock-news.laohu8.com/highlight/detail?id=1112683598","media":"cnbc","summary":"Barclays on Thursday reported a full-year profit of £1.53 billion ($2.11 billion) for 2020, down 38%","content":"<div>\n<p>Barclays on Thursday reported a full-year profit of £1.53 billion ($2.11 billion) for 2020, down 38% from 2019 but outstripping analyst expectations.\nThe British lender posted a fourth-quarter net ...</p>\n\n<a href=\"https://www.cnbc.com/2021/02/18/barclays-q4-2020-earnings.html?&qsearchterm=Barclays\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Barclays reports 38% slide in net profit for 2020, resumes dividend payouts</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBarclays reports 38% slide in net profit for 2020, resumes dividend payouts\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-02-18 15:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/02/18/barclays-q4-2020-earnings.html?&qsearchterm=Barclays><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Barclays on Thursday reported a full-year profit of £1.53 billion ($2.11 billion) for 2020, down 38% from 2019 but outstripping analyst expectations.\nThe British lender posted a fourth-quarter net ...</p>\n\n<a href=\"https://www.cnbc.com/2021/02/18/barclays-q4-2020-earnings.html?&qsearchterm=Barclays\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BARC.UK":"巴克莱银行"},"source_url":"https://www.cnbc.com/2021/02/18/barclays-q4-2020-earnings.html?&qsearchterm=Barclays","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1112683598","content_text":"Barclays on Thursday reported a full-year profit of £1.53 billion ($2.11 billion) for 2020, down 38% from 2019 but outstripping analyst expectations.\nThe British lender posted a fourth-quarter net profit attributable to shareholders of £220 million, despite the U.K. navigating fresh nationwide lockdown measures amid a resurgence of Covid-19.\nAnalysts polled by Refinitiv had expected a fourth-quarter net loss of £44.88 million to bring about a full-year net profit of £1.22 billion.\nThe final earnings report of 2020 followed a surprisingly strong third quarter in which the bank recorded a £611 million net profit.\nFull-year profit in the previous year came in at £2.46 billion with a 2019 fourth-quarter profit of £681 million.\nOther highlights:\n\nCommon equity tier one capital (CET1) ratio was 15.1%, up from 14.6% at the end of the third quarter.\nReturn on tangible equity (RoTE) was 3.2%, down from 5.1% the previous quarter.\nNet interest margin (NIM) was 2.61%, down from 3.09% at the end of 2019.\n\nBarclays also announced that it would resume dividend payments to shareholders of one pence per share and embark on a £700 million share buyback.","news_type":1},"isVote":1,"tweetType":1,"viewCount":67,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":385721841,"gmtCreate":1613577084783,"gmtModify":1704882372818,"author":{"id":"3565272871212062","authorId":"3565272871212062","name":"Terrylikabos","avatar":"https://static.tigerbbs.com/abbe3eacbb08c5542185b511b376fdd1","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"H","listText":"H","text":"H","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":4,"repostSize":0,"link":"https://ttm.financial/post/385721841","repostId":"1109567373","repostType":4,"isVote":1,"tweetType":1,"viewCount":40,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":385723345,"gmtCreate":1613577015087,"gmtModify":1704882371685,"author":{"id":"3565272871212062","authorId":"3565272871212062","name":"Terrylikabos","avatar":"https://static.tigerbbs.com/abbe3eacbb08c5542185b511b376fdd1","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"G//<a href=\"https://laohu8.com/U/3575436061349461\">@Equinoxcry</a>:to ur madder","listText":"G//<a href=\"https://laohu8.com/U/3575436061349461\">@Equinoxcry</a>:to ur madder","text":"G//@Equinoxcry:to ur madder","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/385723345","repostId":"382691888","repostType":1,"repost":{"id":382691888,"gmtCreate":1613438817644,"gmtModify":1704880440150,"author":{"id":"3565272871212062","authorId":"3565272871212062","name":"Terrylikabos","avatar":"https://static.tigerbbs.com/abbe3eacbb08c5542185b511b376fdd1","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"To the moon","listText":"To the moon","text":"To the moon","images":[{"img":"https://static.tigerbbs.com/1d790a109b7883d63d8752476b6062cf","width":"750","height":"1654"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/382691888","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":108,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":382691888,"gmtCreate":1613438817644,"gmtModify":1704880440150,"author":{"id":"3565272871212062","authorId":"3565272871212062","name":"Terrylikabos","avatar":"https://static.tigerbbs.com/abbe3eacbb08c5542185b511b376fdd1","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"To the moon","listText":"To the moon","text":"To the moon","images":[{"img":"https://static.tigerbbs.com/1d790a109b7883d63d8752476b6062cf","width":"750","height":"1654"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":4,"link":"https://ttm.financial/post/382691888","isVote":1,"tweetType":1,"viewCount":173,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":385721841,"gmtCreate":1613577084783,"gmtModify":1704882372818,"author":{"id":"3565272871212062","authorId":"3565272871212062","name":"Terrylikabos","avatar":"https://static.tigerbbs.com/abbe3eacbb08c5542185b511b376fdd1","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"H","listText":"H","text":"H","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":4,"repostSize":0,"link":"https://ttm.financial/post/385721841","repostId":"1109567373","repostType":4,"isVote":1,"tweetType":1,"viewCount":40,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":385846306,"gmtCreate":1613535598305,"gmtModify":1704881740476,"author":{"id":"3565272871212062","authorId":"3565272871212062","name":"Terrylikabos","avatar":"https://static.tigerbbs.com/abbe3eacbb08c5542185b511b376fdd1","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Sell nndm&nbsp;","listText":"Sell nndm&nbsp;","text":"Sell nndm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/385846306","repostId":"1153738409","repostType":4,"repost":{"id":"1153738409","pubTimestamp":1613534408,"share":"https://www.laohu8.com/m/news/1153738409?lang=&edition=full","pubTime":"2021-02-17 12:00","market":"us","language":"en","title":"George Soros Bets on QuantumScape as Palantir Stake Sale Looms","url":"https://stock-news.laohu8.com/highlight/detail?id=1153738409","media":"Bloomberg","summary":"Firm held $280 million QuantumScape stake, exited DraftKingsPalantir position worth $435 million aft","content":"<ul><li>Firm held $280 million QuantumScape stake, exited DraftKings</li><li>Palantir position worth $435 million after stock surge</li></ul><p>Soros Fund Management&nbsp;disclosed a stake in an electric-vehicle-battery startup as the billionaire philanthropist’s investment firm raised tech bets and exited its stake in sports betting company DraftKings Inc.</p><p>George Soros’s firm said it held $4.6 billion in U.S. stocks at the end of the quarter, an $886 million increase from the prior quarterly period, according to a regulatory filing Tuesday.</p><p>Its largest new holding was a $280 million piece of&nbsp;QuantumScape Corp., which is attempting to pioneer solid-state lithium-metal batteries for electric vehicles.</p><p>Soros also disclosed that its holding in Palantir Technologies Inc., the controversial data-mining company co-founded by&nbsp;Peter Thiel, ballooned to $435 million at the end of the year after the stock surged 148% during the quarter.</p><p>Soros originally revealed it owned 18.46 million shares of Palantir in November but quickly issued a&nbsp;statement&nbsp;saying the original investment was made in 2012 and it regretted the decision.</p><p>“SFM made this investment at a time when the negative social consequences of big data were less understood,” the firm said. Soros explained that it had sold all the shares it’s permitted to sell at the time and would keep selling. “SFM does not approve of Palantir’s business practices.”</p><p>A lockup for insiders to sell shares expires this week.</p><p>Soros’s early investment in Palantir was converted into publicly traded shares when the company listed on the New York Stock Exchange in September. The firm, which relies on contracts from government entities including the U.S. Department of Defense and the Central Intelligence Agency for much of its revenue, now has a market valuation of $48.5 billion.</p><p>Soros, 90, has used his vast wealth to become one of the world’s largest funders of groups promoting justice, democracy, human rights and progressive politics through his Open Society Foundations. He’s poured billions into his philanthropic efforts, and most of his firm’s assets now belong to the foundations rather than to the Soros family.</p><p>Over the years the financier’s investments have conflicted with this philanthropic philosophy. His funds have at various times owned stakes in gun manufacturers and coal companies.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>George Soros Bets on QuantumScape as Palantir Stake Sale Looms</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGeorge Soros Bets on QuantumScape as Palantir Stake Sale Looms\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-02-17 12:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-02-17/george-soros-bets-on-quantumscape-as-palantir-stake-sale-looms?srnd=premium-asia><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Firm held $280 million QuantumScape stake, exited DraftKingsPalantir position worth $435 million after stock surgeSoros Fund Management disclosed a stake in an electric-vehicle-battery startup as the ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-02-17/george-soros-bets-on-quantumscape-as-palantir-stake-sale-looms?srnd=premium-asia\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"QS":"Quantumscape Corp.","PLTR":"Palantir Technologies Inc."},"source_url":"https://www.bloomberg.com/news/articles/2021-02-17/george-soros-bets-on-quantumscape-as-palantir-stake-sale-looms?srnd=premium-asia","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1153738409","content_text":"Firm held $280 million QuantumScape stake, exited DraftKingsPalantir position worth $435 million after stock surgeSoros Fund Management disclosed a stake in an electric-vehicle-battery startup as the billionaire philanthropist’s investment firm raised tech bets and exited its stake in sports betting company DraftKings Inc.George Soros’s firm said it held $4.6 billion in U.S. stocks at the end of the quarter, an $886 million increase from the prior quarterly period, according to a regulatory filing Tuesday.Its largest new holding was a $280 million piece of QuantumScape Corp., which is attempting to pioneer solid-state lithium-metal batteries for electric vehicles.Soros also disclosed that its holding in Palantir Technologies Inc., the controversial data-mining company co-founded by Peter Thiel, ballooned to $435 million at the end of the year after the stock surged 148% during the quarter.Soros originally revealed it owned 18.46 million shares of Palantir in November but quickly issued a statement saying the original investment was made in 2012 and it regretted the decision.“SFM made this investment at a time when the negative social consequences of big data were less understood,” the firm said. Soros explained that it had sold all the shares it’s permitted to sell at the time and would keep selling. “SFM does not approve of Palantir’s business practices.”A lockup for insiders to sell shares expires this week.Soros’s early investment in Palantir was converted into publicly traded shares when the company listed on the New York Stock Exchange in September. The firm, which relies on contracts from government entities including the U.S. Department of Defense and the Central Intelligence Agency for much of its revenue, now has a market valuation of $48.5 billion.Soros, 90, has used his vast wealth to become one of the world’s largest funders of groups promoting justice, democracy, human rights and progressive politics through his Open Society Foundations. He’s poured billions into his philanthropic efforts, and most of his firm’s assets now belong to the foundations rather than to the Soros family.Over the years the financier’s investments have conflicted with this philanthropic philosophy. His funds have at various times owned stakes in gun manufacturers and coal companies.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":389237365,"gmtCreate":1612776757957,"gmtModify":1704874030310,"author":{"id":"3565272871212062","authorId":"3565272871212062","name":"Terrylikabos","avatar":"https://static.tigerbbs.com/abbe3eacbb08c5542185b511b376fdd1","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Hi","listText":"Hi","text":"Hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":6,"repostSize":0,"link":"https://ttm.financial/post/389237365","repostId":"1126813487","repostType":4,"repost":{"id":"1126813487","pubTimestamp":1612776380,"share":"https://www.laohu8.com/m/news/1126813487?lang=&edition=full","pubTime":"2021-02-08 17:26","market":"us","language":"en","title":"Moderna Gets Added to Southeast Asia’s Vaccine Arsenal","url":"https://stock-news.laohu8.com/highlight/detail?id=1126813487","media":"Bloomberg","summary":"Moderna Inc. won approval from Singapore for its Covid vaccine and signed a deal to sell doses to th","content":"<p>Moderna Inc. won approval from Singapore for its Covid vaccine and signed a deal to sell doses to the Philippines, becoming the fourth supplier to get regulatory clearance in Southeast Asia.</p>\n<p>Shots by&nbsp;AstraZeneca Plc,Pfizer Inc.-BioNTech SEandSinovac Biotech Ltd.have also been approved by at least one country in the region as inoculations roll out. China and India are giving somefreevaccines to countries like the Philippines, Myanmar and Cambodia.</p>\n<p>Indonesia, Southeast Asia’s biggest and most populous economy,startedits coronavirus vaccination program on Jan. 13, with President Joko Widodo taking thefirst Sinovac jab. More than 784,000 people have received their first dose.</p>\n<p>Wealthier but smaller Singapore -- the first in Southeast Asia to start an official Covid-19 vaccination program -- began inoculatinghealthcareworkers with the Pfizer shot on Dec. 30 and has given the first shot to more than 175,000 people since then. Its prime minister got his first dose on Jan. 8 and has also received his second shot.</p>\n<p>Strategies are evolving across the region as different supply deals are sealed. In the Philippines, President Rodrigo Duterte has said he will take a Russian or Chinese vaccine, but his government’s first approval was for the Pfizer shot.</p>\n<p>Indonesia, which is battling the worst outbreak in Southeast Asia, ended 2020 by switching up who’s on its priority list for shots -- focusing on the elderly first instead of the young as previously announced. It was the earliest in the region to receive a vaccine shipment with a Sinovac supply in December.</p>\n<p>Some countries are also involved in vaccine development and manufacturing, a testament to the variety of strategies employed by Southeast Asian nations. Here’s how the region of more than 650 million people is dealing with differing fiscal, demographic and distribution challenges in their vaccination efforts.</p>\n<p>INDONESIA</p>\n<p>STRATEGY:</p>\n<p>Indonesia seeks to vaccinate 181.5 million people -- about two-thirds of the population -- by March 2022 and President Widodo has called on the cabinet to complete the program by end-2021.</p>\n<p>The nation expects its vaccination program to cost more than 73 trillion rupiah ($5.2 billion). It plans to be able to vaccinate 16 million people a month; the initial phase of inoculations will target more than 1.5 million health workers by the end of February.</p>\n<p>The country will offerfree vaccinesto people. With about 13,000 community health centers and 9,000 hospitals across the country, the government said it will be able to complete its targeted vaccination to achieve mass immunity.</p>\n<ul>\n <li>The world’s fourth most populous nation is banking on both Western and Chinese vaccines, ordering 125.5 million doses from Sinovac, 50 million fromAstraZenecaand another 50 million fromNovavax Inc., while developing 57.6 million of its own Merah Putih</li>\n <li>It is set to get as many as 23.1 million AstraZeneca doses from the GAVI alliance, after requesting 108 million free doses from the global vaccine facility</li>\n <li>Talks are also on with Pfizer for 50 million doses and loaned cold storage facilities for the vaccine</li>\n</ul>\n<p>TIMELINE:</p>\n<p>January, 2021: Sinovac</p>\n<p>(More than 784,000 people have received their first dose.)</p>\n<ul>\n <li>President Widodo got his first dose of the Sinovac shot on Jan. 13 along with public and army representatives, which kicked off Indonesia’s inoculation program</li>\n <li>More than 784,000 people have received their first dose as of Feb. 7, with over 139,000 of them completing their second shot</li>\n <li>China’s Sinovac Biotech shipped 3 million doses of vaccines to the country in December; the local food and drug regulator approved them for emergency use in January, and has since also given the nod for its use among theelderly</li>\n <li>Even before the regulator’s approval, the government started distributing the vaccines to its 34 provinces spread across the world’s largest archipelago</li>\n <li>Sinovac has shipped raw material for 55 million doses to be manufactured by Indonesia’s PT Bio Farma so far. The state firm aims to produce 24 million doses a month</li>\n <li>Bio Farma plans to also produce shots for other countries through the Coalition for Epidemic Preparedness Innovations as early as the fourth quarter, according to Indonesia’s state-owned enterprises ministry. Bio Farma will produce 100 million doses a year for CEPI.</li>\n</ul>\n<p>March, 2021: AstraZeneca</p>\n<ul>\n <li>Indonesia willreceivean initial allocation of between 13.7 million and 23.1 million shots of the AstraZeneca vaccine in the first half through the global Covax initiative</li>\n <li>The vaccines will arrive in stages, with 25%-35% by March and the remainder in the second quarter, according to the government. The shots can be used once the WHO approves the AstraZeneca inoculation for emergency use</li>\n <li>Under a separate deal with the company directly, Indonesia will also get the AstraZeneca vaccines delivered in stages starting from as early as April through the first quarter of 2022. The deal also includes the option for the country to purchase an additional 50 million doses.</li>\n</ul>\n<p>MALAYSIA</p>\n<p>STRATEGY:</p>\n<p>Malaysia is spending $504 million to buy enough shots to cover 26.5 million people, or about 80% of its population. It will start vaccinations from February, according to Prime Minister Muhyiddin Yassin. The government aims to get as many people inoculated within a year of getting the first batch of vaccines in February, Science Minister Khairy Jamaluddin said mid-January.</p>\n<p>The first phase of vaccinations, which will begin by end of February and last until April, will focus on inoculating 500,000 frontline workers, followed by the elderly and high-risk groups between April and August. The third leg will run from May through February 2022 for thoseaged18 and above, the prime minister has said.</p>\n<p>The country will have a “slight extra”stockpileof vaccines as only those 18 years old and above will be inoculated. The excess vaccines will be administered to migrant workers, expatriates, and non-Malaysian residents, the cost of which must be borne by their employers.</p>\n<p>Pfizer vaccines will probably be administered to those in urban areas due to the need for ultra-cold storage, while AstraZeneca vaccines will be deployed to rural areas.</p>\n<ul>\n <li>Malaysia hassecured12.8 million doses of the AstraZeneca vaccine through the Covax facility and directly, enough to inoculate 20% of the country’s population, according to the government</li>\n <li>The country has secured 25 million doses of the Pfizer-BioNTech vaccine, enough to cover 39% of the population</li>\n <li>It has also signed agreements for 12 million doses of China’s Sinovac andup to6.4 million doses of Russia’s Sputnik V vaccine</li>\n <li>Solution Group Bhd.signeda deal to supply the Malaysian government with 3.5 million doses of the Recombinant Ad5-nCoV coronavirus vaccine jointly developed by China’sCanSino Biologics Inc.and Beijing Institute of Biotechnology under the Academy of Military Medical Sciences. The purchase is subject to Solution obtaining product registration and market authorization of the vaccine in the country by April</li>\n <li>The government has also been in talks with Moderna and Johnson &amp; Johnson, according to officials</li>\n <li>Malaysia was due to conduct its first vaccine trial involving 3,000 volunteers in late January. It would be a phase-III trial on a vaccine candidate developed by the Institute of Medical Biology Chinese Academy of Medical Sciences</li>\n <li>Malaysia signed an agreement with China inOctoberto be given priority access to Covid-19 vaccines that China develops.</li>\n</ul>\n<p>TIMELINE:</p>\n<p>February, 2021: Pfizer</p>\n<ul>\n <li>The government secured 12.8 million doses from Pfizer-BioNTech SEin a deal signed in late 2020. The country in January agreed to buy an additional 12.2 million doses</li>\n <li>The first batch is due to arrive on Feb. 26</li>\n <li>The agreement with Pfizer is contingent on the vaccine being approved by the U.S. FDA and Malaysia’s regulator. Malaysia’s National Pharmaceutical Regulatory Agency has granted conditional approval for the vaccine, subject to further information from Pfizer, according to a local media report.</li>\n</ul>\n<p>March/April, 2021: Sinovac</p>\n<ul>\n <li>China’s Sinovac signed an agreement to supply 14 million doses to Malaysia, which may be ready for distribution by the end of March</li>\n <li>As part of this deal,Pharmaniaga Bhd.will supply a total of 12 million doses developed by China’s Sinovac Life Sciences Co. starting in April, the health ministry said in January</li>\n</ul>\n<p>1Q 2021: Sputnik V</p>\n<ul>\n <li>Duopharma Co. (M) will supplyup to6.4 million doses of Russia’s Sputnik V vaccines produced by Gamaleya Research Institute toward the end of March</li>\n</ul>\n<p>2Q 2021: AstraZeneca</p>\n<ul>\n <li>Malaysia hassecured6.4 million doses of the AstraZeneca vaccine through the Covax facility, and another 6.4 million directly</li>\n <li>The first batch is expected in the second quarter of 2021</li>\n</ul>\n<p>MYANMAR</p>\n<p>STRATEGY:</p>\n<p>Myanmar began inoculating its nearly 55 million population at theend ofJanuary. Before the military coup in early February, Aung San Suu Kyi’s administration had said frontline health workers and key government officials would be prioritized in the first phase of vaccinations, to be followed by vulnerable groups such as those older than 65 years.</p>\n<p>Myanmar kicked off vaccination for the general public on Feb. 5, less than a week after the coup. Interim President Myint Swe and officials from all ministries with the rank of director or above were also inoculated, along with the elderly in townships with the highest infection rates, according to the health and sports ministry. Suu Kyi, who is under detention at her residence, was also vaccinated on Feb. 6, according to her party officials.</p>\n<p>Myanmar has vowed to inoculate 38.4 million people older than 18 by the end of this year.</p>\n<p>The previous government had also been cooperating with GAVI, the vaccine alliance, to get shots for 20% of its population through the Covax facility. The Southeast Asian nation was also planning to allow the private sector to import World Health Organization-approved vaccines later this year.</p>\n<ul>\n <li>Other than the AstraZeneca deal it has signed, Myanmar also expected vaccines from Chinese developers to arrive in early 2021, with some doses from the Covax facility expected before April 7.</li>\n</ul>\n<p>TIMELINE:</p>\n<p>January, 2021: AstraZeneca</p>\n<p>(At least 103,142 health workers and volunteers have received shots)</p>\n<ul>\n <li>Myanmarordered30 million doses of the AstraZeneca vaccine produced under license bySerum Institute of Indiato vaccinate 15 million people. The country expects the first batch of this order to arrive in the second week of February</li>\n <li>The country expects an additional 27 million doses from the Covax facility from March</li>\n <li>It nevertheless began vaccinations at the end of January, with a separate 1.5 million doses that were donated by India having arrived Jan. 22</li>\n <li>The nation inoculated 103,142 health workers and volunteers as of Feb. 2, official data show.</li>\n</ul>\n<p>PHILIPPINES</p>\n<p>STRATEGY:</p>\n<p></p>\n<p>The Philippines plans to buy 148 million vaccine doses to inoculateup to70 million people this year, or more than half of its population. But it is negotiating for 178 million doses, enough to inoculate 92 million people, to take into account possible delays in deliveries, according to the finance secretary. The government seeks to vaccinate its entire population of more than 100 million by 2023.</p>\n<p>The nation is eyeing 82.5 billion pesos ($1.7 billion) in vaccinepurchasesthat it plans to fund with financing from multilateral agencies, state-owned banks and companies and bilateral sources, vaccine czar Carlito Galvez said.</p>\n<p>A number of mayors in Metropolitan Manila have separately drafted plans to provide shots to their constituents while waiting for guidelines on how local government units can purchase the vaccines.</p>\n<p>Priority for vaccinations will be given to medical frontliners and workers in industries deemed critical, including low-income groups and those identified as at risk.</p>\n<ul>\n <li>The government has signed deals for 30 million doses of the Covovax vaccine from the Serum Institute of India, and for 17 million doses from AstraZeneca</li>\n <li>It is also in talks with Pfizer, Johnson &amp; Johnson, Sinovac Biotech and Russia’s Gamaleya, according to Galvez</li>\n <li>The Philippines has signed apreliminaryagreement with Moderna following negotiations for as many as 20 million vaccine doses. A final supply deal with Moderna will likely be finished in February</li>\n <li>The nation is also expecting to receive fewer doses from the World Health Organization-backed Covax Facility, Galvez said</li>\n <li>China will donate 500,000 coronavirus vaccine doses to the Philippines</li>\n <li>Pfizer and AstraZeneca have been approved for emergency use by the local FDA, while Gamaleya and Sinovac have applied for the same authorization</li>\n <li>India-basedBharat Biotech International Ltd.has applied for emergency use authorization in the Philippines for its coronavirus vaccine, ABS-CBN News reported, citing the Food and Drug Administration head.</li>\n</ul>\n<p>TIMELINE:</p>\n<p>1Q 2021: Sinovac, Sputnik V</p>\n<ul>\n <li>Vaccinations could start as early as the first quarter of 2021 using Sinovac and Russia’s Sputnik V shots, according to Galvez</li>\n <li>Sinovac, Sputnik V are yet to receive the local FDA approval.</li>\n</ul>\n<p>1Q 2021: Pfizer, AstraZeneca</p>\n<ul>\n <li>At least 5.6 million coronavirus vaccine doses produced by Pfizer-BioNTech and AstraZeneca are expected to arrive in the country within the first quarter through the Covax facility</li>\n <li>The country will also receive as early as May 2.6 million doses of AstraZeneca vaccines purchased by local companies which pooled about800 million pesosto buy 3 million shots.</li>\n</ul>\n<p>SINGAPORE</p>\n<p>STRATEGY:</p>\n<p>The city-state has set aside roughly S$1 billion ($750 million) for vaccines, tapping the likes ofArcturus Therapeutics Holdings Inc.,Moderna, Pfizer and Sinovac for supplies. It estimates it should haveenoughfor its around 5.5 million-strong population by the third quarter of 2021.</p>\n<p>The city-state is prioritizinghealthcareworkers, the elderly and those in jobs or settings where risk of a super-spreading event is high -- such as the construction, marine and process sector, including migrant workers. For the elderly, it began with seniorsaged70 and above.</p>\n<p>Singapore aims to vaccinate the entire adult population, though this will be voluntary. Vaccines will be free for all Singaporeans and long-term residents. It is setting up vaccination centers across the island.</p>\n<p>TIMELINE:</p>\n<p>December, 2020: Pfizer</p>\n<p>(More than 175,000 people given first dose)</p>\n<ul>\n <li>Singapore started vaccinations on Dec. 30, 2020</li>\n <li>Prime Minister Lee Hsien Loong got a first dose of the vaccine on Jan. 8, making him the first member of cabinet to get the coronavirus vaccine shot</li>\n <li>The government said more than 175,000 people have received their first dose of the Covid-19 vaccine as of Feb. 2. Roughly 6,000 have received their second vaccine dose</li>\n <li>The city-state received its first shipment of the Pfizer-BioNTech vaccine on Dec. 21</li>\n <li>Those who have received shots include staff working inhealthcare, frontline and essential services, as well as staff and senior citizens in nursing homes. Some employees at the National Centre for Infectious Diseases have also received their second dose.</li>\n <li>Pilot vaccinations for senior citizensstartedJan. 27.</li>\n</ul>\n<p>March, 2021: Moderna</p>\n<ul>\n <li>Singapore granted interim authorization in February for Moderna’s Covid-19 vaccine to be used in the city-state. Moderna is the second vaccine to be authorized in Singapore</li>\n <li>Singapore’s Ministry of Health said that the country will roll out the Moderna vaccine for individualsaged18 years and above when shipments of the vaccine arrive</li>\n <li>If there are no disruptions to the schedule, the first shipment should arrive around March.</li>\n</ul>\n<p>Early 2021: Arcturus</p>\n<ul>\n <li>Arcturus and Singapore’s Economic Development Board have entered into a supply agreement for the right to buy the ARCT-021 vaccine</li>\n <li>Arcturus may ship the first batch of the Covid-19 vaccine it’s developing with local scientists early 2021</li>\n <li>Results so far show that the vaccine could be effective as a single dose, the Straits Times reported, citing a professor who co-developed the vaccine with Arcturus.</li>\n</ul>\n<p>THAILAND</p>\n<p>STRATEGY:</p>\n<p>Thailand wants to inoculate about 50% of its population by the end of this year.</p>\n<p>It has previously said it will allow private companies and hospitals to import and sell Covid-19 vaccinations as long as those shots have been approved by the nation’s Food and Drug Administration.</p>\n<p>Thailand’s health regulatorendorsedAstraZeneca’s vaccine for emergency use, the health minister said on Jan. 21. It’s the first to win approval in Thailand, which also has ordered shots developed by China’s Sinovac Biotech. Johnson &amp; Johnson has begun the process of seeking domestic approval for its vaccine.</p>\n<p>The Southeast Asian nation plans to distribute shots free of cost, while the imports by private firms would allow those who can afford to pay for inoculations along with non-Thais an alternative pathway to get shots. It won’t procure vaccines through the WHO-backed Covax program for now because theconditionsare too strict.</p>\n<ul>\n <li>The government has so far approved plans to purchase a total of 63 million doses, and the National Vaccine Institute is in talks with several manufacturers for additional supplies for delivery as early as the first quarter. These include 2 million doses from Sinovac and 61 million doses from AstraZeneca</li>\n <li>Not wanting to rely solely on inoculations from abroad, Thailand is also developing its own anti-coronavirus shot</li>\n</ul>\n<p>TIMELINE:</p>\n<p>February, 2021: Sinovac</p>\n<ul>\n <li>The country has said it plans to roll out 200,000 doses of Sinovac vaccines in February, 800,000 in March, and 1 million in April</li>\n</ul>\n<p>February, 2021: AstraZeneca</p>\n<ul>\n <li>Thailand has an advance agreement with AstraZeneca to secure Covid-19 vaccines, which are expected to be distributed by mid-2021, the prime minister has said</li>\n <li>The government expects 50,000 doses to arrive in February</li>\n <li>The government has ordered 61 million shots. The regulatory nod already given will also open the door for imports by private Thai companies for administering the doses to people who can afford to pay</li>\n <li>The country said early January it plans to roll out locally-produced AstraZeneca vaccines in May</li>\n <li>Under agreement with AstraZeneca, Siam Bioscience will produce vaccines at its facilities, and Thailand will receive technology transfer</li>\n <li>Thailand’s prime minister has said the country will supply coronavirus vaccines at “reasonable prices” to Myanmar, Laos, Cambodia and Vietnam when it begins production.</li>\n</ul>\n<p>VIETNAM</p>\n<p>STRATEGY:</p>\n<p>Vietnam is working on developing vaccines and will collaborate with suppliers when doses are available, according to a spokeswoman at the foreign affairs ministry.</p>\n<ul>\n <li>It signed a deal with AstraZeneca to acquire about 30 million doses of the Covid-19 vaccine, Deputy Health Minister Truong Quoc Cuong said during a government briefing in January</li>\n <li>It has also been negotiating to buy vaccines from Pfizer and companies from Russia and China, Cuong said</li>\n <li>Vietnam has four companies and institutes working on developing vaccines.Nanogen Pharmaceutical Biotechnologybegan its human vaccine trials Dec. 17. The Institute of Vaccines and Medical Biologicals started human trials Jan. 21, according to the health ministry.</li>\n</ul>\n<p>TIMELINE:</p>\n<p>1Q 2021: AstraZeneca</p>\n<ul>\n <li>Under the deal with AstraZeneca for about 30 million doses, Vietnam expects to receive vaccines each quarter this year, the deputy health minister said Jan. 4</li>\n <li>In addition, Vietnam expects to receive between 4.9 million to 8.25 million AstraZeneca vaccine doses through the WHO-backed Covax program during the first and second quarters, according to a government posting citing Covax.</li>\n</ul>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Gets Added to Southeast Asia’s Vaccine Arsenal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Gets Added to Southeast Asia’s Vaccine Arsenal\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-02-08 17:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=http://bloomberg.com/news/articles/2021-02-08/moderna-gets-added-to-arsenal-southeast-asia-vaccine-tracker?srnd=markets-vp><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna Inc. won approval from Singapore for its Covid vaccine and signed a deal to sell doses to the Philippines, becoming the fourth supplier to get regulatory clearance in Southeast Asia.\nShots by ...</p>\n\n<a href=\"http://bloomberg.com/news/articles/2021-02-08/moderna-gets-added-to-arsenal-southeast-asia-vaccine-tracker?srnd=markets-vp\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"http://bloomberg.com/news/articles/2021-02-08/moderna-gets-added-to-arsenal-southeast-asia-vaccine-tracker?srnd=markets-vp","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1126813487","content_text":"Moderna Inc. won approval from Singapore for its Covid vaccine and signed a deal to sell doses to the Philippines, becoming the fourth supplier to get regulatory clearance in Southeast Asia.\nShots by AstraZeneca Plc,Pfizer Inc.-BioNTech SEandSinovac Biotech Ltd.have also been approved by at least one country in the region as inoculations roll out. China and India are giving somefreevaccines to countries like the Philippines, Myanmar and Cambodia.\nIndonesia, Southeast Asia’s biggest and most populous economy,startedits coronavirus vaccination program on Jan. 13, with President Joko Widodo taking thefirst Sinovac jab. More than 784,000 people have received their first dose.\nWealthier but smaller Singapore -- the first in Southeast Asia to start an official Covid-19 vaccination program -- began inoculatinghealthcareworkers with the Pfizer shot on Dec. 30 and has given the first shot to more than 175,000 people since then. Its prime minister got his first dose on Jan. 8 and has also received his second shot.\nStrategies are evolving across the region as different supply deals are sealed. In the Philippines, President Rodrigo Duterte has said he will take a Russian or Chinese vaccine, but his government’s first approval was for the Pfizer shot.\nIndonesia, which is battling the worst outbreak in Southeast Asia, ended 2020 by switching up who’s on its priority list for shots -- focusing on the elderly first instead of the young as previously announced. It was the earliest in the region to receive a vaccine shipment with a Sinovac supply in December.\nSome countries are also involved in vaccine development and manufacturing, a testament to the variety of strategies employed by Southeast Asian nations. Here’s how the region of more than 650 million people is dealing with differing fiscal, demographic and distribution challenges in their vaccination efforts.\nINDONESIA\nSTRATEGY:\nIndonesia seeks to vaccinate 181.5 million people -- about two-thirds of the population -- by March 2022 and President Widodo has called on the cabinet to complete the program by end-2021.\nThe nation expects its vaccination program to cost more than 73 trillion rupiah ($5.2 billion). It plans to be able to vaccinate 16 million people a month; the initial phase of inoculations will target more than 1.5 million health workers by the end of February.\nThe country will offerfree vaccinesto people. With about 13,000 community health centers and 9,000 hospitals across the country, the government said it will be able to complete its targeted vaccination to achieve mass immunity.\n\nThe world’s fourth most populous nation is banking on both Western and Chinese vaccines, ordering 125.5 million doses from Sinovac, 50 million fromAstraZenecaand another 50 million fromNovavax Inc., while developing 57.6 million of its own Merah Putih\nIt is set to get as many as 23.1 million AstraZeneca doses from the GAVI alliance, after requesting 108 million free doses from the global vaccine facility\nTalks are also on with Pfizer for 50 million doses and loaned cold storage facilities for the vaccine\n\nTIMELINE:\nJanuary, 2021: Sinovac\n(More than 784,000 people have received their first dose.)\n\nPresident Widodo got his first dose of the Sinovac shot on Jan. 13 along with public and army representatives, which kicked off Indonesia’s inoculation program\nMore than 784,000 people have received their first dose as of Feb. 7, with over 139,000 of them completing their second shot\nChina’s Sinovac Biotech shipped 3 million doses of vaccines to the country in December; the local food and drug regulator approved them for emergency use in January, and has since also given the nod for its use among theelderly\nEven before the regulator’s approval, the government started distributing the vaccines to its 34 provinces spread across the world’s largest archipelago\nSinovac has shipped raw material for 55 million doses to be manufactured by Indonesia’s PT Bio Farma so far. The state firm aims to produce 24 million doses a month\nBio Farma plans to also produce shots for other countries through the Coalition for Epidemic Preparedness Innovations as early as the fourth quarter, according to Indonesia’s state-owned enterprises ministry. Bio Farma will produce 100 million doses a year for CEPI.\n\nMarch, 2021: AstraZeneca\n\nIndonesia willreceivean initial allocation of between 13.7 million and 23.1 million shots of the AstraZeneca vaccine in the first half through the global Covax initiative\nThe vaccines will arrive in stages, with 25%-35% by March and the remainder in the second quarter, according to the government. The shots can be used once the WHO approves the AstraZeneca inoculation for emergency use\nUnder a separate deal with the company directly, Indonesia will also get the AstraZeneca vaccines delivered in stages starting from as early as April through the first quarter of 2022. The deal also includes the option for the country to purchase an additional 50 million doses.\n\nMALAYSIA\nSTRATEGY:\nMalaysia is spending $504 million to buy enough shots to cover 26.5 million people, or about 80% of its population. It will start vaccinations from February, according to Prime Minister Muhyiddin Yassin. The government aims to get as many people inoculated within a year of getting the first batch of vaccines in February, Science Minister Khairy Jamaluddin said mid-January.\nThe first phase of vaccinations, which will begin by end of February and last until April, will focus on inoculating 500,000 frontline workers, followed by the elderly and high-risk groups between April and August. The third leg will run from May through February 2022 for thoseaged18 and above, the prime minister has said.\nThe country will have a “slight extra”stockpileof vaccines as only those 18 years old and above will be inoculated. The excess vaccines will be administered to migrant workers, expatriates, and non-Malaysian residents, the cost of which must be borne by their employers.\nPfizer vaccines will probably be administered to those in urban areas due to the need for ultra-cold storage, while AstraZeneca vaccines will be deployed to rural areas.\n\nMalaysia hassecured12.8 million doses of the AstraZeneca vaccine through the Covax facility and directly, enough to inoculate 20% of the country’s population, according to the government\nThe country has secured 25 million doses of the Pfizer-BioNTech vaccine, enough to cover 39% of the population\nIt has also signed agreements for 12 million doses of China’s Sinovac andup to6.4 million doses of Russia’s Sputnik V vaccine\nSolution Group Bhd.signeda deal to supply the Malaysian government with 3.5 million doses of the Recombinant Ad5-nCoV coronavirus vaccine jointly developed by China’sCanSino Biologics Inc.and Beijing Institute of Biotechnology under the Academy of Military Medical Sciences. The purchase is subject to Solution obtaining product registration and market authorization of the vaccine in the country by April\nThe government has also been in talks with Moderna and Johnson & Johnson, according to officials\nMalaysia was due to conduct its first vaccine trial involving 3,000 volunteers in late January. It would be a phase-III trial on a vaccine candidate developed by the Institute of Medical Biology Chinese Academy of Medical Sciences\nMalaysia signed an agreement with China inOctoberto be given priority access to Covid-19 vaccines that China develops.\n\nTIMELINE:\nFebruary, 2021: Pfizer\n\nThe government secured 12.8 million doses from Pfizer-BioNTech SEin a deal signed in late 2020. The country in January agreed to buy an additional 12.2 million doses\nThe first batch is due to arrive on Feb. 26\nThe agreement with Pfizer is contingent on the vaccine being approved by the U.S. FDA and Malaysia’s regulator. Malaysia’s National Pharmaceutical Regulatory Agency has granted conditional approval for the vaccine, subject to further information from Pfizer, according to a local media report.\n\nMarch/April, 2021: Sinovac\n\nChina’s Sinovac signed an agreement to supply 14 million doses to Malaysia, which may be ready for distribution by the end of March\nAs part of this deal,Pharmaniaga Bhd.will supply a total of 12 million doses developed by China’s Sinovac Life Sciences Co. starting in April, the health ministry said in January\n\n1Q 2021: Sputnik V\n\nDuopharma Co. (M) will supplyup to6.4 million doses of Russia’s Sputnik V vaccines produced by Gamaleya Research Institute toward the end of March\n\n2Q 2021: AstraZeneca\n\nMalaysia hassecured6.4 million doses of the AstraZeneca vaccine through the Covax facility, and another 6.4 million directly\nThe first batch is expected in the second quarter of 2021\n\nMYANMAR\nSTRATEGY:\nMyanmar began inoculating its nearly 55 million population at theend ofJanuary. Before the military coup in early February, Aung San Suu Kyi’s administration had said frontline health workers and key government officials would be prioritized in the first phase of vaccinations, to be followed by vulnerable groups such as those older than 65 years.\nMyanmar kicked off vaccination for the general public on Feb. 5, less than a week after the coup. Interim President Myint Swe and officials from all ministries with the rank of director or above were also inoculated, along with the elderly in townships with the highest infection rates, according to the health and sports ministry. Suu Kyi, who is under detention at her residence, was also vaccinated on Feb. 6, according to her party officials.\nMyanmar has vowed to inoculate 38.4 million people older than 18 by the end of this year.\nThe previous government had also been cooperating with GAVI, the vaccine alliance, to get shots for 20% of its population through the Covax facility. The Southeast Asian nation was also planning to allow the private sector to import World Health Organization-approved vaccines later this year.\n\nOther than the AstraZeneca deal it has signed, Myanmar also expected vaccines from Chinese developers to arrive in early 2021, with some doses from the Covax facility expected before April 7.\n\nTIMELINE:\nJanuary, 2021: AstraZeneca\n(At least 103,142 health workers and volunteers have received shots)\n\nMyanmarordered30 million doses of the AstraZeneca vaccine produced under license bySerum Institute of Indiato vaccinate 15 million people. The country expects the first batch of this order to arrive in the second week of February\nThe country expects an additional 27 million doses from the Covax facility from March\nIt nevertheless began vaccinations at the end of January, with a separate 1.5 million doses that were donated by India having arrived Jan. 22\nThe nation inoculated 103,142 health workers and volunteers as of Feb. 2, official data show.\n\nPHILIPPINES\nSTRATEGY:\n\nThe Philippines plans to buy 148 million vaccine doses to inoculateup to70 million people this year, or more than half of its population. But it is negotiating for 178 million doses, enough to inoculate 92 million people, to take into account possible delays in deliveries, according to the finance secretary. The government seeks to vaccinate its entire population of more than 100 million by 2023.\nThe nation is eyeing 82.5 billion pesos ($1.7 billion) in vaccinepurchasesthat it plans to fund with financing from multilateral agencies, state-owned banks and companies and bilateral sources, vaccine czar Carlito Galvez said.\nA number of mayors in Metropolitan Manila have separately drafted plans to provide shots to their constituents while waiting for guidelines on how local government units can purchase the vaccines.\nPriority for vaccinations will be given to medical frontliners and workers in industries deemed critical, including low-income groups and those identified as at risk.\n\nThe government has signed deals for 30 million doses of the Covovax vaccine from the Serum Institute of India, and for 17 million doses from AstraZeneca\nIt is also in talks with Pfizer, Johnson & Johnson, Sinovac Biotech and Russia’s Gamaleya, according to Galvez\nThe Philippines has signed apreliminaryagreement with Moderna following negotiations for as many as 20 million vaccine doses. A final supply deal with Moderna will likely be finished in February\nThe nation is also expecting to receive fewer doses from the World Health Organization-backed Covax Facility, Galvez said\nChina will donate 500,000 coronavirus vaccine doses to the Philippines\nPfizer and AstraZeneca have been approved for emergency use by the local FDA, while Gamaleya and Sinovac have applied for the same authorization\nIndia-basedBharat Biotech International Ltd.has applied for emergency use authorization in the Philippines for its coronavirus vaccine, ABS-CBN News reported, citing the Food and Drug Administration head.\n\nTIMELINE:\n1Q 2021: Sinovac, Sputnik V\n\nVaccinations could start as early as the first quarter of 2021 using Sinovac and Russia’s Sputnik V shots, according to Galvez\nSinovac, Sputnik V are yet to receive the local FDA approval.\n\n1Q 2021: Pfizer, AstraZeneca\n\nAt least 5.6 million coronavirus vaccine doses produced by Pfizer-BioNTech and AstraZeneca are expected to arrive in the country within the first quarter through the Covax facility\nThe country will also receive as early as May 2.6 million doses of AstraZeneca vaccines purchased by local companies which pooled about800 million pesosto buy 3 million shots.\n\nSINGAPORE\nSTRATEGY:\nThe city-state has set aside roughly S$1 billion ($750 million) for vaccines, tapping the likes ofArcturus Therapeutics Holdings Inc.,Moderna, Pfizer and Sinovac for supplies. It estimates it should haveenoughfor its around 5.5 million-strong population by the third quarter of 2021.\nThe city-state is prioritizinghealthcareworkers, the elderly and those in jobs or settings where risk of a super-spreading event is high -- such as the construction, marine and process sector, including migrant workers. For the elderly, it began with seniorsaged70 and above.\nSingapore aims to vaccinate the entire adult population, though this will be voluntary. Vaccines will be free for all Singaporeans and long-term residents. It is setting up vaccination centers across the island.\nTIMELINE:\nDecember, 2020: Pfizer\n(More than 175,000 people given first dose)\n\nSingapore started vaccinations on Dec. 30, 2020\nPrime Minister Lee Hsien Loong got a first dose of the vaccine on Jan. 8, making him the first member of cabinet to get the coronavirus vaccine shot\nThe government said more than 175,000 people have received their first dose of the Covid-19 vaccine as of Feb. 2. Roughly 6,000 have received their second vaccine dose\nThe city-state received its first shipment of the Pfizer-BioNTech vaccine on Dec. 21\nThose who have received shots include staff working inhealthcare, frontline and essential services, as well as staff and senior citizens in nursing homes. Some employees at the National Centre for Infectious Diseases have also received their second dose.\nPilot vaccinations for senior citizensstartedJan. 27.\n\nMarch, 2021: Moderna\n\nSingapore granted interim authorization in February for Moderna’s Covid-19 vaccine to be used in the city-state. Moderna is the second vaccine to be authorized in Singapore\nSingapore’s Ministry of Health said that the country will roll out the Moderna vaccine for individualsaged18 years and above when shipments of the vaccine arrive\nIf there are no disruptions to the schedule, the first shipment should arrive around March.\n\nEarly 2021: Arcturus\n\nArcturus and Singapore’s Economic Development Board have entered into a supply agreement for the right to buy the ARCT-021 vaccine\nArcturus may ship the first batch of the Covid-19 vaccine it’s developing with local scientists early 2021\nResults so far show that the vaccine could be effective as a single dose, the Straits Times reported, citing a professor who co-developed the vaccine with Arcturus.\n\nTHAILAND\nSTRATEGY:\nThailand wants to inoculate about 50% of its population by the end of this year.\nIt has previously said it will allow private companies and hospitals to import and sell Covid-19 vaccinations as long as those shots have been approved by the nation’s Food and Drug Administration.\nThailand’s health regulatorendorsedAstraZeneca’s vaccine for emergency use, the health minister said on Jan. 21. It’s the first to win approval in Thailand, which also has ordered shots developed by China’s Sinovac Biotech. Johnson & Johnson has begun the process of seeking domestic approval for its vaccine.\nThe Southeast Asian nation plans to distribute shots free of cost, while the imports by private firms would allow those who can afford to pay for inoculations along with non-Thais an alternative pathway to get shots. It won’t procure vaccines through the WHO-backed Covax program for now because theconditionsare too strict.\n\nThe government has so far approved plans to purchase a total of 63 million doses, and the National Vaccine Institute is in talks with several manufacturers for additional supplies for delivery as early as the first quarter. These include 2 million doses from Sinovac and 61 million doses from AstraZeneca\nNot wanting to rely solely on inoculations from abroad, Thailand is also developing its own anti-coronavirus shot\n\nTIMELINE:\nFebruary, 2021: Sinovac\n\nThe country has said it plans to roll out 200,000 doses of Sinovac vaccines in February, 800,000 in March, and 1 million in April\n\nFebruary, 2021: AstraZeneca\n\nThailand has an advance agreement with AstraZeneca to secure Covid-19 vaccines, which are expected to be distributed by mid-2021, the prime minister has said\nThe government expects 50,000 doses to arrive in February\nThe government has ordered 61 million shots. The regulatory nod already given will also open the door for imports by private Thai companies for administering the doses to people who can afford to pay\nThe country said early January it plans to roll out locally-produced AstraZeneca vaccines in May\nUnder agreement with AstraZeneca, Siam Bioscience will produce vaccines at its facilities, and Thailand will receive technology transfer\nThailand’s prime minister has said the country will supply coronavirus vaccines at “reasonable prices” to Myanmar, Laos, Cambodia and Vietnam when it begins production.\n\nVIETNAM\nSTRATEGY:\nVietnam is working on developing vaccines and will collaborate with suppliers when doses are available, according to a spokeswoman at the foreign affairs ministry.\n\nIt signed a deal with AstraZeneca to acquire about 30 million doses of the Covid-19 vaccine, Deputy Health Minister Truong Quoc Cuong said during a government briefing in January\nIt has also been negotiating to buy vaccines from Pfizer and companies from Russia and China, Cuong said\nVietnam has four companies and institutes working on developing vaccines.Nanogen Pharmaceutical Biotechnologybegan its human vaccine trials Dec. 17. The Institute of Vaccines and Medical Biologicals started human trials Jan. 21, according to the health ministry.\n\nTIMELINE:\n1Q 2021: AstraZeneca\n\nUnder the deal with AstraZeneca for about 30 million doses, Vietnam expects to receive vaccines each quarter this year, the deputy health minister said Jan. 4\nIn addition, Vietnam expects to receive between 4.9 million to 8.25 million AstraZeneca vaccine doses through the WHO-backed Covax program during the first and second quarters, according to a government posting citing Covax.","news_type":1},"isVote":1,"tweetType":1,"viewCount":14,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3565253685310367","authorId":"3565253685310367","name":"Xxiiaode","avatar":"https://static.tigerbbs.com/49227d36a02c46c13f9d970f14f5c92c","crmLevel":1,"crmLevelSwitch":0},"content":"Redply my comment","text":"Redply my comment","html":"Redply my comment"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":360542135,"gmtCreate":1613959860527,"gmtModify":1704886156247,"author":{"id":"3565272871212062","authorId":"3565272871212062","name":"Terrylikabos","avatar":"https://static.tigerbbs.com/abbe3eacbb08c5542185b511b376fdd1","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/VXRT\">$Vaxart, Inc(VXRT)$</a>J","listText":"<a href=\"https://laohu8.com/S/VXRT\">$Vaxart, Inc(VXRT)$</a>J","text":"$Vaxart, Inc(VXRT)$J","images":[{"img":"https://static.tigerbbs.com/1ead8d1f455ca58ad2f5dbf61e64f261","width":"828","height":"1434"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":5,"repostSize":0,"link":"https://ttm.financial/post/360542135","isVote":1,"tweetType":1,"viewCount":142,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":385845645,"gmtCreate":1613535722487,"gmtModify":1704881744034,"author":{"id":"3565272871212062","authorId":"3565272871212062","name":"Terrylikabos","avatar":"https://static.tigerbbs.com/abbe3eacbb08c5542185b511b376fdd1","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/VXRT\">$Vaxart, Inc(VXRT)$</a>Diamond hands","listText":"<a href=\"https://laohu8.com/S/VXRT\">$Vaxart, Inc(VXRT)$</a>Diamond hands","text":"$Vaxart, Inc(VXRT)$Diamond hands","images":[{"img":"https://static.tigerbbs.com/69ea328b9dd31b0cf58ce5c2eaaaef6a","width":"828","height":"1434"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":4,"repostSize":0,"link":"https://ttm.financial/post/385845645","isVote":1,"tweetType":1,"viewCount":2,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":385846657,"gmtCreate":1613535608879,"gmtModify":1704881740799,"author":{"id":"3565272871212062","authorId":"3565272871212062","name":"Terrylikabos","avatar":"https://static.tigerbbs.com/abbe3eacbb08c5542185b511b376fdd1","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Sell nndm","listText":"Sell nndm","text":"Sell nndm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/385846657","repostId":"1153738409","repostType":4,"repost":{"id":"1153738409","pubTimestamp":1613534408,"share":"https://www.laohu8.com/m/news/1153738409?lang=&edition=full","pubTime":"2021-02-17 12:00","market":"us","language":"en","title":"George Soros Bets on QuantumScape as Palantir Stake Sale Looms","url":"https://stock-news.laohu8.com/highlight/detail?id=1153738409","media":"Bloomberg","summary":"Firm held $280 million QuantumScape stake, exited DraftKingsPalantir position worth $435 million aft","content":"<ul><li>Firm held $280 million QuantumScape stake, exited DraftKings</li><li>Palantir position worth $435 million after stock surge</li></ul><p>Soros Fund Management&nbsp;disclosed a stake in an electric-vehicle-battery startup as the billionaire philanthropist’s investment firm raised tech bets and exited its stake in sports betting company DraftKings Inc.</p><p>George Soros’s firm said it held $4.6 billion in U.S. stocks at the end of the quarter, an $886 million increase from the prior quarterly period, according to a regulatory filing Tuesday.</p><p>Its largest new holding was a $280 million piece of&nbsp;QuantumScape Corp., which is attempting to pioneer solid-state lithium-metal batteries for electric vehicles.</p><p>Soros also disclosed that its holding in Palantir Technologies Inc., the controversial data-mining company co-founded by&nbsp;Peter Thiel, ballooned to $435 million at the end of the year after the stock surged 148% during the quarter.</p><p>Soros originally revealed it owned 18.46 million shares of Palantir in November but quickly issued a&nbsp;statement&nbsp;saying the original investment was made in 2012 and it regretted the decision.</p><p>“SFM made this investment at a time when the negative social consequences of big data were less understood,” the firm said. Soros explained that it had sold all the shares it’s permitted to sell at the time and would keep selling. “SFM does not approve of Palantir’s business practices.”</p><p>A lockup for insiders to sell shares expires this week.</p><p>Soros’s early investment in Palantir was converted into publicly traded shares when the company listed on the New York Stock Exchange in September. The firm, which relies on contracts from government entities including the U.S. Department of Defense and the Central Intelligence Agency for much of its revenue, now has a market valuation of $48.5 billion.</p><p>Soros, 90, has used his vast wealth to become one of the world’s largest funders of groups promoting justice, democracy, human rights and progressive politics through his Open Society Foundations. He’s poured billions into his philanthropic efforts, and most of his firm’s assets now belong to the foundations rather than to the Soros family.</p><p>Over the years the financier’s investments have conflicted with this philanthropic philosophy. His funds have at various times owned stakes in gun manufacturers and coal companies.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>George Soros Bets on QuantumScape as Palantir Stake Sale Looms</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGeorge Soros Bets on QuantumScape as Palantir Stake Sale Looms\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-02-17 12:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-02-17/george-soros-bets-on-quantumscape-as-palantir-stake-sale-looms?srnd=premium-asia><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Firm held $280 million QuantumScape stake, exited DraftKingsPalantir position worth $435 million after stock surgeSoros Fund Management disclosed a stake in an electric-vehicle-battery startup as the ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-02-17/george-soros-bets-on-quantumscape-as-palantir-stake-sale-looms?srnd=premium-asia\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"QS":"Quantumscape Corp.","PLTR":"Palantir Technologies Inc."},"source_url":"https://www.bloomberg.com/news/articles/2021-02-17/george-soros-bets-on-quantumscape-as-palantir-stake-sale-looms?srnd=premium-asia","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1153738409","content_text":"Firm held $280 million QuantumScape stake, exited DraftKingsPalantir position worth $435 million after stock surgeSoros Fund Management disclosed a stake in an electric-vehicle-battery startup as the billionaire philanthropist’s investment firm raised tech bets and exited its stake in sports betting company DraftKings Inc.George Soros’s firm said it held $4.6 billion in U.S. stocks at the end of the quarter, an $886 million increase from the prior quarterly period, according to a regulatory filing Tuesday.Its largest new holding was a $280 million piece of QuantumScape Corp., which is attempting to pioneer solid-state lithium-metal batteries for electric vehicles.Soros also disclosed that its holding in Palantir Technologies Inc., the controversial data-mining company co-founded by Peter Thiel, ballooned to $435 million at the end of the year after the stock surged 148% during the quarter.Soros originally revealed it owned 18.46 million shares of Palantir in November but quickly issued a statement saying the original investment was made in 2012 and it regretted the decision.“SFM made this investment at a time when the negative social consequences of big data were less understood,” the firm said. Soros explained that it had sold all the shares it’s permitted to sell at the time and would keep selling. “SFM does not approve of Palantir’s business practices.”A lockup for insiders to sell shares expires this week.Soros’s early investment in Palantir was converted into publicly traded shares when the company listed on the New York Stock Exchange in September. The firm, which relies on contracts from government entities including the U.S. Department of Defense and the Central Intelligence Agency for much of its revenue, now has a market valuation of $48.5 billion.Soros, 90, has used his vast wealth to become one of the world’s largest funders of groups promoting justice, democracy, human rights and progressive politics through his Open Society Foundations. He’s poured billions into his philanthropic efforts, and most of his firm’s assets now belong to the foundations rather than to the Soros family.Over the years the financier’s investments have conflicted with this philanthropic philosophy. His funds have at various times owned stakes in gun manufacturers and coal companies.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":369665901,"gmtCreate":1614040639003,"gmtModify":1704887190605,"author":{"id":"3565272871212062","authorId":"3565272871212062","name":"Terrylikabos","avatar":"https://static.tigerbbs.com/abbe3eacbb08c5542185b511b376fdd1","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Hvgvg","listText":"Hvgvg","text":"Hvgvg","images":[{"img":"https://static.tigerbbs.com/c18ece95df0f3f0f3c4b0de43c73711c","width":"750","height":"1762"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":4,"repostSize":0,"link":"https://ttm.financial/post/369665901","isVote":1,"tweetType":1,"viewCount":123,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":369662049,"gmtCreate":1614040549681,"gmtModify":1704887189143,"author":{"id":"3565272871212062","authorId":"3565272871212062","name":"Terrylikabos","avatar":"https://static.tigerbbs.com/abbe3eacbb08c5542185b511b376fdd1","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"H","listText":"H","text":"H","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/369662049","repostId":"1100241886","repostType":4,"repost":{"id":"1100241886","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1613990937,"share":"https://www.laohu8.com/m/news/1100241886?lang=&edition=full","pubTime":"2021-02-22 18:48","market":"fut","language":"en","title":"Bitcoin slips sharply from record highs","url":"https://stock-news.laohu8.com/highlight/detail?id=1100241886","media":"Reuters","summary":"Bitcoin fell sharply on Monday after surging to a record $58,354 a day earlier, as a selloff in glob","content":"<p>Bitcoin fell sharply on Monday after surging to a record $58,354 a day earlier, as a selloff in global equities curbed risk appetite.</p>\n<p>The most popular cryptocurrency rallied over the weekend to record levels, almost doubling year-to-date. It hit a market capitalisation of $1 trillion on Friday.</p>\n<p>Bitcoin’s gains have been fueled by signs it is gaining acceptance among mainstream investors and companies, from Tesla Inc and Mastercard Inc to BNY Mellon.</p>\n<p>It fell as much as 6% on Monday, and was last trading down 4.4% at $54,941. Rival cryptocurrency ether fell 7% to $1,798 after also hitting a record high on Saturday.</p>\n<p>Traders said the move was largely technical, and not tied to any particular news catalyst.</p>\n<p>“We did finally see some momentum gathering over the weekend, but weekend rallies haven’t been sustainable lately,” said Joseph Edwards of Enigma Securities, a cryptocurrency broker in London.</p>\n<p>“We do tend to think that there’s a good chance of a down week and small correction coming in off of this, although it does little to dull medium-term prospects.”</p>\n<p>Tesla boss Elon Musk, whose tweets on bitcoin have added fuel to the cryptocurrency’s rally, said on Saturday the price of bitcoin and ethereum seemed high.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bitcoin slips sharply from record highs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBitcoin slips sharply from record highs\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-02-22 18:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Bitcoin fell sharply on Monday after surging to a record $58,354 a day earlier, as a selloff in global equities curbed risk appetite.</p>\n<p>The most popular cryptocurrency rallied over the weekend to record levels, almost doubling year-to-date. It hit a market capitalisation of $1 trillion on Friday.</p>\n<p>Bitcoin’s gains have been fueled by signs it is gaining acceptance among mainstream investors and companies, from Tesla Inc and Mastercard Inc to BNY Mellon.</p>\n<p>It fell as much as 6% on Monday, and was last trading down 4.4% at $54,941. Rival cryptocurrency ether fell 7% to $1,798 after also hitting a record high on Saturday.</p>\n<p>Traders said the move was largely technical, and not tied to any particular news catalyst.</p>\n<p>“We did finally see some momentum gathering over the weekend, but weekend rallies haven’t been sustainable lately,” said Joseph Edwards of Enigma Securities, a cryptocurrency broker in London.</p>\n<p>“We do tend to think that there’s a good chance of a down week and small correction coming in off of this, although it does little to dull medium-term prospects.”</p>\n<p>Tesla boss Elon Musk, whose tweets on bitcoin have added fuel to the cryptocurrency’s rally, said on Saturday the price of bitcoin and ethereum seemed high.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GBTC":"Grayscale Bitcoin Trust"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1100241886","content_text":"Bitcoin fell sharply on Monday after surging to a record $58,354 a day earlier, as a selloff in global equities curbed risk appetite.\nThe most popular cryptocurrency rallied over the weekend to record levels, almost doubling year-to-date. It hit a market capitalisation of $1 trillion on Friday.\nBitcoin’s gains have been fueled by signs it is gaining acceptance among mainstream investors and companies, from Tesla Inc and Mastercard Inc to BNY Mellon.\nIt fell as much as 6% on Monday, and was last trading down 4.4% at $54,941. Rival cryptocurrency ether fell 7% to $1,798 after also hitting a record high on Saturday.\nTraders said the move was largely technical, and not tied to any particular news catalyst.\n“We did finally see some momentum gathering over the weekend, but weekend rallies haven’t been sustainable lately,” said Joseph Edwards of Enigma Securities, a cryptocurrency broker in London.\n“We do tend to think that there’s a good chance of a down week and small correction coming in off of this, although it does little to dull medium-term prospects.”\nTesla boss Elon Musk, whose tweets on bitcoin have added fuel to the cryptocurrency’s rally, said on Saturday the price of bitcoin and ethereum seemed high.","news_type":1},"isVote":1,"tweetType":1,"viewCount":407,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":382248312,"gmtCreate":1613458103936,"gmtModify":1704880667251,"author":{"id":"3565272871212062","authorId":"3565272871212062","name":"Terrylikabos","avatar":"https://static.tigerbbs.com/abbe3eacbb08c5542185b511b376fdd1","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Reply my comment//<a href=\"https://laohu8.com/U/3565253685310367\">@Xxiiaode</a>:Hi&nbsp;","listText":"Reply my comment//<a href=\"https://laohu8.com/U/3565253685310367\">@Xxiiaode</a>:Hi&nbsp;","text":"Reply my comment//@Xxiiaode:Hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/382248312","repostId":"2110026963","repostType":4,"repost":{"id":"2110026963","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1613109422,"share":"https://www.laohu8.com/m/news/2110026963?lang=&edition=full","pubTime":"2021-02-12 13:57","market":"us","language":"en","title":"Here's the formula for spotting genuinely undervalued companies, claims this investment house","url":"https://stock-news.laohu8.com/highlight/detail?id=2110026963","media":"Dow Jones","summary":"The growth stock vs. value stock dichotomy doesn't make sense, says ValuAnalysis. For most of 2020, investors poured money into names like online retailer Amazon $$, electric-car maker Tesla $$, and e-commerce platform Shopify -- \"growth\" stocks that kept indexes afloat in a turbulent year that hammered share prices across the board.But when news broke in early November 2020 that drug company Pfizer $$ and its partner BioNTech $$ had developed an effective vaccine against COVID-19, something pro","content":"<p>MW Here's the formula for spotting genuinely undervalued companies, claims this investment house</p>\n<p>The growth stock vs. value stock dichotomy doesn't make sense, says ValuAnalysis</p>\n<p>For most of 2020, investors poured money into names like online retailer Amazon <a href=\"https://laohu8.com/S/AMZN\">$(AMZN)$</a>, electric-car maker Tesla <a href=\"https://laohu8.com/S/TSLA\">$(TSLA)$</a>, and e-commerce platform Shopify (SHOP.T)-- \"growth\" stocks that kept indexes afloat in a turbulent year that hammered share prices across the board.</p>\n<p>But when news broke in early November 2020 that drug company Pfizer <a href=\"https://laohu8.com/S/PFE\">$(PFE)$</a> and its partner BioNTech <a href=\"https://laohu8.com/S/BNTX\">$(BNTX)$</a> had developed an effective vaccine against COVID-19, something profound happened in financial markets.</p>\n<p>Investors rotated out of these investments in favor of \"value\" stocks hammered by the COVID-19 pandemic, like airlines.</p>\n<p>This rotation was based on an essential concept in investing: There are some stocks that are clearly undervalued based on standard metrics.</p>\n<p>And it is completely flawed, according to research from ValuAnalysis, a London-based fund manager and equity investment boutique, which specializes in valuation.</p>\n<p>The apparent difference between growth stocks and value stocks is that the former is overvalued based on fundamental metrics while the latter is undervalued.</p>\n<p>\"Everyone knows that this thing doesn't make any sense because growth is not the opposite of value,\" Pascal Costantini, who led the research at ValuAnalysis, tells MarketWatch.</p>\n<p>\"It should be high-growth and low-growth, and I can imagine that, somewhere in an office, some guy said 'well this is not catchy enough, so how about growth and value?'\"</p>\n<p>Analysts and investors use metrics like the price-to-earnings ratio, or price multiple, to value stocks. ValuAnalysis uses price as a multiple of normalized net free cash flow as its benchmark, and identifies the imaginary dividing line between value and growth stocks at 35x, which is the market median.</p>\n<p>The value vs. growth divide would suggest that a company trading at a 17x earnings multiple is undervalued. In reality, ValuAnalysis says it is likely a company that won't grow.</p>\n<p>In reality, a stock's value is based on the company's ability to grow free cash flow in an environment where the cost of capital is 5% to 6%. So if a company isn't outpacing that by improving revenue and margins, the multiple won't increase and the stock price is unlikely to rise.</p>\n<p>Stocks that are actually undervalued will trade between 25x and 35x free cash flow, Costantini says, outpacing the cost of capital but not breaking past the market median.</p>\n<p>To have potential, a company's accumulation of assets or revenue growth must outpace increases in global gross domestic product, and ideally show signs of accelerating. There must also be an increase in operational leverage through revenue or margins. A decrease in the risk premium, such as through advances in controlling carbon emissions, helps.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's the formula for spotting genuinely undervalued companies, claims this investment house</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's the formula for spotting genuinely undervalued companies, claims this investment house\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-02-12 13:57</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>MW Here's the formula for spotting genuinely undervalued companies, claims this investment house</p>\n<p>The growth stock vs. value stock dichotomy doesn't make sense, says ValuAnalysis</p>\n<p>For most of 2020, investors poured money into names like online retailer Amazon <a href=\"https://laohu8.com/S/AMZN\">$(AMZN)$</a>, electric-car maker Tesla <a href=\"https://laohu8.com/S/TSLA\">$(TSLA)$</a>, and e-commerce platform Shopify (SHOP.T)-- \"growth\" stocks that kept indexes afloat in a turbulent year that hammered share prices across the board.</p>\n<p>But when news broke in early November 2020 that drug company Pfizer <a href=\"https://laohu8.com/S/PFE\">$(PFE)$</a> and its partner BioNTech <a href=\"https://laohu8.com/S/BNTX\">$(BNTX)$</a> had developed an effective vaccine against COVID-19, something profound happened in financial markets.</p>\n<p>Investors rotated out of these investments in favor of \"value\" stocks hammered by the COVID-19 pandemic, like airlines.</p>\n<p>This rotation was based on an essential concept in investing: There are some stocks that are clearly undervalued based on standard metrics.</p>\n<p>And it is completely flawed, according to research from ValuAnalysis, a London-based fund manager and equity investment boutique, which specializes in valuation.</p>\n<p>The apparent difference between growth stocks and value stocks is that the former is overvalued based on fundamental metrics while the latter is undervalued.</p>\n<p>\"Everyone knows that this thing doesn't make any sense because growth is not the opposite of value,\" Pascal Costantini, who led the research at ValuAnalysis, tells MarketWatch.</p>\n<p>\"It should be high-growth and low-growth, and I can imagine that, somewhere in an office, some guy said 'well this is not catchy enough, so how about growth and value?'\"</p>\n<p>Analysts and investors use metrics like the price-to-earnings ratio, or price multiple, to value stocks. ValuAnalysis uses price as a multiple of normalized net free cash flow as its benchmark, and identifies the imaginary dividing line between value and growth stocks at 35x, which is the market median.</p>\n<p>The value vs. growth divide would suggest that a company trading at a 17x earnings multiple is undervalued. In reality, ValuAnalysis says it is likely a company that won't grow.</p>\n<p>In reality, a stock's value is based on the company's ability to grow free cash flow in an environment where the cost of capital is 5% to 6%. So if a company isn't outpacing that by improving revenue and margins, the multiple won't increase and the stock price is unlikely to rise.</p>\n<p>Stocks that are actually undervalued will trade between 25x and 35x free cash flow, Costantini says, outpacing the cost of capital but not breaking past the market median.</p>\n<p>To have potential, a company's accumulation of assets or revenue growth must outpace increases in global gross domestic product, and ideally show signs of accelerating. There must also be an increase in operational leverage through revenue or margins. A decrease in the risk premium, such as through advances in controlling carbon emissions, helps.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/15e20574f8fb568333181d61bb200086","relate_stocks":{"PFE":"辉瑞","AMZN":"亚马逊","TSLA":"特斯拉"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2110026963","content_text":"MW Here's the formula for spotting genuinely undervalued companies, claims this investment house\nThe growth stock vs. value stock dichotomy doesn't make sense, says ValuAnalysis\nFor most of 2020, investors poured money into names like online retailer Amazon $(AMZN)$, electric-car maker Tesla $(TSLA)$, and e-commerce platform Shopify (SHOP.T)-- \"growth\" stocks that kept indexes afloat in a turbulent year that hammered share prices across the board.\nBut when news broke in early November 2020 that drug company Pfizer $(PFE)$ and its partner BioNTech $(BNTX)$ had developed an effective vaccine against COVID-19, something profound happened in financial markets.\nInvestors rotated out of these investments in favor of \"value\" stocks hammered by the COVID-19 pandemic, like airlines.\nThis rotation was based on an essential concept in investing: There are some stocks that are clearly undervalued based on standard metrics.\nAnd it is completely flawed, according to research from ValuAnalysis, a London-based fund manager and equity investment boutique, which specializes in valuation.\nThe apparent difference between growth stocks and value stocks is that the former is overvalued based on fundamental metrics while the latter is undervalued.\n\"Everyone knows that this thing doesn't make any sense because growth is not the opposite of value,\" Pascal Costantini, who led the research at ValuAnalysis, tells MarketWatch.\n\"It should be high-growth and low-growth, and I can imagine that, somewhere in an office, some guy said 'well this is not catchy enough, so how about growth and value?'\"\nAnalysts and investors use metrics like the price-to-earnings ratio, or price multiple, to value stocks. ValuAnalysis uses price as a multiple of normalized net free cash flow as its benchmark, and identifies the imaginary dividing line between value and growth stocks at 35x, which is the market median.\nThe value vs. growth divide would suggest that a company trading at a 17x earnings multiple is undervalued. In reality, ValuAnalysis says it is likely a company that won't grow.\nIn reality, a stock's value is based on the company's ability to grow free cash flow in an environment where the cost of capital is 5% to 6%. So if a company isn't outpacing that by improving revenue and margins, the multiple won't increase and the stock price is unlikely to rise.\nStocks that are actually undervalued will trade between 25x and 35x free cash flow, Costantini says, outpacing the cost of capital but not breaking past the market median.\nTo have potential, a company's accumulation of assets or revenue growth must outpace increases in global gross domestic product, and ideally show signs of accelerating. There must also be an increase in operational leverage through revenue or margins. A decrease in the risk premium, such as through advances in controlling carbon emissions, helps.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":382693531,"gmtCreate":1613438731923,"gmtModify":1704880439159,"author":{"id":"3565272871212062","authorId":"3565272871212062","name":"Terrylikabos","avatar":"https://static.tigerbbs.com/abbe3eacbb08c5542185b511b376fdd1","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Hi","listText":"Hi","text":"Hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/382693531","repostId":"2110904027","repostType":4,"isVote":1,"tweetType":1,"viewCount":1,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":380448831,"gmtCreate":1612580009723,"gmtModify":1704873046941,"author":{"id":"3565272871212062","authorId":"3565272871212062","name":"Terrylikabos","avatar":"https://static.tigerbbs.com/abbe3eacbb08c5542185b511b376fdd1","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"H","listText":"H","text":"H","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":4,"repostSize":0,"link":"https://ttm.financial/post/380448831","repostId":"1142907763","repostType":4,"repost":{"id":"1142907763","pubTimestamp":1612514969,"share":"https://www.laohu8.com/m/news/1142907763?lang=&edition=full","pubTime":"2021-02-05 16:49","market":"us","language":"en","title":"Luckin Coffee’s Restructuring Efforts Move Forward with Commencement of its Chapter 15 Case in the United States","url":"https://stock-news.laohu8.com/highlight/detail?id=1142907763","media":"globenewswire","summary":"Coordination between the Cayman Court and the U.S. Bankruptcy Court to Protect the Interests of Stak","content":"<p><i>Coordination between the Cayman Court and the U.S. Bankruptcy Court to Protect the Interests of Stakeholders and Facilitate LuckinCoffee’s Restructuring of its Financial Obligations</i></p>\n<p><i>All Company Stores Remain Open and Serving Customers in China; No Material Impact on Daily Operations Expected</i></p>\n<p><i>Company Continues to Meet Trade Obligations in the Ordinary Course of Business, Including Paying Suppliers, Vendors and Employees</i></p>\n<p>BEIJING, Feb. 05, 2021 (GLOBE NEWSWIRE) -- The Joint Provisional Liquidators (the “JPLs”) of Luckin Coffee Inc. (the “Company”) (OTC:LKNCY), Alexander Lawson of Alvarez &amp; Marsal Cayman Islands Limited and Wing Sze Tiffany Wong of Alvarez &amp; Marsal Asia Limited, today filed a verified petition under chapter 15 of title 11 of the United States Code (the “Chapter 15 Petition”) with the United States Bankruptcy Court for the Southern District of New York (the “U.S. Bankruptcy Court”). The Chapter 15 Petition seeks, among other things, recognition in the United States of the Company’s provisional liquidation pending before the Grand Court of the Cayman Islands (the “Cayman Court”), Financial Services Division, Cause No. 157 of 2020 (ASCJ) (the “Cayman Proceeding”)1and related relief.</p>\n<p>The Company is negotiating with its stakeholders regarding the restructuring of the Company’s financial obligations, to strengthen the Company’s balance sheet and enable it to emerge from the Cayman Proceeding as a going concern, for the benefit of all stakeholders. The relief sought in the Chapter 15 Petition is an important component of the Company’s restructuring. This relief will promote centralized administration of the Company’s assets by permitting coordination between the Cayman Court and the U.S. Bankruptcy Court, to protect the interests of stakeholders while facilitating the Company’s restructuring.</p>\n<p>All Company stores remain open for business, offering products with high quality, affordability and convenience to its customers in China. The filing of the Chapter 15 Petition is not expected to materially impact the Company’s day-to-day operations. The Company continues to meet its trade obligations in the ordinary course of business, including paying suppliers, vendors and employees.</p>\n<p>______</p>\n<p>1The Company previously disclosed the commencement of the Cayman Proceeding on July 15, 2020.</p>\n<p><b>Safe Harbor Statement</b></p>\n<p>This announcement contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “potential,” “continue,” “ongoing,” “targets,” “guidance” and similar statements. The Company may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the “SEC”), in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties, including Joint Provisional Liquidators. Any statements that are not historical facts, including statements about the Company’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: the expense, timing and outcome of existing or future legal and governmental proceedings, investigations in connection with the Company; the outcome and effect of the ongoing restructuring of the Company’s financial obligations; the Company’s growth strategies; its future business development, results of operations and financial condition; the effect of the non-reliance identified in, and the resultant restatement of, certain of the Company’s previously issued financial results; the timing of the completion or outcome of the audit of the Company’s financial statements; the effectiveness of its internal control; its ability to retain and attract its customers; its ability to maintain and enhance the recognition and reputation of its brand; its ability to maintain and improve quality control policies and measures; its ability to establish and maintain relationships with its suppliers and business partners; trends and competition in China’s coffee industry or China’s food and beverage sector in general; changes in its revenues and certain cost or expense items; the expected growth of China’s coffee industry or China’s food and beverage sector in general; PRC governmental policies and regulations relating to the Company’s industry; the potential effects of COVID-19; and general economic and business conditions globally and in China and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks, uncertainties or factors is included in the Company’s filings with the SEC. All information provided in this press release and in the attachments is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.</p>\n<p><b>About Luckin Coffee Inc.</b></p>\n<p>Luckin Coffee Inc.&nbsp;(OTC:LKNCY) has pioneered a technology-driven retail network to provide coffee and other products of high quality, high affordability, and high convenience to customers. Empowered by big data analytics, AI, and proprietary technologies, the Company pursues its mission to be part of everyone’s everyday life, starting with coffee. The Company was founded in 2017 and is based in&nbsp;China. </p>","source":"lsy1573717531661","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Luckin Coffee’s Restructuring Efforts Move Forward with Commencement of its Chapter 15 Case in the United States</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLuckin Coffee’s Restructuring Efforts Move Forward with Commencement of its Chapter 15 Case in the United States\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-02-05 16:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=http://www.globenewswire.com/news-release/2021/02/05/2170477/0/en/Luckin-Coffee-s-Restructuring-Efforts-Move-Forward-with-Commencement-of-its-Chapter-15-Case-in-the-United-States.html><strong>globenewswire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Coordination between the Cayman Court and the U.S. Bankruptcy Court to Protect the Interests of Stakeholders and Facilitate LuckinCoffee’s Restructuring of its Financial Obligations\nAll Company Stores...</p>\n\n<a href=\"http://www.globenewswire.com/news-release/2021/02/05/2170477/0/en/Luckin-Coffee-s-Restructuring-Efforts-Move-Forward-with-Commencement-of-its-Chapter-15-Case-in-the-United-States.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/3d12f820102df1859c1d25e4011ee104","relate_stocks":{"LKNCY":"瑞幸咖啡","LK":"瑞幸咖啡"},"source_url":"http://www.globenewswire.com/news-release/2021/02/05/2170477/0/en/Luckin-Coffee-s-Restructuring-Efforts-Move-Forward-with-Commencement-of-its-Chapter-15-Case-in-the-United-States.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1142907763","content_text":"Coordination between the Cayman Court and the U.S. Bankruptcy Court to Protect the Interests of Stakeholders and Facilitate LuckinCoffee’s Restructuring of its Financial Obligations\nAll Company Stores Remain Open and Serving Customers in China; No Material Impact on Daily Operations Expected\nCompany Continues to Meet Trade Obligations in the Ordinary Course of Business, Including Paying Suppliers, Vendors and Employees\nBEIJING, Feb. 05, 2021 (GLOBE NEWSWIRE) -- The Joint Provisional Liquidators (the “JPLs”) of Luckin Coffee Inc. (the “Company”) (OTC:LKNCY), Alexander Lawson of Alvarez & Marsal Cayman Islands Limited and Wing Sze Tiffany Wong of Alvarez & Marsal Asia Limited, today filed a verified petition under chapter 15 of title 11 of the United States Code (the “Chapter 15 Petition”) with the United States Bankruptcy Court for the Southern District of New York (the “U.S. Bankruptcy Court”). The Chapter 15 Petition seeks, among other things, recognition in the United States of the Company’s provisional liquidation pending before the Grand Court of the Cayman Islands (the “Cayman Court”), Financial Services Division, Cause No. 157 of 2020 (ASCJ) (the “Cayman Proceeding”)1and related relief.\nThe Company is negotiating with its stakeholders regarding the restructuring of the Company’s financial obligations, to strengthen the Company’s balance sheet and enable it to emerge from the Cayman Proceeding as a going concern, for the benefit of all stakeholders. The relief sought in the Chapter 15 Petition is an important component of the Company’s restructuring. This relief will promote centralized administration of the Company’s assets by permitting coordination between the Cayman Court and the U.S. Bankruptcy Court, to protect the interests of stakeholders while facilitating the Company’s restructuring.\nAll Company stores remain open for business, offering products with high quality, affordability and convenience to its customers in China. The filing of the Chapter 15 Petition is not expected to materially impact the Company’s day-to-day operations. The Company continues to meet its trade obligations in the ordinary course of business, including paying suppliers, vendors and employees.\n______\n1The Company previously disclosed the commencement of the Cayman Proceeding on July 15, 2020.\nSafe Harbor Statement\nThis announcement contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “potential,” “continue,” “ongoing,” “targets,” “guidance” and similar statements. The Company may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the “SEC”), in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties, including Joint Provisional Liquidators. Any statements that are not historical facts, including statements about the Company’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: the expense, timing and outcome of existing or future legal and governmental proceedings, investigations in connection with the Company; the outcome and effect of the ongoing restructuring of the Company’s financial obligations; the Company’s growth strategies; its future business development, results of operations and financial condition; the effect of the non-reliance identified in, and the resultant restatement of, certain of the Company’s previously issued financial results; the timing of the completion or outcome of the audit of the Company’s financial statements; the effectiveness of its internal control; its ability to retain and attract its customers; its ability to maintain and enhance the recognition and reputation of its brand; its ability to maintain and improve quality control policies and measures; its ability to establish and maintain relationships with its suppliers and business partners; trends and competition in China’s coffee industry or China’s food and beverage sector in general; changes in its revenues and certain cost or expense items; the expected growth of China’s coffee industry or China’s food and beverage sector in general; PRC governmental policies and regulations relating to the Company’s industry; the potential effects of COVID-19; and general economic and business conditions globally and in China and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks, uncertainties or factors is included in the Company’s filings with the SEC. All information provided in this press release and in the attachments is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.\nAbout Luckin Coffee Inc.\nLuckin Coffee Inc. (OTC:LKNCY) has pioneered a technology-driven retail network to provide coffee and other products of high quality, high affordability, and high convenience to customers. Empowered by big data analytics, AI, and proprietary technologies, the Company pursues its mission to be part of everyone’s everyday life, starting with coffee. The Company was founded in 2017 and is based in China.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":360024678,"gmtCreate":1613798682094,"gmtModify":1704885175357,"author":{"id":"3565272871212062","authorId":"3565272871212062","name":"Terrylikabos","avatar":"https://static.tigerbbs.com/abbe3eacbb08c5542185b511b376fdd1","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/VXRT\">$Vaxart, Inc(VXRT)$</a>Hi","listText":"<a href=\"https://laohu8.com/S/VXRT\">$Vaxart, Inc(VXRT)$</a>Hi","text":"$Vaxart, Inc(VXRT)$Hi","images":[{"img":"https://static.tigerbbs.com/1ead8d1f455ca58ad2f5dbf61e64f261","width":"828","height":"1434"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":1,"link":"https://ttm.financial/post/360024678","isVote":1,"tweetType":1,"viewCount":319,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":360026705,"gmtCreate":1613798460707,"gmtModify":1704885172122,"author":{"id":"3565272871212062","authorId":"3565272871212062","name":"Terrylikabos","avatar":"https://static.tigerbbs.com/abbe3eacbb08c5542185b511b376fdd1","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"H","listText":"H","text":"H","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/360026705","repostId":"1143100356","repostType":4,"repost":{"id":"1143100356","pubTimestamp":1613792715,"share":"https://www.laohu8.com/m/news/1143100356?lang=&edition=full","pubTime":"2021-02-20 11:45","market":"us","language":"en","title":"2 Top Tech Stocks to Buy Now for Big Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=1143100356","media":"Nasdaq","summary":"The S&P 500 and the tech-heavy Nasdaq slipped during the week of February 15, after they closed at new records last week. Despite the drop in some of the big tech names such as AppleAAPL, FacebookFB, MicrosoftMSFT, Zoom VideoZM, and countless others this week, the market fundamentals remain relatively strong.Ebbs and flows, as well as pullbacks and corrections are healthy aspects of the market. And they need not be viewed as anything but normal occurrences, especially as strong earnings results ","content":"<p>The S&amp;P 500 and the tech-heavy Nasdaq slipped during the week of February 15, after they closed at new records last week. Despite the drop in some of the big tech names such as AppleAAPL, FacebookFB, MicrosoftMSFT, Zoom VideoZM, and countless others this week, the market fundamentals remain relatively strong.</p><p>Ebbs and flows, as well as pullbacks and corrections are healthy aspects of the market. And they need not be viewed as anything but normal occurrences, especially as strong earnings results continue to pour in. Better yet, the outlook for the first quarter and the rest of 2021 has improved significantly.</p><p>Vaccine distribution will hopefully help the economy roar back by the summer and lift some of the hardest-hit areas of the economy. Meanwhile, Wall Street is banking on more spending under the Biden administration and the Fed remains firmly committed to keeping interest rates low.</p><p>All of these factors set up a bullish outlook for 2021. But instead of focusing on companies that need a vaccine to really grow, let’s look at two tech stocks that have posted big sales growth during the pandemic and are ready to expand for years within futuristic industries…</p><p><b>NIO Inc.NIO</b></p><p>Every major automaker, from FordFto Volvo, is racing to roll out more electric vehicles as they try to catch TeslaTSLA. Luckily for investors, the EV market is far from a zero-sum game and newcomers continue to enter the space. Chinese EV maker NIO is a rising star in the booming market, as its sales continue to grow. The company is also focused on autonomous driving tech, as well as batteries, which are the lifeblood of the industry.</p><p>NIO sells multiple models that are somewhat in-line with Tesla, from smaller SUVs to sedans. The company said in early January that it delivered 17,353 vehicles in the fourth quarter, which marked a 110% jump.</p><p>Overall, NIO’s full-year deliveries surged 113% to nearly 44,000 vehicles in 2020. And its January 2021 figures were even more impressive, with deliveries up 350% from the year-ago period to push its overall cumulative deliveries to 83K.</p><p>With this in mind, Zacks estimates call for NIO’s FY20 revenue to jump 120% to $2.49 billion, with FY21 projected to come in another 97% higher to reach $4.89 billion. The Chinese EV company is also expected to significantly shrink its adjusted losses during this stretch.</p><p>NIO has topped our EPS estimates in the trailing two periods and its positive earnings revisions help it land a Zacks Rank #2 (Buy) heading into the release of its Q4 results on March 1.</p><p><img src=\"https://static.tigerbbs.com/5b6233d1784a5cb7db62b437f7632a3f\" tg-width=\"620\" tg-height=\"314\" referrerpolicy=\"no-referrer\"></p><p>NIO, which rocks an “A” grade for Growth in our Style Scores system, has seen its stock skyrocket over 1,000% in the last year and 300% in the past six months. Luckily for investors who missed the ride, NIO has cooled down, up only 12% in the last three months.</p><p>At roughly $55 per share, it’s down about 13% from its late January records. The recent downturn has seen it fall from overbought in terms of the Relative Strength Index to around 45—an RSI above 70 is often regarded as overbought, with any number below 30 considered oversold.</p><p>NIO’s recent price performance could give it room to run if it’s able to impress Wall Street. And the stock jumped over 1% through morning trading Friday, as it bounces off its 50-day moving average. NIO shares also trade at a discount compared to other high-flyers at 12.7X forward sales, which marks a discount against Tesla’s 15.5X and comes in 25% below its own six-months highs.</p><p>Three out of the nine brokerage recommendations that Zacks has for NIO come in at a “Strong Buy,” with none below a “Hold.” NIO might be worth buying as a long-term play that’s far less expensive than Tesla ($784 a share), in a world where EVs already accounted for over 30% of Volvo’s new car sales in Europe in 2020. And let’s remember that China is one of the world’s largest EV markets.</p><p><b>CrowdStrikeCRWD</b></p><p>CrowdStrike is a cloud-focused cybersecurity firm that utilizes machine learning and AI to protect endpoints and cloud workloads. This is crucial in the cloud age that’s full of rapidly expanding endpoints, which include laptops, desktops, smartphones, IoT devices, and more.</p><p>Remote work and schooling pushed this area of the ever-growing cybersecurity space to the forefront, but it was already booming. More importantly, as devices proliferate and our digitally-connected world grows more complex, it becomes more vulnerable.</p><p>CrowdStrike on February announced plans to bolster its offerings through the acquisition of Humio for $400 million—expected to close in the first quarter. Humio provides high-performance cloud log management and observability technology. The deal is set to “further expand its eXtended Detection and Response (XDR) capabilities by ingesting and correlating data from any log, application or feed to deliver actionable insights and real-time protection.”</p><p><img src=\"https://static.tigerbbs.com/9f684cfbac7ba46e2cf8ab6e063461a2\" tg-width=\"620\" tg-height=\"280\" referrerpolicy=\"no-referrer\"></p><p>CrowdStrike, which went public in the summer of 2019, has soared nearly 280% in the past 12 months. More recently, the stock is up 65% in the last six months, and it already bounced back to new records—which it hit earlier in the week—after it slipped in mid-January.</p><p>The stock is firmly a growth play at the moment, trading at 42.7X forward sales, which puts it right in line with e-commerce giant ShopifySHOP. Despite its run, the stock is not currently considered overbought, with an RSI of 64.</p><p>CRWD’s positive earnings revisions help it grab a Zacks Rank #2 (Buy) at the moment, with it set to release its fourth quarter fiscal 2021 results on March 16. Meanwhile, 14 of the 19 brokerage ratings Zacks has for CRWD come in at a “Strong Buy,” with none lower than a “Hold.”</p><p>Looking back, the company crushed our Q3 estimates in December, with sales up 86%. CrowdStrike also lifted its guidance at the time. Zacks estimates currently call for it to swing from an adjusted loss of -$0.02 a share in the year-ago period to +$0.09 in the fourth quarter on 65% stronger sales.</p><p>In total, the cybersecurity firm is projected to soar from a loss of -$0.42 a share to +$0.23 in fiscal 2021. Plus, CRWD’s FY22 EPS figure is projected to climb another 70% higher, all the way to $0.39 a share. Meanwhile, its revenue is projected to jump 79% to hit $861 million in FY21 and then climb another 42% to $1.22 billion in FY22.</p><p>CrowdStrike’s expected growth would come on top of FY20’s 93% sales expansion. The stock has clearly already gone on an impressive run. But it is poised to continue to grow in a world where everything is connected and data is endless. Therefore, cybersecurity firms such as CrowdStrike might make for strong long-term growth plays.</p><p><b>These Stocks Are Poised to Soar Past the Pandemic</b>The COVID-19 outbreak has shifted consumer behavior dramatically, and a handful of high-tech companies have stepped up to keep America running. Right now, investors in these companies have a shot at serious profits. For example, Zoom jumped 108.5% in less than 4 months while most other stocks were sinking.</p><p>Our research shows that 5 cutting-edge stocks could skyrocket from the exponential increase in demand for “stay at home” technologies. This could be one of the biggest buying opportunities of this decade, especially for those who get in early.</p>","source":"lsy1604288433698","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Top Tech Stocks to Buy Now for Big Growth</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Top Tech Stocks to Buy Now for Big Growth\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-02-20 11:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.nasdaq.com/articles/2-top-tech-stocks-to-buy-now-for-big-growth-2021-02-19><strong>Nasdaq</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The S&P 500 and the tech-heavy Nasdaq slipped during the week of February 15, after they closed at new records last week. Despite the drop in some of the big tech names such as AppleAAPL, FacebookFB, ...</p>\n\n<a href=\"https://www.nasdaq.com/articles/2-top-tech-stocks-to-buy-now-for-big-growth-2021-02-19\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.nasdaq.com/articles/2-top-tech-stocks-to-buy-now-for-big-growth-2021-02-19","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1143100356","content_text":"The S&P 500 and the tech-heavy Nasdaq slipped during the week of February 15, after they closed at new records last week. Despite the drop in some of the big tech names such as AppleAAPL, FacebookFB, MicrosoftMSFT, Zoom VideoZM, and countless others this week, the market fundamentals remain relatively strong.Ebbs and flows, as well as pullbacks and corrections are healthy aspects of the market. And they need not be viewed as anything but normal occurrences, especially as strong earnings results continue to pour in. Better yet, the outlook for the first quarter and the rest of 2021 has improved significantly.Vaccine distribution will hopefully help the economy roar back by the summer and lift some of the hardest-hit areas of the economy. Meanwhile, Wall Street is banking on more spending under the Biden administration and the Fed remains firmly committed to keeping interest rates low.All of these factors set up a bullish outlook for 2021. But instead of focusing on companies that need a vaccine to really grow, let’s look at two tech stocks that have posted big sales growth during the pandemic and are ready to expand for years within futuristic industries…NIO Inc.NIOEvery major automaker, from FordFto Volvo, is racing to roll out more electric vehicles as they try to catch TeslaTSLA. Luckily for investors, the EV market is far from a zero-sum game and newcomers continue to enter the space. Chinese EV maker NIO is a rising star in the booming market, as its sales continue to grow. The company is also focused on autonomous driving tech, as well as batteries, which are the lifeblood of the industry.NIO sells multiple models that are somewhat in-line with Tesla, from smaller SUVs to sedans. The company said in early January that it delivered 17,353 vehicles in the fourth quarter, which marked a 110% jump.Overall, NIO’s full-year deliveries surged 113% to nearly 44,000 vehicles in 2020. And its January 2021 figures were even more impressive, with deliveries up 350% from the year-ago period to push its overall cumulative deliveries to 83K.With this in mind, Zacks estimates call for NIO’s FY20 revenue to jump 120% to $2.49 billion, with FY21 projected to come in another 97% higher to reach $4.89 billion. The Chinese EV company is also expected to significantly shrink its adjusted losses during this stretch.NIO has topped our EPS estimates in the trailing two periods and its positive earnings revisions help it land a Zacks Rank #2 (Buy) heading into the release of its Q4 results on March 1.NIO, which rocks an “A” grade for Growth in our Style Scores system, has seen its stock skyrocket over 1,000% in the last year and 300% in the past six months. Luckily for investors who missed the ride, NIO has cooled down, up only 12% in the last three months.At roughly $55 per share, it’s down about 13% from its late January records. The recent downturn has seen it fall from overbought in terms of the Relative Strength Index to around 45—an RSI above 70 is often regarded as overbought, with any number below 30 considered oversold.NIO’s recent price performance could give it room to run if it’s able to impress Wall Street. And the stock jumped over 1% through morning trading Friday, as it bounces off its 50-day moving average. NIO shares also trade at a discount compared to other high-flyers at 12.7X forward sales, which marks a discount against Tesla’s 15.5X and comes in 25% below its own six-months highs.Three out of the nine brokerage recommendations that Zacks has for NIO come in at a “Strong Buy,” with none below a “Hold.” NIO might be worth buying as a long-term play that’s far less expensive than Tesla ($784 a share), in a world where EVs already accounted for over 30% of Volvo’s new car sales in Europe in 2020. And let’s remember that China is one of the world’s largest EV markets.CrowdStrikeCRWDCrowdStrike is a cloud-focused cybersecurity firm that utilizes machine learning and AI to protect endpoints and cloud workloads. This is crucial in the cloud age that’s full of rapidly expanding endpoints, which include laptops, desktops, smartphones, IoT devices, and more.Remote work and schooling pushed this area of the ever-growing cybersecurity space to the forefront, but it was already booming. More importantly, as devices proliferate and our digitally-connected world grows more complex, it becomes more vulnerable.CrowdStrike on February announced plans to bolster its offerings through the acquisition of Humio for $400 million—expected to close in the first quarter. Humio provides high-performance cloud log management and observability technology. The deal is set to “further expand its eXtended Detection and Response (XDR) capabilities by ingesting and correlating data from any log, application or feed to deliver actionable insights and real-time protection.”CrowdStrike, which went public in the summer of 2019, has soared nearly 280% in the past 12 months. More recently, the stock is up 65% in the last six months, and it already bounced back to new records—which it hit earlier in the week—after it slipped in mid-January.The stock is firmly a growth play at the moment, trading at 42.7X forward sales, which puts it right in line with e-commerce giant ShopifySHOP. Despite its run, the stock is not currently considered overbought, with an RSI of 64.CRWD’s positive earnings revisions help it grab a Zacks Rank #2 (Buy) at the moment, with it set to release its fourth quarter fiscal 2021 results on March 16. Meanwhile, 14 of the 19 brokerage ratings Zacks has for CRWD come in at a “Strong Buy,” with none lower than a “Hold.”Looking back, the company crushed our Q3 estimates in December, with sales up 86%. CrowdStrike also lifted its guidance at the time. Zacks estimates currently call for it to swing from an adjusted loss of -$0.02 a share in the year-ago period to +$0.09 in the fourth quarter on 65% stronger sales.In total, the cybersecurity firm is projected to soar from a loss of -$0.42 a share to +$0.23 in fiscal 2021. Plus, CRWD’s FY22 EPS figure is projected to climb another 70% higher, all the way to $0.39 a share. Meanwhile, its revenue is projected to jump 79% to hit $861 million in FY21 and then climb another 42% to $1.22 billion in FY22.CrowdStrike’s expected growth would come on top of FY20’s 93% sales expansion. The stock has clearly already gone on an impressive run. But it is poised to continue to grow in a world where everything is connected and data is endless. Therefore, cybersecurity firms such as CrowdStrike might make for strong long-term growth plays.These Stocks Are Poised to Soar Past the PandemicThe COVID-19 outbreak has shifted consumer behavior dramatically, and a handful of high-tech companies have stepped up to keep America running. Right now, investors in these companies have a shot at serious profits. For example, Zoom jumped 108.5% in less than 4 months while most other stocks were sinking.Our research shows that 5 cutting-edge stocks could skyrocket from the exponential increase in demand for “stay at home” technologies. This could be one of the biggest buying opportunities of this decade, especially for those who get in early.","news_type":1},"isVote":1,"tweetType":1,"viewCount":206,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":386203365,"gmtCreate":1613179562957,"gmtModify":1704879238859,"author":{"id":"3565272871212062","authorId":"3565272871212062","name":"Terrylikabos","avatar":"https://static.tigerbbs.com/abbe3eacbb08c5542185b511b376fdd1","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Hi","listText":"Hi","text":"Hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/386203365","repostId":"2110904027","repostType":4,"isVote":1,"tweetType":1,"viewCount":17,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":360548674,"gmtCreate":1613959796298,"gmtModify":1704886153471,"author":{"id":"3565272871212062","authorId":"3565272871212062","name":"Terrylikabos","avatar":"https://static.tigerbbs.com/abbe3eacbb08c5542185b511b376fdd1","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"K","listText":"K","text":"K","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/360548674","repostId":"1145886989","repostType":4,"repost":{"id":"1145886989","pubTimestamp":1613957711,"share":"https://www.laohu8.com/m/news/1145886989?lang=&edition=full","pubTime":"2021-02-22 09:35","market":"us","language":"en","title":"Pfizer-BioNTech Shot Stops Covid Spread, Israeli Study Shows","url":"https://stock-news.laohu8.com/highlight/detail?id=1145886989","media":"Bloomberg","summary":"Vaccine reported to be 89% effective at preventing infections\nStopping virus transmission is key to ","content":"<ul>\n <li>Vaccine reported to be 89% effective at preventing infections</li>\n <li>Stopping virus transmission is key to ending Covid-19 pandemic</li>\n</ul>\n<p>The&nbsp;Pfizer Inc.&nbsp;and&nbsp;BioNTech SE&nbsp;Covid-19 vaccine appeared to stop the vast majority of recipients in Israel becoming infected, providing the first real-world indication that the immunization will curb transmission of the coronavirus.</p>\n<p>The vaccine, which is being rolled out in a national immunization program that began Dec. 20, was 89.4% effective at preventing laboratory-confirmed infections, according to a copy of a draft publication that was posted on Twitter and confirmed by a person familiar with the work. The companies worked with Israel’s Health Ministry on the preliminary observational analysis, which wasn’t peer-reviewed. Some scientists disputed its accuracy.</p>\n<p>The results, also reported in&nbsp;Der Spiegel, are the latest in aseries&nbsp;of&nbsp;positive&nbsp;data to emerge out of Israel, which has given more Covid vaccines per capita than anywhere else in the world. Almost half of the population has had at least one dose of vaccine. Separately, Israeli authorities on Saturday said the Pfizer-BioNTech shot was 99% effective at&nbsp;preventing deaths&nbsp;from the virus.</p>\n<p>If confirmed, the early results on lab-tested infections are encouraging because they indicate the vaccine may also prevent asymptomatic carriers from spreading the virus that causes Covid-19. That’s not been clear because the clinical trials that tested the safety and efficacy of vaccines focused on the ability to stop symptomatic infections.</p>\n<p><b>Herd Immunity</b></p>\n<p>“These are the data we need to see to estimate the potential for achieving herd immunity with vaccines,” said Raina MacIntyre, professor of biosecurity at the University of New South Wales in Sydney, in an email Monday. “However, we do need to be able to see the data published in a peer-reviewed journal and to be able to scrutinize the data in detail.”</p>\n<p>Pfizer and BioNTech said they are working on a real-world analysis of data from Israel, which will be shared as soon as it’s complete. Spokespeople declined to comment on unpublished data.</p>\n<p>The study wasn’t designed to accurately measure a reduction in transmission of SARS-CoV-2 because it used national testing data without accounting for differences in testing rates between vaccinated and unvaccinated people, said&nbsp;Zoe McLaren, an associate professor in the school of public policy at the University of Maryland Baltimore County.</p>\n<p>“The main result overstates the reduction in transmission from the Pfizer vaccine,” McLaren said in an email.</p>\n<p>The study compares the number of reported cases between those who had been fully vaccinated and those who hadn’t been vaccinated, but vaccinated people are less likely to get tested so the data will undercount cases, especially asymptomatic cases, in this group, she said.</p>\n<p><b>‘Need More Evidence’</b></p>\n<p>“That means that the true reduction in transmission is lower than the estimate of 89.4%,” McLaren said. “How much lower? We need more evidence to know for sure. But I expect that, once we account for the bias, we’ll still find that this vaccine does reduce transmission. And that would be very good news.”</p>\n<p>About 80% of SARS-CoV-2 cases in Israel during the time period of the study, from Jan. 17 to Feb. 6, were caused by the more transmissible strain first identified in the U.K. Israel’s vaccination drive began just before the so-called B.1.1.7 variant emerged, fueling infections and leading to a third lockdown on Jan. 8.</p>\n<p>Through Feb. 6, about 27% of peopleaged15 and older in Israel were fully vaccinated, with the Pfizer-BioNTech shot the only vaccine available in the country at the time. People were considered fully vaccinated and included in the analysis if the data collected were more than seven days after they received their second dose.</p>\n<p>Based on SARS-CoV-2’s infectiousness, a vaccine that is 89% effective at preventing infection is likely to be effective at eliminating Covid-19 in a population in which high vaccination coverage is achieved, said Helen Petousis-Harris, a vaccinologist at the University of Auckland.</p>\n<p>Elimination of Covid-19 will depend on potential “reservoirs” of SARS-CoV-2 in animals, genetic changes in the virus that might enable it to escape vaccine-induced immunity, and the ability to stop transmission across the world, said Petousis-Harris, who is co-leader of the Global Vaccine Data Network, a multinational group that collaborates on vaccine safety studies.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer-BioNTech Shot Stops Covid Spread, Israeli Study Shows</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer-BioNTech Shot Stops Covid Spread, Israeli Study Shows\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-02-22 09:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-02-21/pfizer-biontech-shot-stops-covid-s-spread-israeli-study-shows><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Vaccine reported to be 89% effective at preventing infections\nStopping virus transmission is key to ending Covid-19 pandemic\n\nThe Pfizer Inc. and BioNTech SE Covid-19 vaccine appeared to stop the vast...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-02-21/pfizer-biontech-shot-stops-covid-s-spread-israeli-study-shows\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","BNTX":"BioNTech SE"},"source_url":"https://www.bloomberg.com/news/articles/2021-02-21/pfizer-biontech-shot-stops-covid-s-spread-israeli-study-shows","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1145886989","content_text":"Vaccine reported to be 89% effective at preventing infections\nStopping virus transmission is key to ending Covid-19 pandemic\n\nThe Pfizer Inc. and BioNTech SE Covid-19 vaccine appeared to stop the vast majority of recipients in Israel becoming infected, providing the first real-world indication that the immunization will curb transmission of the coronavirus.\nThe vaccine, which is being rolled out in a national immunization program that began Dec. 20, was 89.4% effective at preventing laboratory-confirmed infections, according to a copy of a draft publication that was posted on Twitter and confirmed by a person familiar with the work. The companies worked with Israel’s Health Ministry on the preliminary observational analysis, which wasn’t peer-reviewed. Some scientists disputed its accuracy.\nThe results, also reported in Der Spiegel, are the latest in aseries of positive data to emerge out of Israel, which has given more Covid vaccines per capita than anywhere else in the world. Almost half of the population has had at least one dose of vaccine. Separately, Israeli authorities on Saturday said the Pfizer-BioNTech shot was 99% effective at preventing deaths from the virus.\nIf confirmed, the early results on lab-tested infections are encouraging because they indicate the vaccine may also prevent asymptomatic carriers from spreading the virus that causes Covid-19. That’s not been clear because the clinical trials that tested the safety and efficacy of vaccines focused on the ability to stop symptomatic infections.\nHerd Immunity\n“These are the data we need to see to estimate the potential for achieving herd immunity with vaccines,” said Raina MacIntyre, professor of biosecurity at the University of New South Wales in Sydney, in an email Monday. “However, we do need to be able to see the data published in a peer-reviewed journal and to be able to scrutinize the data in detail.”\nPfizer and BioNTech said they are working on a real-world analysis of data from Israel, which will be shared as soon as it’s complete. Spokespeople declined to comment on unpublished data.\nThe study wasn’t designed to accurately measure a reduction in transmission of SARS-CoV-2 because it used national testing data without accounting for differences in testing rates between vaccinated and unvaccinated people, said Zoe McLaren, an associate professor in the school of public policy at the University of Maryland Baltimore County.\n“The main result overstates the reduction in transmission from the Pfizer vaccine,” McLaren said in an email.\nThe study compares the number of reported cases between those who had been fully vaccinated and those who hadn’t been vaccinated, but vaccinated people are less likely to get tested so the data will undercount cases, especially asymptomatic cases, in this group, she said.\n‘Need More Evidence’\n“That means that the true reduction in transmission is lower than the estimate of 89.4%,” McLaren said. “How much lower? We need more evidence to know for sure. But I expect that, once we account for the bias, we’ll still find that this vaccine does reduce transmission. And that would be very good news.”\nAbout 80% of SARS-CoV-2 cases in Israel during the time period of the study, from Jan. 17 to Feb. 6, were caused by the more transmissible strain first identified in the U.K. Israel’s vaccination drive began just before the so-called B.1.1.7 variant emerged, fueling infections and leading to a third lockdown on Jan. 8.\nThrough Feb. 6, about 27% of peopleaged15 and older in Israel were fully vaccinated, with the Pfizer-BioNTech shot the only vaccine available in the country at the time. People were considered fully vaccinated and included in the analysis if the data collected were more than seven days after they received their second dose.\nBased on SARS-CoV-2’s infectiousness, a vaccine that is 89% effective at preventing infection is likely to be effective at eliminating Covid-19 in a population in which high vaccination coverage is achieved, said Helen Petousis-Harris, a vaccinologist at the University of Auckland.\nElimination of Covid-19 will depend on potential “reservoirs” of SARS-CoV-2 in animals, genetic changes in the virus that might enable it to escape vaccine-induced immunity, and the ability to stop transmission across the world, said Petousis-Harris, who is co-leader of the Global Vaccine Data Network, a multinational group that collaborates on vaccine safety studies.","news_type":1},"isVote":1,"tweetType":1,"viewCount":283,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":360541238,"gmtCreate":1613959770424,"gmtModify":1704886152328,"author":{"id":"3565272871212062","authorId":"3565272871212062","name":"Terrylikabos","avatar":"https://static.tigerbbs.com/abbe3eacbb08c5542185b511b376fdd1","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"B","listText":"B","text":"B","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/360541238","repostId":"1145886989","repostType":4,"repost":{"id":"1145886989","pubTimestamp":1613957711,"share":"https://www.laohu8.com/m/news/1145886989?lang=&edition=full","pubTime":"2021-02-22 09:35","market":"us","language":"en","title":"Pfizer-BioNTech Shot Stops Covid Spread, Israeli Study Shows","url":"https://stock-news.laohu8.com/highlight/detail?id=1145886989","media":"Bloomberg","summary":"Vaccine reported to be 89% effective at preventing infections\nStopping virus transmission is key to ","content":"<ul>\n <li>Vaccine reported to be 89% effective at preventing infections</li>\n <li>Stopping virus transmission is key to ending Covid-19 pandemic</li>\n</ul>\n<p>The&nbsp;Pfizer Inc.&nbsp;and&nbsp;BioNTech SE&nbsp;Covid-19 vaccine appeared to stop the vast majority of recipients in Israel becoming infected, providing the first real-world indication that the immunization will curb transmission of the coronavirus.</p>\n<p>The vaccine, which is being rolled out in a national immunization program that began Dec. 20, was 89.4% effective at preventing laboratory-confirmed infections, according to a copy of a draft publication that was posted on Twitter and confirmed by a person familiar with the work. The companies worked with Israel’s Health Ministry on the preliminary observational analysis, which wasn’t peer-reviewed. Some scientists disputed its accuracy.</p>\n<p>The results, also reported in&nbsp;Der Spiegel, are the latest in aseries&nbsp;of&nbsp;positive&nbsp;data to emerge out of Israel, which has given more Covid vaccines per capita than anywhere else in the world. Almost half of the population has had at least one dose of vaccine. Separately, Israeli authorities on Saturday said the Pfizer-BioNTech shot was 99% effective at&nbsp;preventing deaths&nbsp;from the virus.</p>\n<p>If confirmed, the early results on lab-tested infections are encouraging because they indicate the vaccine may also prevent asymptomatic carriers from spreading the virus that causes Covid-19. That’s not been clear because the clinical trials that tested the safety and efficacy of vaccines focused on the ability to stop symptomatic infections.</p>\n<p><b>Herd Immunity</b></p>\n<p>“These are the data we need to see to estimate the potential for achieving herd immunity with vaccines,” said Raina MacIntyre, professor of biosecurity at the University of New South Wales in Sydney, in an email Monday. “However, we do need to be able to see the data published in a peer-reviewed journal and to be able to scrutinize the data in detail.”</p>\n<p>Pfizer and BioNTech said they are working on a real-world analysis of data from Israel, which will be shared as soon as it’s complete. Spokespeople declined to comment on unpublished data.</p>\n<p>The study wasn’t designed to accurately measure a reduction in transmission of SARS-CoV-2 because it used national testing data without accounting for differences in testing rates between vaccinated and unvaccinated people, said&nbsp;Zoe McLaren, an associate professor in the school of public policy at the University of Maryland Baltimore County.</p>\n<p>“The main result overstates the reduction in transmission from the Pfizer vaccine,” McLaren said in an email.</p>\n<p>The study compares the number of reported cases between those who had been fully vaccinated and those who hadn’t been vaccinated, but vaccinated people are less likely to get tested so the data will undercount cases, especially asymptomatic cases, in this group, she said.</p>\n<p><b>‘Need More Evidence’</b></p>\n<p>“That means that the true reduction in transmission is lower than the estimate of 89.4%,” McLaren said. “How much lower? We need more evidence to know for sure. But I expect that, once we account for the bias, we’ll still find that this vaccine does reduce transmission. And that would be very good news.”</p>\n<p>About 80% of SARS-CoV-2 cases in Israel during the time period of the study, from Jan. 17 to Feb. 6, were caused by the more transmissible strain first identified in the U.K. Israel’s vaccination drive began just before the so-called B.1.1.7 variant emerged, fueling infections and leading to a third lockdown on Jan. 8.</p>\n<p>Through Feb. 6, about 27% of peopleaged15 and older in Israel were fully vaccinated, with the Pfizer-BioNTech shot the only vaccine available in the country at the time. People were considered fully vaccinated and included in the analysis if the data collected were more than seven days after they received their second dose.</p>\n<p>Based on SARS-CoV-2’s infectiousness, a vaccine that is 89% effective at preventing infection is likely to be effective at eliminating Covid-19 in a population in which high vaccination coverage is achieved, said Helen Petousis-Harris, a vaccinologist at the University of Auckland.</p>\n<p>Elimination of Covid-19 will depend on potential “reservoirs” of SARS-CoV-2 in animals, genetic changes in the virus that might enable it to escape vaccine-induced immunity, and the ability to stop transmission across the world, said Petousis-Harris, who is co-leader of the Global Vaccine Data Network, a multinational group that collaborates on vaccine safety studies.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer-BioNTech Shot Stops Covid Spread, Israeli Study Shows</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer-BioNTech Shot Stops Covid Spread, Israeli Study Shows\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-02-22 09:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-02-21/pfizer-biontech-shot-stops-covid-s-spread-israeli-study-shows><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Vaccine reported to be 89% effective at preventing infections\nStopping virus transmission is key to ending Covid-19 pandemic\n\nThe Pfizer Inc. and BioNTech SE Covid-19 vaccine appeared to stop the vast...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-02-21/pfizer-biontech-shot-stops-covid-s-spread-israeli-study-shows\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","BNTX":"BioNTech SE"},"source_url":"https://www.bloomberg.com/news/articles/2021-02-21/pfizer-biontech-shot-stops-covid-s-spread-israeli-study-shows","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1145886989","content_text":"Vaccine reported to be 89% effective at preventing infections\nStopping virus transmission is key to ending Covid-19 pandemic\n\nThe Pfizer Inc. and BioNTech SE Covid-19 vaccine appeared to stop the vast majority of recipients in Israel becoming infected, providing the first real-world indication that the immunization will curb transmission of the coronavirus.\nThe vaccine, which is being rolled out in a national immunization program that began Dec. 20, was 89.4% effective at preventing laboratory-confirmed infections, according to a copy of a draft publication that was posted on Twitter and confirmed by a person familiar with the work. The companies worked with Israel’s Health Ministry on the preliminary observational analysis, which wasn’t peer-reviewed. Some scientists disputed its accuracy.\nThe results, also reported in Der Spiegel, are the latest in aseries of positive data to emerge out of Israel, which has given more Covid vaccines per capita than anywhere else in the world. Almost half of the population has had at least one dose of vaccine. Separately, Israeli authorities on Saturday said the Pfizer-BioNTech shot was 99% effective at preventing deaths from the virus.\nIf confirmed, the early results on lab-tested infections are encouraging because they indicate the vaccine may also prevent asymptomatic carriers from spreading the virus that causes Covid-19. That’s not been clear because the clinical trials that tested the safety and efficacy of vaccines focused on the ability to stop symptomatic infections.\nHerd Immunity\n“These are the data we need to see to estimate the potential for achieving herd immunity with vaccines,” said Raina MacIntyre, professor of biosecurity at the University of New South Wales in Sydney, in an email Monday. “However, we do need to be able to see the data published in a peer-reviewed journal and to be able to scrutinize the data in detail.”\nPfizer and BioNTech said they are working on a real-world analysis of data from Israel, which will be shared as soon as it’s complete. Spokespeople declined to comment on unpublished data.\nThe study wasn’t designed to accurately measure a reduction in transmission of SARS-CoV-2 because it used national testing data without accounting for differences in testing rates between vaccinated and unvaccinated people, said Zoe McLaren, an associate professor in the school of public policy at the University of Maryland Baltimore County.\n“The main result overstates the reduction in transmission from the Pfizer vaccine,” McLaren said in an email.\nThe study compares the number of reported cases between those who had been fully vaccinated and those who hadn’t been vaccinated, but vaccinated people are less likely to get tested so the data will undercount cases, especially asymptomatic cases, in this group, she said.\n‘Need More Evidence’\n“That means that the true reduction in transmission is lower than the estimate of 89.4%,” McLaren said. “How much lower? We need more evidence to know for sure. But I expect that, once we account for the bias, we’ll still find that this vaccine does reduce transmission. And that would be very good news.”\nAbout 80% of SARS-CoV-2 cases in Israel during the time period of the study, from Jan. 17 to Feb. 6, were caused by the more transmissible strain first identified in the U.K. Israel’s vaccination drive began just before the so-called B.1.1.7 variant emerged, fueling infections and leading to a third lockdown on Jan. 8.\nThrough Feb. 6, about 27% of peopleaged15 and older in Israel were fully vaccinated, with the Pfizer-BioNTech shot the only vaccine available in the country at the time. People were considered fully vaccinated and included in the analysis if the data collected were more than seven days after they received their second dose.\nBased on SARS-CoV-2’s infectiousness, a vaccine that is 89% effective at preventing infection is likely to be effective at eliminating Covid-19 in a population in which high vaccination coverage is achieved, said Helen Petousis-Harris, a vaccinologist at the University of Auckland.\nElimination of Covid-19 will depend on potential “reservoirs” of SARS-CoV-2 in animals, genetic changes in the virus that might enable it to escape vaccine-induced immunity, and the ability to stop transmission across the world, said Petousis-Harris, who is co-leader of the Global Vaccine Data Network, a multinational group that collaborates on vaccine safety studies.","news_type":1},"isVote":1,"tweetType":1,"viewCount":163,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":385845019,"gmtCreate":1613535694631,"gmtModify":1704881743549,"author":{"id":"3565272871212062","authorId":"3565272871212062","name":"Terrylikabos","avatar":"https://static.tigerbbs.com/abbe3eacbb08c5542185b511b376fdd1","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"To jurong","listText":"To jurong","text":"To jurong","images":[{"img":"https://static.tigerbbs.com/1541aae0bcf4ee87a4d0371a0ee1689e","width":"750","height":"1762"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/385845019","isVote":1,"tweetType":1,"viewCount":1,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"lives":[]}